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Abstract 
Epilepsy is a chronic neurological disease characterised by recurrent seizures, 
premature mortality and several associated comorbidities such as motor disorder, anxiety, 
depression, social deficits and cognitive impairment.  
Here, the effect of cannabidiol (CBD) in three different preclinical models of epilepsy 
was investigated. First, the effect of 9-weeks oral CBD administration (200 mg/kg/day) on 
seizures, motor function, gait and cognition in a reduced intensity status epilepticus induced 
spontaneous recurrent seizures (RISE-SRS) rat model of temporal lobe epilepsy (TLE) was 
evaluated. Subsequently, the effect of long-term CBD administration (100 mg/kg, twice daily 
s.c. injections from postnatal day 8 (P8) to 25/death) on survivability and a number of welfare 
parameters such as natural activity, reflex/response to touch, total neonatal welfare, orbital 
tightening and body condition in the Scn1a-/- mouse model was investigated. Finally, the 
effect of chronic CBD administration (100 mg/kg, twice daily s.c. injections from P8 to 
52/death) on premature mortality and comorbidities such as motor dysfunction, social 
deficits, anxiety, depression and cognitive impairment in the Scn1a+/- mouse model of Dravet 
syndrome was assessed.  
I demonstrated for the first time that chronic CBD treatment improved seizures, motor 
function and cognition without producing any adverse effect on gait in RISE-SRS rat model 
of TLE. Further, I showed that CBD treatment extended survivability and improved the 
neonatal welfare parameters in the Scn1a-/- mouse model. Moreover, I established the novel 
finding that chronic CBD-treatment prevented premature mortality and improved the 
comorbidities associated with the Scn1a+/- mouse model of Dravet syndrome. 
Although the anticonvulsant property of CBD has been shown in animal models of 
seizures, I am the first to demonstrate that CBD has disease modifying potential, and 
improves seizures, survivability and comorbidities associated with preclinical models of 
epilepsy. Notably, this project formed a core part in the development and US-FDA approval 
of Epidiolex® (GW Pharmaceuticals) in 2018.   
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 Epilepsy 
Epilepsy is a progressive, chronic neurological disorder characterised by recurrent 
seizures  (Blume et al., 2001). An epileptic seizure can be defined as ‘‘transient occurrence 
of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the 
brain’’ (Fisher et al., 2005). However, a more severe form of seizure termed ‘status 
epilepticus’ (SE) can also occur in which an individual exhibits seizure continuously for more 
than five minutes or repetitive seizures within this time frame without gaining consciousness 
(Trinka et al., 2015). If SE persists for more than half an hour it might lead to long-term after 
effects such as neuronal injury, neuronal death and shift of neuronal networks (Trinka et al., 
2015). Epilepsy remains a significant health concern as almost more than 65 million people 
worldwide are diagnosed with this neurological disease (Thurman et al., 2011). Further, the 
morbidity associated with epilepsy is so high that individuals with the disease are often 
stigmatised and become isolated from the society (Dilorio et al., 2003; Tekle-Haimanot et al., 
1991; Atadzhanov et al., 2010; Baker et al., 2000; Baker et al., 2005). Epilepsy is more 
prevalent in low- and middle-income countries; almost 80% people with epilepsy live in these 
countries (WHO, 2018). The higher prevalence in these countries is mainly attributed to 
inadequate treatment facilities and only about 20% epileptic patients receive treatment 
(Mbuba et al., 2008). It is notable that >50% of brain diseases show seizure as a secondary 
symptom so, while not primary epilepsy, carry many of the same problems (WHO, 2018).  
There has always been a matter of debate and confusion among the clinicians and 
researchers on the diagnosis of epilepsy. According to the International League Against 
Epilepsy (ILAE), a person can be considered as epileptic if he/she had two unprovoked 
seizure in more than 24 hours apart, or one unprovoked seizure together with a probability of 
minimum 60% general recurrence risk for the next 10 years, or diagnosed with an epilepsy 
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syndrome (Fisher et al., 2014). According to the authors this definition would be helpful for 
an early diagnosis and intervention to avoid unnecessary injuries associated with accidents 
during epileptic attacks or prevent the disease progression. However, issues have been raised 
on the inclusion of the percentage value (60%) in the second part of the definition by Dr. 
Hauser, which according to him ‘represents an expert consensus and has limited substantive 
data to support the recommendations’ (Hauser, 2014). The agreed definition of epilepsy 
therefore remains open to debate.  
Next, I will provide a brief historical background of epilepsy before discussing its 
aetiology, pathophysiology, therapy, classification and animal models. I will also briefly 
illustrate temporal lobe epilepsy (TLE) and Dravet syndrome due to their importance in this 
project. 
1.1.1 Historical background 
The history of epilepsy is closely linked to the history of human civilization, with the 
first account of epileptic seizures traced back to ~2000 BC in a Mesopotamian text written in 
Akkadian language (Temkin, 1945). The text described a person having seizures and termed 
the condition as ‘antasubbû’ (the hand of sin) (Labat, 1951). It was believed that the goddess 
of the moon punished him for breaching religious/social laws (Labat, 1951).  The description 
of epilepsy can also be found in ancient Egyptian, Babylonian and Greek texts (Daras et al., 
1994; Longrigg, 2000). However, during that time epilepsy was not considered as a disease 
but the outcome of divine possession or punishment. Interestingly, Atreya, an Indian medical 
author (~600 BC) attributed epilepsy to a brain disorder and rejected the age-old concept of 
divine possession in his famous text ‘‘Caraka Saṃhitā Sutra’’ (Pirkner, 1929). Nevertheless, 
epilepsy was not well understood until the famous Greek author Hippocrates suggested a 
possible aetiology and therapy (Hippocrates, 1950). In his book ‘On Sacred Disease’ (~400 
BC) he mentioned epilepsy as a great disease from where the term ‘grand mal’ originated 
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(Hippocrates, 1950). During the post-Hippocratic era a notable contribution was made by 
Aretaeus (~100 AD) who first described the premonitory symptoms of seizures such as 
hallucinations, smelling odours, tremors or sensations in the limbs (Aretaeus, 1856). 
Unfortunately, research on epilepsy became stagnant during the medieval period (~500-1500 
BC) where religious superstitions overshadowed the scientific merit and as a result, epilepsy 
was attributed to demonic possessions or outcome of sins (Beyerstein, 1988).  
Epilepsy research regained its scientific importance at the beginning of 16th century 
and during this time the Swiss-German physician Paracelsus highlighted that epilepsy had 
natural origins such as hereditary, malnutrition or weakness of semen rather than any divine 
possessions (Paracelsus, 1933). Further progress in understanding the pathophysiology and 
therapy was made during the 18th century. For example, Herman Boerhaave, a Dutch doctor 
tried to define epilepsy as the sudden elimination of vital body functions with increased 
muscle movement and convulsion (Boerhaave, 1761). Swiss physician Simmon Tissot 
compiled a large set of previous works in his ‘Traite de l’ epilepsie’ which set up a milestone 
for epilepsy research (Tissot, 1770). He accepted epilepsy as a hereditary disease and 
suggested epileptic individual not to get married. Then in 19th century, the French psychiatrist 
J.D. Esquirol and M. Flourens made significant contribution in understanding different forms 
of epileptic seizures and their possible origins (Flourens, 1823; Esquirol, 1838). Further, 
British physician J.C. Prichard described the typical symptoms of an epileptic seizure and he 
was the first to coin the term ‘partial epilepsy’ (Prichard, 1828). In addition to understanding 
the disease, researches were carried on to develop therapies for epilepsy and it gained the 
success with the introduction of potassium bromide by Edward Sieveking as the first 
antiepileptic drug (Sieveking, 1857). Among other notable works during this time, the famous 
book ‘Epilepsy: Its Symptoms, Treatment and Relation to Other Chronic Convulsive 
Diseases’ written by British neurologist J.R. Reynold was important where he differentiated 
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‘epilepsy proper’ from that of ‘idiopathic epilepsy’ (Reynolds, 1861). Further, J.H. Jackson 
(1835-1911), who was also known as the father of modern epileptology, suggested that 
epilepsy is caused due to sudden, rapid and excessive local discharges from grey matter in the 
brain (Jackson, 1863; Jackson, 1864). Almost a decade later, Richard Caton first recorded 
electrical activities in the cerebral hemispheres of rabbits and monkeys using a galvanometer 
which paved the way for using electrophysiology in epilepsy research (Caton, 1875).  
Epilepsy research received a fast pace thereafter in 20th century. For instance, In 1912, 
Kaufman and Pravdicz-Neminsky induced experimental seizures in dogs and suggested a link 
between the abnormal electrical discharge and epilepsy (Kaufman, 1912; Pravdicz-Neminski, 
1912). In the same year, Alfred Hauptmann discovered the anticonvulsant action of 
phenobarbital which is considered as a major landmark in the history of antiepileptic drug 
discovery (Hauptmann, 1912). A decade later, the German psychiatrist Hans Berger first 
performed electroencephalography (EEG) on a human patient during generalised tonic-clonic 
seizures (Berger, 1929). Almost at the same time, Merritt and Putnam made a serendipitous 
discovery of the anticonvulsant efficacy of phenytoin (Merritt and Putnam, 1938). In the 
middle of the 20th century, several other drugs such as carbamazepine (Schindler and 
Häfliger, 1954), ethosuximide (Vossen, 1958) and sodium valproate (Meunier et al., 1963) 
were subsequently introduced. Among other prominent figures in mid to late 20th century, 
Henri Gastaut made significant contribution in the field of epilepsy. He first defined five 
major EEG patterns (lambda waves, mu rhythm, pi rhythm, rolandic spikes and posterior 
theta rhythm) in human and also characterised a number of epilepsy types including Lennox-
Gastaut syndrome (Dravet and Roger, 1996). Several notable discoveries have been made in 
the field of epilepsy research since the late 20th centuries till date which will be highlighted in 
the coming sections.  
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1.1.2 Aetiology 
Epilepsy is a complex neurological disease with multiple aetiological factors that may 
influence the risk of developing the disease (Thomas and Berkovic, 2014). For instance, brain 
tumours including melanoma, multiple metastases, haemorrhagic lesions, slowly growing 
primary tumours, gangliogliomas, low grade astrocytomas, dysembryoplastic neuroepithelial 
tumours and oligodendrogliomas are common causes of epilepsy (Liigant et al., 2001; 
Brahimaj et al., 2014). Further, brain injury is considered as an important factor as around 
20% cases of all symptomatic epilepsy are associated with prior brain injury (Lowenstein, 
2009). Stroke can also promote the development of epilepsy as it has been reported that about 
2-4% of stroke patients experience epilepsy in their lifetime (Olsen, 2001). Moreover, 
malformations of cortical development significantly contributed to the origin of symptomatic 
focal epilepsy in children (Fujiwara and Shigematsu, 2004). Interestingly, age serves an 
important aetiological factor, a meta-analysis study showed that the incidence rate of epilepsy 
among the children and the elderly are the highest compared to those in between the age of 
20-40 years (Cloyd et al., 2006). Among others, cerebral and metabolic anoxia, infection and 
developmental abnormalities are pertinent risk factors in people of early age, whereas 
vascular malformations, trauma and hippocampal sclerosis are the predominant causative 
factors in adolescents, and trauma, tumour and stroke are significant risk factors in elderly 
people (Pomeroy et al., 1990; Fujiwara and Shigematsu, 2004; Panayiotopoulos, 2005). An 
important association between Alzheimer’s disease progression and epilepsy has also been 
documented as around 16% of Alzheimer’s disease patients experience at least one 
unprovoked generalised tonic-clonic seizure (Romanelli et al., 1990). Further, a higher risk of 
developing epilepsy is noticed in several autoimmune encephalopathies such as Rasmussen 
encephalitis, systemic lupus erythematosus and Behcet’s disease (Bien et al., 2005; Liou et 
al., 1996; Aykutlu et al., 2002). Moreover, chronic heavy alcohol users are reported to be at 
   
  Chapter 1 
7 
 
higher risk of developing epilepsy and the risk is often dose dependent (Samokhvalov et al., 
2010).  
Besides these physiological impacts, certain genes play important role in various 
idiopathic epilepsy syndromes such as Juvenile myoclonic epilepsy (GABRA1 and EFHC1), 
absence epilepsy (CACNA1A), Dravet syndrome (SCN1A), autosomal dominant frontal lobe 
epilepsy (CHRNA4), benign familial neonatal convulsion (KCNQ2) and benign familial 
neonatal-infantile seizures (SCN2A) (Scheffer et al., 1995; Ronen et al., 1993; Claes et al., 
2003; Lopes-Cendes, 2008). Of all these genetic epilepsies, the incidence rates of juvenile 
myoclonic epilepsy and absence epilepsy are the highest which contribute to 5-11% and 2-8% 
of all epilepsies, respectively (Lopes-Cendes, 2008).  
1.1.3 Pathophysiology 
The pathogenesis of epilepsy is intricate where several factors interplay to create an 
imbalance between brain’s inhibitory and excitatory circuitry that ultimately leads to 
manifestation of spontaneous seizures (Scharfman, 2007). The process through which the 
neuronal network inside brain shifts from normal to an excitatory one and produces 
unprovoked seizures is known as epileptogenesis (Engel, 2001; Pitkanen and Lukasiuk, 
2011). During the epileptogenesis process a widespread molecular and structural changes 
along with genetic and epigenetic alterations take place in both neuronal and non-neuronal 
cells in the brain which ultimately makes the neuronal circuits dysfunctional (Devinsky et al., 
2018c).  
Glutamate and γ-aminobutyric acid (GABA) are the two main neurotransmitters 
which play crucial roles in epilepsy (Rowley et al., 1995). Glutamate, the main excitatory 
neurotransmitter is released from the presynaptic vesicles with the help of calcium ions 
(Takumi et al., 1998). Glutamate acts through several receptors such as ionotropic α-amino-3-
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hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA), N-methyl-D-aspartic acid (NMDA) 
and kainate, as well as metabotropic G protein coupled receptors (mGluRs) to produce 
excitatory postsynaptic depolarisation (Meldrum et al., 1999; Kew and Kemp, 2005). AMPA 
receptors are important for fast excitatory neurotransmission via the sodium-potassium 
channels whereas NMDA receptors are responsible for slow but sustained phase of calcium 
mediated excitatory neurotransmission (Benke et al., 1998). Further, the mGluRs play 
important part in modulating glutamatergic signalling in epilepsy (Ure et al., 2006). 
Following its action, glutamate is transported back into the presynaptic vesicles by glutamate 
aspartate transporter (GLAST) and glutamate transporter 1 (GLT1) (Lehre et al., 1995). An 
excessive glutamatergic activity due to upregulation of glutamatergic receptors, increased 
glutamate concentration in the synaptic cleft or dysfunction of glutamate transporters 
produces hyperexcitability manifested by seizures (Seifert et al., 2002; Aronica et al., 2000; 
Yi and Hazell, 2006). 
In contrast to glutamate, GABA is an inhibitory neurotransmitter which 
hyperpolarises neurons and produces inhibitory postsynaptic potentials (Treiman, 2001). 
GABA acts through mainly two receptors namely GABAA and GABAB (Takeuchi and 
Onodera, 1972; Kaupmann et al., 1997). The GABAA are ligand-gated ion channel receptors 
that regulate fast inhibitory presynaptic potentials by mediating chloride influx, whereas 
GABAB are G-protein coupled receptors that regulate slow inhibitory presynaptic potentials 
by enhancing the conductance of potassium and decreasing the entry of calcium (Meldrum, 
1989; Takeuchi and Onodera, 1972; Kaupmann et al., 1997) . A reduction in GABAergic 
inhibition due to an impairment of GABA synthesis or release, alteration of GABA receptors 
and loss of GABAergic neurons increases the probability of generation of excitatory 
postsynaptic potentials and development of epilepsy (Schwarzer et al., 1997; Brooks-Kayal et 
al., 1998; Knopp et al., 2008). 
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Apart from GABA and glutamate other neurotransmitters such as serotonin, 
adrenaline and dopamine have also been found to play important roles in the pathogenesis of 
epilepsy (compiled and reviewed in (Svob Strac et al., 2016)). It has been demonstrated in 
animal studies that a lower level of serotonin or a lacking in serotonin receptors 5-HT1A or 5-
HT2C (5-hydroxytryptamine 1A or 2C) are associated with the generation of seizures (Dailey 
et al., 1992; Applegate and Tecott, 1998; Sarnyai et al., 2000). Serotonin also indirectly 
modulates the glutamatergic or GABAergic neurotransmission (Schmitz et al., 1995; 
Katsurabayashi et al., 2003; Ciranna, 2006). Further, the protective role of noradrenaline 
against seizures has also been reported where a depletion of endogenous noradrenaline 
increased the neuronal damage and seizure susceptibility (Szot et al., 1999; Weinshenker et 
al., 2001). On the contrary, dopamine plays an complex role in the pathology of epilepsy and 
often based on the type of receptor it acts on (Barone et al., 1991). Studies have suggested 
that an activation of dopamine D1 receptor exerts proconvulsant effect, whereas the D2 
receptor activation exerts anticonvulsant effect (Clinckers et al., 2004; Barone et al., 1991). 
Furthermore, a reduced binding potential of dopamine to its transporters has also been shown 
to be involved in juvenile myoclonic epilepsy (Bagdy et al., 2007).  
In addition to the neurotransmitters discussed above, ion channels play crucial roles in 
the maintenance of neuronal network homeostasis. A dysfunction of ion channels or 
channelopathy has been reported to be associated with epilepsy (Poolos and Johnston, 2012; 
Lerche et al., 2013). For example, mutations in the genes that code the voltage gated ion 
channels such as potassium, sodium, calcium and chloride, and ligand gated ion channel 
receptors for GABA and acetylcholine have been documented in various genetic epilepsy 
syndromes (Claes et al., 2001; Baulac et al., 2001; Charlier et al., 1998; Dedek et al., 2001; 
Niemeyer et al., 2004; Bertrand et al., 2002). Moreover, transcriptional and post-translational 
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modifications of the ion channels might also occur in acquired epilepsies (Scheffer and 
Berkovic, 2003; Helbig et al., 2008).  
Apart from the above mentioned pathophysiological process, several other 
intracellular signalling and gene expression pathways; including mechanistic target of 
rapamycin (mTOR), brain-derived neurotrophic factor (BDNF), transforming growth factor-β 
(TGFβ) and adenosine kinase (AK) are also reported to be involved in epileptogenesis (for 
review see (Staley, 2015)). However, a detailed discussion of these are beyond the scope of 
this thesis and are not discussed here. 
1.1.4 Antiepileptic drugs (AEDs) and their mechanism of action 
The antiepileptic drugs (AEDs) may be divided into three classes based on their 
development i.e. i) first generation (1857-1958; e.g. potassium bromide, phenobarbital, 
mephobarbital, ethosuximide etc.) ii) second generation (1960-1975; carbamazepine, 
valproate, and various benzodiazepines) and iii) third generation (post 1975; e.g. felbamate, 
lamotrigine, levetiracetam, gabapentin, pregabalin, oxcarbazepine, tiagabine, vigabatrin, 
zonisamide, topiramate, lacosamide, rufinamide, eslicarbazepine, perampanel, ezogabine, and 
stiripentol) (Scharfman, 2015; Kanner et al., 2018b; Kanner et al., 2018a).  
Most of the AEDs act through one or more of these five mechanisms- i) blocking 
voltage-gated sodium channels, ii) blocking voltage-gated calcium channels, iii) antagonising 
glutamatergic neurotransmission, iv) enhancing GABAergic neurotransmission and v) 
modulating potassium channels. Sodium channels are responsible for initiation and 
transmission of action potentials and thus play important role in epilepsy (Wallace et al., 
1998). Drugs such as phenytoin, carbamazepine, oxcarbazepine, lacosamide and lamotrigine 
exert their anticonvulsant activity mainly by blocking the voltage gated sodium channels 
(Brodie, 2017). The T-type calcium channels regulates the intrinsic thalamocortical 
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oscillations which trigger the spike-wave discharges in generalised absence seizures 
(Huguenard, 2002). Ethosuximide acts by inhibiting these subtypes of calcium channels in the 
thalamocortical network thus demonstrates high efficacy in the treatment of absence seizures 
(Coulter et al., 1989). Additionally, the effectiveness of zonisamide and valproate in absence 
epilepsy may also be attributed to their action on T-type calcium channels (Broicher et al., 
2007). Further, AEDs such as phenobarbital, primidone and benzodiazepines (e.g. diazepam, 
lorazepam, clonazepam) demonstrate their anticonvulsant action by modulating the GABAA 
receptor and enhancing the GABAergic neurotransmission. Again, tiagabine and vigabatrin 
act indirectly by enhancing the GABAergic tone which are mediated by inhibition of GABA 
transporter GAT1 and antagonisation of the GABA transaminase, respectively (Thompson 
and Gahwiler, 1992; Loscher et al., 1989). The mechanism of action of valproate is although 
not clear, it has been suggested that valproate mainly acts through enhancing the GABA 
concentration in the brain (Meldrum, 1980). As previously mentioned that glutamate is the 
main excitatory neurotransmitter in the brain, thereby blockade of fast ionotropic AMPA 
glutamate receptor by perampanel also demonstrates antiseizure activity (Hanada et al., 
2011). Topiramate has a diverse mode of actions which includes inhibition of voltage-gated 
sodium channels, enhancement of GABAergic neurotransmission via modulating the 
GABAA-receptor, antagonising the AMPA glutamate receptor, and inhibition of the carbonic 
anhydrase enzyme (McMillin and Krasowski, 2016). Voltage-gated potassium channels help 
to maintain the ionic balance in the neurons by permitting the efflux of potassium ions in 
response to the depolarisation caused due to sodium ion influx, thus a positive modulation of 
potassium ion channels help in the control of seizures (Rundfeldt, 1997). AEDs such as 
Ezogabine and retigabine are acting as agonist of Kv7 potassium channels (Kv7.2–Kv7.5), 
present in the nervous system and have been demonstrated to be efficacious in the treatment 
of focal seizures (Tatulian and Brown, 2003; Rundfeldt, 1997).  
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Despite the availability of a large number of AEDs, refractoriness or drug-resistance 
remain a major concern as approximately 30% of people with epilepsy are resistant to one or 
more of these AEDs (WHO, 2018). Additionally, drug related adverse effects contribute to 
poor quality of life (discussed in Section 1.2). All these highlight the need for discovery of 
new safe but efficacious AEDs. 
 
1.1.5 Classification of seizures 
The ILAE has recently categorised seizures into three types (Figure 1.1) such as focal, 
generalised and unknown types depending on their origin (Fisher et al., 2017). Focal seizures 
originate in a small area of one cerebral hemisphere, whereas generalised seizures begin in 
both hemispheres of the brain and involve the whole brain neuronal network. Further, the 
type of seizures whose origin/onset are unknown are considered as ‘unknown-onset’ type 
(Fisher et al., 2017).  
State of awareness has been optionally included in further classifying focal seizures 
into ‘aware’ (formerly known as simple) and ‘impaired awareness’ (formerly known as 
complex) seizures which however can be ignored if the awareness level is unknown (Fisher et 
al., 2017). The focal seizures are further subclassified into motor and nonmotor types. Motor 
seizures may be of different types such as atonic (loss of body tone), tonic (sustained 
stiffening of limbs and neck), clonic (rhythmic jerking of limbs), myoclonic (irregular, brief 
jerking of limbs) and epileptic spasm (flexion or extension of arms and flexion of trunk) 
(Fisher et al., 2017; Blume et al., 2001). An example of nonmotor seizure is behavioural 
arrest which is characterised by cessation of movement and unresponsiveness. Seizures which 
after focal onset become generalised tonic-clonic (previously known as grand mal) are called 
as ‘focal to bilateral tonic-clonic seizures’ (Fisher et al., 2017). Tonic-clonic seizures present 
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with bilateral symmetric convulsive movements (stiffening followed by jerking) of all limbs 
(Blume et al., 2001). 
In case of classifying generalised onset seizures, awareness level is not considered 
because in most of the cases awareness is impaired, thus these types of seizures are classified 
into motor and nonmotor/absence (sudden cessation of activity and awareness) categories. 
Motor generalised seizures include tonic-clonic or other motor such as atonic, tonic, clonic 
and myoclonic seizures (Fisher et al., 2017).  
Similar to generalised onset seizures, the unknown type seizures are also subclassified 
as motor and nonmotor types. Additionally, an ‘unclassified’ section has been kept in the 
‘unknown onset’ type to represent the seizures that do not fit into other categories or the 
available information are inadequate to categorise them. ILAE cited an example to explain 
the unclassified seizures ‘‘A 75-year-old man known to have epilepsy reports an internal 
sense of body trembling and a sense of confusion. No other information is available. EEG 
and MRI are normal. This event is unclassified.’’ (Fisher et al., 2017) 
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Figure 1.1. ILAE 2017 classification of seizure types (basic version). Adapted from 
(Fisher et al., 2017). Seizures are primarily classified into focal, generalised and unknown 
types based on their origin/onset. Awareness level is optionally added for classification of 
focal seizures. Focal, generalised and unknown types are further subclassified into motor and 
nonmotor types. Focal seizures if become generalised tonic-clonic then they are termed as 
‘focal to bilateral tonic-clonic seizures’. Seizures with insufficient information or that do not 
fit into other categories are termed as ‘unclassified’.  
 
1.1.6 Classification of epilepsy 
In 2017, the ILAE classified epilepsy into four major categories i) focal ii) 
generalised, iii) combined generalised and focal, and iv) unknown (Scheffer et al., 2017) 
(Figure 1.2). This classification provides the clinicians a well-defined therapeutic approach to 
treat epilepsies. In the new epilepsy classification framework, the first step for clinicians is to 
identify the seizure type which is followed by the classification of the epilepsy type (Scheffer 
et al., 2017). This classification has the provision for diagnosis of more specific epilepsy 
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syndromes such as West syndrome, childhood absence epilepsy and Dravet syndrome. An 
epilepsy syndrome is a cluster of clinical, electrical and age-dependent features which 
together define a specific epileptic disorder  (ILAE, 1989). It is to be noted that a person must 
be diagnosed as epileptic according to the definition of epilepsy given by the ILAE in 2014 
before his/her epilepsy type can be classified (Fisher et al., 2014). In this classification, a 
major focus has been given on aetiologies and comorbidities in every step of the diagnostic 
process (Scheffer et al., 2017).  
 
Figure 1.2. ILAE classification of epilepsies. Adapted from (Scheffer et al., 2017). Based 
on different types of seizures, epilepsy has been classified into four major types i.e. focal, 
generalised, combined generalised and focal, and unknown. The third level in this 
classification system is to identify the specific epilepsy syndrome where possible. Further, 
aetiologies and comorbidities need to be considered for a precise diagnosis of the epilepsy 
type. 
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Currently a large number of epilepsy types are recognised, all of which are mentioned 
on the website of the Epilepsy Foundation (Scharfman, 2015), but in the interest of this 
project I will only highlight two of them i.e. temporal lobe epilepsy and Dravet syndrome in 
the next two sections.  
1.1.7 Temporal lobe epilepsy (TLE) 
Temporal lobe epilepsy (TLE) is one of the most common form of epilepsy characterised 
by recurrent, unprovoked focal seizures which originate in the temporal lobe of the brain 
(Manford et al., 1992; Fisher et al., 2017). Inside the temporal lobe, the seizure foci of TLE 
usually are located in the hippocampus, amygdala, subiculum and entorhinal cortex (Bertram, 
2009). A focal seizure in TLE may spreads across other brain areas to become a focal to 
bilateral seizure (Bone et al., 2012). Several etiologies have been attributed to TLE which 
includes head injury, cerebral stroke, structural lesion, brain tumour, brain infection or 
idiopathic (Blair, 2012). TLE may be of two types i.e. mesial temporal lobe epilepsy (MTLE) 
and lateral temporal lobe epilepsy (LTLE) (Engel, 2001). The MTLE is the most common 
type where seizure foci are located at the medial or inner aspect of the temporal lobe such as 
hippocampus, parahippocampal gyrus and amygdala (Engel, 2001). The LTLE is in contrast a 
rarer type where seizure foci are located at the lateral or outer surface of the temporal lobe 
(Engel, 2001). TLE, though rare may be of hereditary e.g. autosomal dominant LTLE which 
is associated with LGI1 gene (Nobile et al., 2009). In addition to clinical manifestation of 
spontaneous seizures, TLE is often accompanied by several pathological features like 
hippocampal sclerosis, mossy fiber sprouting, dispersion in the granule cell, astrogliosis and 
blood brain barrier damage (Pitkanen and Lukasiuk, 2011; Vrinda et al., 2018). Along with 
seizures several other diseases/conditions such as anxiety, depression, suicidality, motor 
deficit and memory impairment are often associated with TLE which significantly reduced 
the patient’s quality of life (England et al., 2012) (See section 1.2). Of importance, TLE is 
   
  Chapter 1 
17 
 
often refractory in nature and none of the presently available drugs can provide satisfactory 
control over seizures and associated conditions (comorbidities) (Asadi-Pooya et al., 2017). 
1.1.8 Dravet syndrome 
Dravet syndrome is a severe form of myoclonic epilepsy in children that usually begins 
at six to nine months of age with the first presentation of seizures (Dravet et al., 2005). In 
1978, Dr Charlotte Dravet first characterised this disease as severe myoclonic epilepsy of 
infancy (SMEI) and this early onset,  distinguishes it from other similar paediatric epilepsies 
such as Lennox-Gastaut syndrome, which typically manifests after the age of one (Dravet et 
al., 2005; Kalume, 2013). Dravet syndrome is a rare (orphan) disease affecting ~1 in 20,000-
40,000 children (Shmuely et al., 2016). It is typically triggered by a fever which initiates the 
first generalised or partial seizure (Dravet et al., 2005). During the first year of life, seizures 
are relatively infrequent but, over time, can lead to status epilepticus. In subsequent years the 
symptoms become more severe with generalised tonic-clonic, myoclonic, absence and focal 
seizures being common, status epilepticus rarely occurs after 10 years of age (Akiyama et al., 
2010). A premature mortality rate of 21% has been reported in Dravet syndrome patients 
(Dravet et al., 2005; Genton et al., 2011). Apart from seizures, several additional 
comorbidities are associated with Dravet syndrome (e.g. psychomotor developmental delay, 
gait abnormality (crouch gait), hyperactivity, attention deficit, autism, sleep disorder, anxiety-
like behaviours, language impairment and severe cognitive deficits) which exert a profound 
adverse effect upon patient quality of life (Black and Gaebler-Spira, 2016; Brunklaus et al., 
2011; Genton et al., 2011; Li et al., 2011).   
The SCN1A gene which encodes NaV1.1, a voltage-gated sodium channel, plays a 
pivotal role in Dravet Syndrome.  It has been reported that 70-80% of patients exhibit a 
deletion or mutation (truncating, missense or splice site mutations leading to loss of function) 
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of this gene on chromosome 2q, where 85% are de novo mutations (Harkin et al., 2007; 
Marini et al., 2011). Although the SCN1A gene is expressed in neuronal cell membranes of 
the central and peripheral nervous systems (Black and Gaebler-Spira, 2016), higher 
expression has been observed in hippocampal GABAergic inhibitory interneurons such that a 
loss-of-function mutation leads to abnormal interneuron firing and subsequent disinhibition to 
promote the severe myoclonic epilepsy observed in Dravet Syndrome (Cheah et al., 2012; Yu 
et al., 2006). Mutations in some other epilepsy-associated genes e.g. SCN1B, STXBP1, 
GABRA1, GABRA2, CHD2 and PCDH19 have also been reported to play a role in Dravet 
syndrome (Carvill et al., 2014; Depienne and LeGuern, 2012). The genetic mutation often 
contributes to the manifestation of the disease independently of the seizures, which is why 
Dravet syndrome is also referred as a ‘channelopathy’ (Brunklaus and Zuberi, 2014).  
Presently the major therapeutic strategies include a conventional AED (e.g. valproate, 
clonazepam etc.) in combination with a newer drug (e.g. stiripentol, topiramate etc.) 
(Ceulemans et al., 2004; Chiron, 2005). Since conventional sodium channel blocking AEDs 
(e.g. carbamazepine and lamotrigine) affect the NaV1.1 channel, their use can actually worsen 
seizures in Dravet syndrome and has been associated with premature death (Arzimanoglou, 
2009; Guerrini et al., 1998). Seizures in Dravet syndrome are largely refractory to treatment 
and none of the presently available medications offer satisfactory control of symptoms 
(Devinsky et al., 2017; Devinsky et al., 2018b).  
1.1.9 Animal models of seizures and epilepsy 
Animal models of seizures and epilepsy provide valuable information on disease 
pathogenesis and help in the discovery of new AEDs. In the scope of this thesis, here I will 
provide a general overview of animal models that are currently in use for drug screening and 
then specifically describe the models of TLE and Dravet syndrome.  
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Animal models that are presently used for the screening of novel AEDs are mainly the 
models of epileptic seizures such as maximal electroshock seizure (MES), 6 Hz psychomotor 
seizure and subcutaneous pentylenetetrazole (s.c. PTZ) tests (White et al., 1995; Patra et al., 
2018). The MES test is predictive of generalised tonic-clonic seizures where a suprathreshold 
electrical stimulus is applied to a rat (150 mA) or mouse (50 mA) transcorneally for a brief 
period of time (0.2 seconds) for seizure induction (White et al., 1995; Patra et al., 2018). The 
6-Hz psychomotor seizure model in mice is also a useful model for drug screening of 
refractory partial epilepsy (White et al., 1995; Patra et al., 2018). In this model, a 6 Hz 
corneal stimulation is applied at two currents (22 mA and 44 mA) for 3 seconds (White et al., 
1995; Patra et al., 2018). Notably, 22 mA current intensity is able to evoke seizures in 97% of 
test mice (Barton et al., 2001). The typical characteristics of this type of seizures are 
exhibited by a minimal clonic phase followed by stereotyped behaviours that are considered 
similar to the aura of human with partial seizures (Toman et al., 1952; Barton et al., 2001). 
The s.c. PTZ seizure test is considered suitable test to assess the anticonvulsive effect of non-
convulsive seizures such as absence or myoclonic seizures. For this test, a convulsive dose of 
PTZ (that causes clonic seizure in 97% animals for 3 seconds duration) is injected to an 
animal and observed for 30 minutes. Another popular model for drug screening is corneal 
kindling model of focal seizures (Matagne and Klitgaard, 1998; Patra et al., 2018) where 
kindling is done by stimulating the optic nerve through corneal electrodes (3 mA, 60 Hz, 3 
seconds) until the animals reach a criterion of 5 consecutive secondarily generalised seizures 
(Stage 4 or 5, as described by Racine (Racine, 1972)). This is not an acute model and usually 
takes 10-15 days for animals to be kindled and ready for drug testing (Matagne and Klitgaard, 
1998; Patra et al., 2018). The above-mentioned models are easy to generate, aid rapid 
screening of a large number of compounds and are able to predict the clinical efficacy of 
AEDs to a certain extent (White et al., 1995; Barker-Haliski et al., 2017). However, the major 
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drawback is that they do not reproduce the spontaneous recurrent seizures (SRS), thus cannot 
be considered as true models of epilepsy (Modebadze et al., 2016). 
Currently the pilocarpine model of SRS is used in preclinical research to investigate 
effects of candidate drugs on SE, epileptogenesis, SRS or TLE (Andre et al., 2007; Francois 
et al., 2011; Furtado et al., 2011). In this model, a single large dose of pilocarpine (300-400 
mg/kg) is used to induce SE in rats (Biagini et al., 2006; Goffin et al., 2007). Pilocarpine is a 
muscarinic M1 acetylcholine receptor agonist, therefore activation of cholinergic neuron leads 
to an increased level of glutamate in hippocampus region. This increased level of glutamate 
then damages the fine excitatory and inhibitory neuronal networks resulting into 
manifestation of seizure (Smolders et al., 1997). NMDA receptors activation then helps in 
maintenance of seizure (Smolders et al., 1997). However, the most significant problem with 
this model lies in its high mortality rate during or immediately after SE induction (20-85%) 
(Andre et al., 2007; Mueller et al., 2009). Therefore, this model has been refined to reduce 
the mortality rate and to produce progressive neurodegeneration and epileptogenesis. During 
this refinement process, the lithium pilocarpine model was initially introduced where pre-
administration of lithium chloride potentiates pilocarpine’s convulsant properties thereby 
manifestation of SE can be observed at a comparatively lower dose of pilocarpine (Jope et al., 
1986; Mueller et al., 2009). A further refinement to this model is termed as the reduced 
intensity status epilepticus induced spontaneous recurrent seizures (RISE-SRS) where 
repeated low doses of pilocarpine are used instead of a single high dose along with 
administration of muscle relaxant like xylazine in between the SE process and finally a stop 
solution which helps the animals to recover from SE state (details given in chapter 2) (Glien 
et al., 2001; Curia et al., 2008; Modebadze et al., 2016). The RISE-SRS model exhibits a 
similar disease progression and pathology as the traditional post-SE models, but with reduced 
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mortality during the immediate post-SE period (Modebadze et al., 2016). This model is thus 
suitable for testing candidate drugs to investigate their prolonged disease modification effects. 
The conventional AED screening models do not represent the genetic epilepsy like 
Dravet syndrome as the former models are largely based on chemical or electrical insults.  
Currently, various mouse models are available which represent the loss of SCN1A gene 
function as commonly observed in human Dravet syndrome. These models include knock-out 
models which were developed following a targeted deletion of exon 1 (Scn1atm1Kea) (Miller et 
al., 2014) and exon 26 (Scn1atm1Wac) (Yu et al., 2006) of the mouse Scn1a gene. Further, 
specific point mutation knock-in mouse model such as Scn1a R1407X (Ogiwara et al., 2007), 
Scn1a R1648H (Martin et al., 2010) and Scn1a E1099X (Tsai et al., 2015) are also exist. 
 Comorbidities associated with epilepsy 
When other distinct clinical diseases or syndromes are present alongside the index 
disease (e.g. epilepsy) then these associated diseases/syndromes are referred as comorbidities 
of that index disease (Feinstein, 1970). It is reported that ~50% of epileptic adult individuals 
have at least one comorbidity (Forsgren, 1992). According to Boro and Haunt “nearly every 
patient with epilepsy will experience a comorbid medical condition at some point during the 
course of treatment” (Boro and Haut, 2003). The comorbidities commonly associated with 
epilepsy includes psychiatric, cognitive and medical conditions such as depression, anxiety, 
suicidality, attention deficit hyperactivity disorder (ADHD) and autism, memory impairment, 
and motor deficits (Hesdorffer et al., 1996; Hesdorffer et al., 2006; Hesdorffer et al., 2012; 
England et al., 2012; Chang et al., 2011; Cleary et al., 2004). These comorbidities have 
significant consequences including high premature mortality, poor quality of life, increased 
medical expenses and poor prognosis of disease (Kwan et al., 2009; Fazel et al., 2013; 
Kanner et al., 2012). Moreover, the treatment of these comorbidities (e.g. antidepressant 
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therapy) sometimes results into poor seizure outcome (Coupland et al., 2011; Hill et al., 
2015). Studies have indicated that AEDs could also worsen comorbidities which leads to 
discontinuation of antiepileptic therapy and thereby poor disease management (Perucca et al., 
2009; Chen et al., 2017a; Chen et al., 2017b). Hence, it is imperative to understand the 
complex association between the comorbidities and epilepsy for a better therapeutic outcome. 
In this section, I will focus on the most common comorbidities associated with epilepsy. 
1.2.1 Depression 
It has been documented in epidemiological studies that depression is more prevalent 
in people with epilepsy compared to other diseases (Mendez et al., 1986). The lifetime 
prevalence rate of depression among people with epilepsy extends from 11 to 62% (Wiglusz 
et al., 2012). Interestingly, a meta-analysis conducted on 5,434 epileptic patients across the 
globe reported that depression is more prevalent in female than in male patients (26.4% vs 
16.7%) (Kim et al., 2018). In paediatric epileptic patients, the rate of depression ranges from 
30-70% (Plioplys, 2003; Kanner, 2003) which is especially higher in adolescent (Thome-
Souza et al., 2004). The amygdala and the hippocampus, two key structures of the temporal 
lobe are associated with the pathology of depression (and also anxiety) (Jones et al., 2008; 
Lopes et al., 2016). It has been observed from imaging studies that individuals with TLE and 
depression have hippocampal atrophy (Rosso et al., 2005; Richardson et al., 2007). 
Moreover, the condition is aggravated if epilepsy and depression both persist together 
(Richardson et al., 2007; Gilliam et al., 2007). However, the relationship between epilepsy 
and depression is unlikely to be unidirectional as several reports suggested that people with 
depression are also with higher risk of developing epilepsy. For instance, data obtained from 
UK General Practice Research Database showed a significantly higher incidence-rate ratio of 
depression in people three years before they were diagnosed with epilepsy (Hesdorffer et al., 
2012). Other studies have supported this notion and reported that people with depression have 
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up to 7 times higher risk of developing epilepsy (Hesdorffer et al., 2006; Hesdorffer et al., 
2000; Salpekar and Mula, 2018).  
1.2.2 Anxiety 
Prevalence of anxiety disorders among people with epilepsy is also significantly 
higher. As an example, data obtained from two United States national surveys showed that 
people with epilepsy have two times higher incidence of anxiety disorders than the general 
population (Ottman et al., 2011; Kobau et al., 2006). A large Canadian national population 
health survey also reported a similar trend (Tellez-Zenteno et al., 2007). According to this 
study, anxiety disorders were observed in 22.8% people with epilepsy in contrast to only 
11.2% in general population without epilepsy (Tellez-Zenteno et al., 2007).  Further, a 
national population based study in the UK using clinical interviews reported a strong 
association of epilepsy with anxiety disorders (Rai et al., 2012). However, it is interesting to 
note that the prevalence of anxiety amongst people with epilepsy also depends on the 
methods of diagnosis. For example, a meta-analysis conducted on published data until July 
2016 involving 3,221 epileptic patients across the world showed that the prevalence of 
anxiety was only 8.1% when diagnosis of anxiety was based on unstructured clinical 
assessment, whereas this rate was 27.3% when structured clinical interviews were conducted 
(Scott et al., 2017). Notably, the two key structures of brain, amygdala and hippocampus are 
associated with both the anxiety and epilepsy, thus a bidirectional relationship cannot be 
ignored i.e. anxiety not only follows epilepsy, but vice-versa might be true (Jones et al., 2008; 
Lopes et al., 2016). This is supported by a longitudinal cohort study including 3,773 reported 
epilepsy cases from 1993-2005 in the UK general practice research database observed anxiety 
disorders were prevalent in epileptic patients before they were diagnosed with epilepsy 
(Hesdorffer et al., 2012). Again, a Swedish population based case-control study reported that 
patients hospitalised with anxiety disorders are at >2 times higher risk of developing epilepsy 
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(Adelow et al., 2012). Like depression, anxiety disorders are also found to be associated with 
drug related adverse effects (Jacoby et al., 2015; Gómez-Arias et al., 2012). 
1.2.3 Suicidality 
Patients with epilepsy are at higher risk of suicides. A multicentre study by Jones et 
al. reported a suicide rate of about 12% among individuals with epilepsy compared with 1.1-
1.2% in the general population (Jones et al., 2003). Further, a large Danish population-based 
case-control study investigated 21,169 suicide cases where they reported a three-fold higher 
risk of suicide among the people with epilepsy than those without epilepsy (Christensen et al., 
2007). In addition to the occurrence of suicide cases, the attempted suicide or suicidal 
intention are also higher among the people with epilepsy (Jones et al., 2003). Based on the 
meta-analysis of  the data obtained from the clinical trials the United States Food and Drug 
Administration (US-FDA) reported that the treatment with AEDs enhance the suicidal 
thoughts among individuals with epilepsy (FDA, 2008). A population-based retrospective 
cohort study in the UK assessed the magnitude of the association between suicide attempts 
and epilepsy where they suggested a common underlying biology in between them 
(Hesdorffer et al., 2016). 
1.2.4 ADHD 
ADHD is a persistent pattern of inattention, hyperactivity and impulsivity which 
affects the normal functioning and development of children (APA, 2013). It is one of the 
most common comorbidities of epilepsy in children (Dunn and Austin, 2004; Thome-Souza 
et al., 2004). ADHD plays a significant impact on the quality of life of the children with 
epilepsy as it not only associated with academic and developmental disabilities but also 
exacerbates other comorbidities such as anxiety and depression (Kwong et al., 2016). The 
prevalence rate of ADHD in children with epilepsy has been reported from 30% to 40% 
   
  Chapter 1 
25 
 
(Cohen et al., 2013; Dunn et al., 2003; Chou et al., 2013). Moreover, approximately 2.5-5.5 
times higher prevalence of ADHD has been observed in epileptic children than those without 
epilepsy (Aaberg et al., 2016). The relationship between epilepsy and ADHD is again 
bidirectional with 3.94 times higher rate of epilepsy in ADHD children compared to the 
children without ADHD (Chou et al., 2013). Further, AEDs such as valproate is associated 
with exacerbation of ADHD (Ahmed and Mohamed, 2015). ADHD if not treated, symptoms 
may persist through adulthood (Ettinger et al., 2015; Salpekar and Mishra, 2014). However, 
ADHD in epilepsy is often untreated because of the common concept that stimulants may 
reduce seizure threshold which further worsen the patients’ quality of life (Davis et al., 2010; 
Salpekar and Mishra, 2014). 
1.2.5 Autism spectrum disorder 
Autism spectrum disorder is a neurodevelopmental disorder characterised by social 
interaction and communication deficits and presence of restricted and repetitive behaviours 
(APA, 2013). Autism is one of the most common comorbidities seen in patients with epilepsy 
especially in children and adolescent (Rai et al., 2012; Selassie et al., 2014). The prevalence 
rate of autism among patients with epilepsy varied from 4 to 21% (Tuchman et al., 2013; 
Reilly et al., 2014; Rai et al., 2012). On the other hand, around 30% of autistic individuals 
develops epilepsy (Viscidi et al., 2013). Interestingly, epileptiform activities have often 
noticed in EEG recordings of autistic children even in the absence of manifestation of 
seizures (Rossi et al., 1995; Mulligan and Trauner, 2014). The reason behind this 
bidirectional relationship between epilepsy and autism may be attributed to involvement of 
common pathophysiology such as a deficit in interneuron function which results in reduced 
inhibitory GABA activity in both the cases (Jacob, 2016). Intellectual disability characterised 
by a low intelligence quotient score (IQ; <70) was reported in patients having both autism 
and epilepsy (Viscidi et al., 2013). A high prevalence of autism have been documented in 
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patients with epileptic encephalopathies including Dravet syndrome and Landau-Kleffner 
syndrome (Besag et al., 2016; Chepure et al., 2018; Rosander and Hallbook, 2015).  
1.2.6 Cognitive impairment 
Epileptic patients often experience cognitive deficits which severely affect their 
quality of life (Nau et al., 2018; de la Loge et al., 2016; Arinzechi et al., 2016; Verche et al., 
2018). The extent of cognitive decline in epilepsy often determined by the type of epilepsy, 
the area of damage, presently active epilepsy, AED treatment, and age and reserve capacities 
of individual (Elger et al., 2004). Cognitive deficits across multiple domains have been 
reported in a range of epilepsy types. For instance, a significant decline in verbal memory 
(Griffith et al., 2003), executive function (Keller et al., 2009), working memory (Winston et 
al., 2013) and alertness (Liu et al., 2016) have been demonstrated in patients with TLE. 
Further, a meta-analysis conducted on the data obtained from studies on frontal lobe epilepsy 
patients reported a higher rate of cognitive problems, particularly in the areas involved in the 
functioning of frontal lobe such as executive functions, attention, and motor skills than 
general population without epilepsy (Verche et al., 2018). Severe cognitive and intellectual 
disability are often encountered by the children with epileptic encephalopathies like Dravet 
syndrome (Acha et al., 2015), Landau Kleffner syndrome (Riccio and Vidrine, 2017) and 
West Syndrome (Riikonen, 1996). It has been reported that patients with Dravet syndrome 
often have severe intellectual deficit, in majority of cases the intelligence quotient (IQ) scores 
remain below 50% (Akiyama et al., 2010). The degree of cognitive decline is also positively 
correlated with the duration of epilepsy i.e. longer the duration worse the cognitive outcome 
(Jokeit and Ebner, 2002).  Further, several AEDs e.g. carbamazepine (Forsythe et al., 1991; 
Meador et al., 2001), phenobarbital (Farwell et al., 1990; Calandre et al., 1990), sodium 
valproate (Stores et al., 1992; Masur et al., 2013), topiramate (Brandl et al., 2010; Dooley et 
al., 1999) have been reported to be associated with memory impairment in epileptic patients. 
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However, the mechanism behind cognitive impairment in epilepsy is far more complex and 
perhaps bidirectional, similar to other comorbidities as described above (Keezer et al., 2016). 
Moreover, the parts of the brain and neuronal network associated with learning and memory 
are often associated with epilepsy, therefore a common pathophysiological pathway might be 
involved in both the conditions (Titiz et al., 2014; Verche et al., 2018). 
1.2.7 Motor disorder and gait abnormalities 
Apart from neurological comorbidities, motor impairment is also frequently reported 
in patients with epilepsy (Beckung and Urebrant, 1997; Gloersen et al., 2000; Reijs et al., 
2010; Kowalski and Di Fabio, 1995; Ottman et al., 2011). A study conducted on 100 patients 
with focal motor epilepsy found that the most common type of motor abnormalities in those 
patients were myoclonus, dystonia, chorea, stereotypies, myoclonus-dystonia and tremor 
(Fasano et al., 2018). Another study conducted on 87 children with cryptogenic partial and 
idiopathic generalised epilepsies found a slowing of psychomotor speed in the epileptic 
children where the authors suggested that cortical inhibition due to excessive neuronal 
discharge in epilepsy might be the reason of this slowing of psychomotor speed (Boelen et 
al., 2005). Further, abnormal gait has also been reported in epileptic children especially those 
with Dravet syndrome (Gitiaux et al., 2016; Rodda et al., 2012). Additionally, treatment with 
AEDs such as phenobarbital, valproic acid, phenytoin and lacosamide have adverse effects on 
motor function and gait in the patients with epilepsy (Zaccara et al., 2004; Ristić et al., 2006; 
Zaccara et al., 2013; Bainbridge et al., 2017). 
1.2.8 Other medical conditions 
Several other medical conditions such as migraine (Ottman and Lipton, 1994), 
multiple sclerosis (Allen et al., 2013), diabetes (Weatherburn et al., 2017) and cardiovascular 
diseases (Rowan, 2005) may also be seen in patients with epilepsy. Moreover, allergy, asthma 
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and osteoporosis although not directly linked to the epilepsy itself, are often linked to AED 
adverse effects (Tellez-Zenteno et al., 2005; Gaitatzis et al., 2012; Pack et al., 2003).   
 Cannabis and cannabinoids 
Cannabis (also known as marijuana) has been used since prehistoric times for 
medicinal, recreational and religious purposes as documented in ancient texts from 
Mesopotamia, India and China (Abel, 1980). The use of marijuana in the treatment of 
convulsions also lie in reports from the Middle East that were ascribed to the scholar Al-
Mayusi (Lozano, 2001) in 1100 and the historian, Ibn al-Badri in 1464 (Aldrich, 1997). 
However, it was not until 1649 that Nicholas Culpeper translated the ‘Pharmacopoeia 
Londonensis’ from Latin into English, and suggested marijuana as a treatment of 
‘inflammation of the head’ (Crawford, 2002). Thereafter, there appears to be no further 
mention of this therapeutic use of marijuana until its introduction to Western medicine from 
India in the 19th century by William O’Shaughnessy (O'Shaughnessy, 1840). Here, alongside 
other reports from the same period describing the control seizures with marijuana extracts 
(McMeens, 1856; McMeens, 1860; Reynolds, 1868). 
Cannabis is mainly obtained from an herbaceous annual plant Cannabis sativa (also 
known as Indian hemp) (Russo et al., 2008). This plant comprises more than 525 chemically 
active natural compounds including cannabinoids, flavonoids, terpenoids and alkaloids 
(Radwan et al., 2009). Of all these the cannabinoids are the most active compounds that 
belong to a C21 terpenophenolic class of compounds and are mainly found in the trichomes 
of female flowers (Elsohly and Gul, 2014). More than 100 cannabinoids have been identified 
so far from the cannabis plant which are popularly known as phytocannabinoids that include 
Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD), cannabidivarin (CBDV), 
cannabigerol (CBG), cannabinol (CBN), Δ9-tetrahydrocannabivarin (Δ9-THCV) and 
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cannabichromene (CBC) (Elsohly and Gul, 2014). These phytocannabinoids primarily exert 
their effects by modulating the endogenous cannabinoid system (discussed below) that plays 
an important physiological role in the regulation of brain, immune and endocrine functions. 
Subsequently, several chemical compounds have been synthesised that can modulate the 
endocannabinoid system which are collectively known as synthetic cannabinoids. 
In the scope of this project, here in this section I will discuss the endocannabinoid 
system and cannabinoids with a prime focus on their role in epilepsy. As this project mainly 
deals with CBD, its therapeutic potential in other diseases will also be briefly discussed.  
1.3.1 The endocannabinoid system 
The endocannabinoid system (Figure 1.3) plays an important physiological role in 
modifying excitatory and inhibitory synaptic transmission in the brain. The canonical 
endocannabinoid system consists of two G protein coupled receptors, CB1 and CB2, with 
endogenous ligands 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide 
(anandamide or AEA), each with unique degradation machinery (Pertwee, 2006; Di Marzo et 
al., 1998). Of the two cannabinoid receptor subtypes, CB1 is most widely expressed in the 
central nervous system, particularly in the mossy cell-granule cell synapses of the 
hippocampus, microglia, astrocytes and oligodendrocytes (Di Marzo et al., 1998). Once 
thought to be exclusively expressed outside the central nervous system, current research 
suggests that CB2 receptors are also expressed in the brain (Li and Kim, 2015), mediating 
neuronal excitability (Kim and Li, 2015) and inflammation in microglia (Atwood and 
Mackie, 2010). Importantly, in addition to acting via the canonical cannabinoid receptors, the 
endocannabinoids can also act via interactions with other receptor types such as the G-protein 
coupled receptor, GPR55 and the transient receptor potential vanilloid receptor (type 1), 
TRPV1 (Armstrong et al., 2009).  
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Of importance in activity-dependent pathophysiological processes such as 
epileptogenesis and epilepsy, the synthesis of endocannabinoids typically occurs “on 
demand” from postsynaptic membrane phospholipids although pre-synthesised 
endocannabinoid reserves are also contained within intracellular storage organelles 
(Maccarrone et al., 2010; Min et al., 2010). However, most commonly, postsynaptic neuronal 
depolarisation triggers membrane phospholipid breakdown by the enzymes diacylglycerol 
lipase (DAGL) and N-acylphosphatidylethanolamine-hydrolysing phospholipase D (NAPE-
PLD) to form 2-AG and AEA respectively (Bisogno et al., 2003; Okamoto et al., 2004). 
Following their synthesis, the endocannabinoids passively diffuse across the presynapse in a 
retrograde fashion to orthosterically bind to and activate presynaptically located CB1 receptor 
to inhibit the release of glutamate or GABA from principal or GABAergic neurons 
respectively (Kano et al., 2009; Armstrong et al., 2009).  The endocannabinoid-mediated 
inhibition of excitatory glutamate or inhibitory GABA release are respectively known as 
depolarised-induced suppression of excitation (DSE) or inhibition (DSI) (Armstrong et al., 
2009).   
Endocannabinoid signalling is thought to play an important role in epileptogenesis 
and the subsequently developed epilepsy. Supplementing depolarisation-induced postsynaptic 
synthesis, endocannabinoids are also synthesised following activation of metabotropic 
glutamate and muscarinic acetylcholine receptors (Maejima et al., 2001; Ohno-Shosaku et al., 
2003). Therefore, in addition to the activity-dependent phasic control of neurotransmitter 
release described previously, this tonic control of endocannabinoid release mediated by G-
protein couple receptors may play an important role in epileptogenesis (Armstrong et al., 
2009). Furthermore, the complexities of endocannabinoid signalling also extend to the 
pharmacological properties of the two principal endocannabinoids. Here, 2-AG (Ki=472 nM), 
while acting as a full agonist at CB1 receptor, exhibits lower affinity for CB1 receptor than 
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AEA (Ki=32 nM) which acts as a partial agonist although 2-AG levels are, on average ~170-
fold higher in brain than AEA (Vemuri and Makriyannis, 2009). Therefore, overall effects on 
the development of seizures may be driven by relative levels of the endocannabinoids in 
particular brain areas (von Rüden et al., 2015; Sugiura et al., 2000). Finally, following 
dissociation from the CB1 receptors, endocannabinoids are rapidly degraded (Alger, 2014); 2-
AG and AEA are catabolised by the enzymes monoacylglycerol lipase (MAGL) and 
alpha/beta-hydrolase domain containing 6 (ABHD6) (Marrs et al., 2010) or fatty acid amide 
hydrolase (FAAH), respectively (McKinney and Cravatt, 2005; Dinh et al., 2002). 
Furthermore, activation of TRPV1 by AEA can trigger enhanced glutamate release 
following an increase in intracellular Ca+2 concentrations (Bhaskaran and Smith, 2010), 
although the concentration of AEA required to activate TRPV1 is greater than that required 
for CB1 receptor activation (Ross, 2003; Manna and Umathe, 2012). Moreover, TRPV1 
activation rapidly leads to desensitisation which, in the presence of persistently raised AEA 
levels, could lead to reduced neuronal activity (Carletti et al., 2016).  
   
  Chapter 1 
32 
 
 
Figure 1.3. Schematic diagram representing the endocannabinoid retrograde signalling 
mechanism (taken from (Zou and Kumar, 2018)). Endocannabinoids are mainly 
synthesised and released from postsynaptic terminals. 2-AG is synthesised from DAG by 
DAGLα, whereas AEA is synthesised from NAPE by NAPE-PLD. The endocannabinoids act 
retrogradely to activate CB1 receptors (CB1Rs) at presynaptic terminals. Activated CB1Rs 
inhibit neurotransmitter (NT) release by suppression of calcium influx. 2-AG can also 
activate CB1Rs at astrocytes to release glutamate. Following its action, 2-AG is degraded to 
arachidonic acid (AA) and glycerol by MAGL. In addition to CB1Rs, AEA can activate the 
TRPV1. Finally, AEA is degraded to AA and ethanolamine (EtNH2) by FAAH. NAPE-PLD 
may also expressed in presynaptic terminals. Thick arrows represent translocation; thin 
arrows represent enzymatic process; blunted arrow represent inhibition. 
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1.3.2 Synthetic cannabinoids  
A number of synthetic cannabinoids have been tested preclinically to assess their role 
in seizures and epilepsy, and it has been discussed in detail in our review article (Rosenberg 
et al., 2017b). The synthetic cannabinoid URB597, an inhibitor of FAAH (degradative 
enzyme of AEA) has been shown to have anticonvulsive effect in a number of preclinical 
seizure models such as MES (Naderi et al., 2011), PTZ-induced (Vilela et al., 2013) and KA-
induced (Shubina et al., 2015) models of seizure. Further, URB602 and WWL123, the 
inhibitors of MAGL and ABHD6 (degradative enzymes of 2-AG), respectively also 
demonstrate anticonvulsive action in PTZ-induced seizure model (Naderi et al., 2011; 
Naydenov et al., 2014). Moreover, AM404, an AEA reuptake inhibitor demonstrated to be 
anticonvulsant in KA-induced (Shubina et al., 2015) and PTZ-induced seizure models 
(Manna and Umathe, 2012). However, at a higher dose it exerts proconvulsant effect in PTZ-
induced seizure model (Manna and Umathe, 2012).  
Direct agonism of CB1 receptor by WIN55,212 produced an anti-convulsant effect in 
MES (Wallace et al., 2001; Naderi et al., 2008; Luszczki et al., 2011) and PTZ-induced 
(Payandemehr et al., 2015; Naderi et al., 2011) rodent models of seizures. Another direct CB1 
receptor agonist, arachidonyl-2'-chloroethylamide (ACEA) also showed anticonvulsive effect 
in MES (Luszczki et al., 2006; Luszczki et al., 2010; Andres-Mach et al., 2012) and PTZ-
induced (Bahremand et al., 2008; Naderi et al., 2015) models of seizure. However, a pro-
convulsant effect of both WIN55,212 and ACEA have also been reported on PTZ seizures 
(Vilela et al., 2013). In addition to the role of CB1 receptors in reducing seizures, recent 
studies suggest that activation of mixed CB1/CB2 receptors or CB2 receptor alone, may 
regulate excitability in the hippocampus, increase excitatory transmission (Kim and Li, 2015), 
and trigger cell-type specific hyperpolarisation following sustained stimulation (Stempel et 
al., 2016). AM1241, a CB2 receptor agonist has been reported to be pro-convulsant in PTZ-
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induced seizure model (de Carvalho et al., 2016). On contrary, studies with mixed CB1/CB2 
receptor agonists (e.g. anandamide, or closely related palmitoylethanolamide) demonstrate 
primarily anti-convulsive effects in MES (Lambert et al., 2001; Wallace et al., 2002) and 
PTZ-induced seizures (Aghaei et al., 2015).  
1.3.3 Phytocannabinoids 
1.3.3.1 Δ9-tetrahydrocannabinol (Δ9-THC) 
Δ9-THC is the most abundantly present chemical constituents of cannabis and is 
primarily responsible for the psychoactive effects accompanying with cannabis smoking 
(Shen and Thayer, 1999). It exerts its action mainly by acting as a partial agonist on the two 
cannabinoid receptors i.e. CB1 and CB2 (Pertwee, 2008). However, non-cannabinoid receptor 
mediated action of Δ9-THC by acting as a positive allosteric modulator of opioid receptors (μ 
and δ) has also been demonstrated (Kathmann et al., 2006). The psychotropic and 
anticonvulsant effects of Δ9-THC are believed to be mediated by CB1 receptor (Shen and 
Thayer, 1999). However, the anticonvulsant effect of Δ9-THC is widely disputed, and 
variable results have been demonstrated in both preclinical and clinical studies; a recent 
review compiled 34 studies involving 6 different animal species reported that Δ9-THC 
showed anticonvulsant in 21, proconvulsant in 1, mixed in 1 and no efficacy in 11 studies 
(Rosenberg et al., 2015). Δ9-THC showed a mixed response in humans as well; for example, a 
study conducted in five children treated with Δ9-THC reported that epilepsy was controlled in 
two of them whereas three patients showed no significant response (Davis and Ramsey, 
1949). Apart from CB1 mediated anticonvulsant effect, its potent anti-inflammatory and 
analgesic effects have been demonstrated in various preclinical models (Sofia et al., 1975; 
Chesher et al., 1973; Rock et al., 2018). Further,  the beneficial effects of Δ9-THC to improve 
neuropathic pain associated with diabetes (Wallace et al., 2015; Selvarajah et al., 2010), HIV 
infection (Ellis et al., 2009; Abrams et al., 2007), brachial plexus avulsion (Berman et al., 
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2004) and multiple sclerosis (Wissel et al., 2006) have been reported in clinical trials. Due to 
its demonstrable efficacy as an analgesic, nabiximols containing  a ratio of 1:1 Δ9-THC:CBD 
(Sativex®; oromucosal spray; GW Pharmaceuticals) has been approved in Europe and Canada 
for the treatment of pain associated with multiple sclerosis (Rog et al., 2007; Langford et al., 
2013; Russo et al., 2016), cancer (Johnson et al., 2013) and rheumatoid arthritis (Blake et al., 
2006). Further, dronabinol and nabilone, the two synthetic Δ9-THC are used for the treatment 
of nausea and vomiting associated with cancer chemotherapy (Badowski, 2017). Moreover, 
dronabinol is beneficial in the treatment of weight loss and loss of appetite in acquired 
immune deficiency syndrome (AIDS) and cancer patients (Badowski and Yanful, 2018). 
Although Δ9-THC has so many beneficial effects, it is associated with several adverse effects 
which limit its use as a therapeutic agent. For example, Δ9-THC has been demonstrated to 
cause sedation, hypomotility (Katsidoni et al., 2013; Rock et al., 2015) and even catalepsy 
(Prescott et al., 1992) in rats. In humans, Δ9-THC has been reported to produce psychosis 
(Kraft et al., 2008; D'Souza et al., 2004), anxiety (D'Souza et al., 2004), euphoria (Wallace et 
al., 2007), slow response (Lee et al., 2013) and impaired decision making (Ramaekers et al., 
2006). Δ9-THC also impairs episodic and working memories in human in a dose dependent 
manner (Curran et al., 2002; Hart et al., 2001). However, recent studies have shown low dose 
Δ9-THC is able to improve memory in old mice (Bilkei-Gorzo et al., 2017; Sarne et al., 2018) 
and provide protection against inflammation induced cognitive damage (Fishbein-
Kaminietsky et al., 2014).  
1.3.3.2 Cannabidivarin (CBDV) 
CBDV is a non-psychoactive cannabinoid which has shown its anticonvulsive effect 
both in vitro and in vivo (Hill et al., 2012). CBDV has been demonstrated to reduce 
epileptiform local field potentials (LFPs) in rat hippocampal brain slices when induced by 4-
aminopyridine (4-AP) and Mg++ (Hill et al., 2012). Further, in a PTZ induced rat seizure 
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model, CBDV significantly attenuated the severity and mortality in the treated group (Hill et 
al., 2012). Moreover, CBDV reduced the tonic-clonic convulsion frequency in mouse models 
of audiogenic and maximal electroshock seizure comparable to sodium valproate (Hill et al., 
2012). Encouragingly, CBDV does not produce any antagonistic effect to commonly 
available antiepileptic drugs and does not induce any significant motor side effect when 
tested by static beam and grip strength task (Hill et al., 2012). The mechanism through which 
CBDV exerts its anticonvulsant action is still not clear. CBDV has little affinity at CB1 
receptor and it has been demonstrated that its anticonvulsant effect is CB1 receptor-
independent (Hill et al., 2013). Further, CBDV has been shown to act through CB2 dependent 
pathways (Scutt and Williamson, 2007). Some in vitro studies also reported that CBDV 
activates TRPV2, transient receptor potential of ankyrin type 1 (TRPA1) and transient 
receptor potential of ankyrin type 2 (TRPA2) receptors, inhibits the L-α-
lysophosphatidylinositol, transient receptor potential of melastatin type 8 (TRPM8) and 
diacylglycerol lipase-α, but whether these contribute to its anticonvulsant action is still not 
clear  (Anavi-Goffer et al., 2012; De Petrocellis et al., 2012; De Petrocellis et al., 2011).  
1.3.3.3 Cannabidiol (CBD) 
CBD is a major non-psychoactive constituent of cannabis which exerts its therapeutic 
potential against several diseases including epilepsy (Thomas et al., 1998). Unlike Δ9-THC, 
CBD shows very low affinity towards CB1 and CB2 receptors which makes it non-
psychoactive (Thomas et al., 1998; Bisogno et al., 2001). However, it has been reported that 
CBD might also act as a negative allosteric modulator of CB1 and CB2 receptors (Thomas et 
al., 2007). At sub- to low- micromolar concentrations, CBD acts as an antagonist of the 
GPR55 (Ryberg et al., 2007), TRPM8 channel (De Petrocellis et al., 2008), and the 
equilibrative nucleoside transporter (ENT), whereas it shows agonistic activity on the TRPA1 
channel (De Petrocellis et al., 2011), the 5-HT1A receptor (Russo et al., 2005), the glycine 
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receptors (Ahrens et al., 2009), and has a bidirectional effect on intracellular calcium (Ryan 
et al., 2009). On the other hand, at higher micromolar concentrations, CBD activates the 
TRPV1 and TRPV2 channels (De Petrocellis et al., 2011), and the peroxisome proliferator-
activated receptor γ (PPARγ) (O'Sullivan et al., 2009). It also inhibits cellular uptake and 
FAAH-catalysed degradation of anandamide (Bisogno et al., 2001). Further, CBD prevents 
adenosine reuptake by blocking the equilibrative nucleoside transporter (Carrier et al., 2006). 
This broad range of action makes CBD a potential candidate for the treatment of several 
diseases which are discussed briefly below. 
1.3.3.3.1 Epilepsy 
The role of CBD in epilepsy has been demonstrated both in preclinical and clinical 
studies. CBD showed marked antiepileptiform properties in vitro in rat brain slices 
experiencing seizure-like activity induced by 4-AP or Mg2+ removal (Jones et al., 2012). 
CBD also reduced both the seizure frequency and mortality in PTZ, penicillin and pilocarpine 
induced acute seizure model of rats (Chiu et al., 1979; Consroe et al., 1982; Hill et al., 2013; 
Hansen et al., 2009; Jones et al., 2010; Jones et al., 2012). Further, the anticonvulsive effect 
of CBD has recently been demonstrated independently by our group and Klein et al. in MES, 
6 Hz psychomotor seizure, and PTZ acute seizure tests and corneal kindling model of chronic 
seizures in mice (Klein et al., 2017; Patra et al., 2018). Our group has also established that a 
single intravenous dose of CBD (10 mg/kg) attenuates the maximum seizure severity in a rat 
model of pilocarpine-induced SE (Patra et al., 2018). Further, CBD (100 mg/kg twice daily; 
i.p. for 5 consecutive days) has been shown to reduce seizures in animal models of Dravet 
syndrome (Kaplan et al., 2017). The same group also demonstrated that a single dose of CBD 
(10 mg/kg; i.p.) improved social deficit in these mice (Kaplan et al., 2017).  
Several clinical studies reported positive effect of CBD on infantile spasms, Lennox-
Gastaut syndrome, tuberous sclerosis complex and other intractable epilepsies in children 
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(Hess et al., 2016; Tzadok et al., 2016; Hussain et al., 2015). An open-label Phase-2 study 
conducted on 137 patients with various epilepsies, reported that CBD exerted a 36.5% 
median reduction in monthly motor seizures and was safe and tolerable (Devinsky et al., 
2016). Further, a randomised double-blind placebo-controlled Phase 3 clinical trial on 120 
drug resistant Dravet syndrome patients reported CBD was well tolerable and reduced 
monthly median seizure frequency from 12.4 to 5.9 in comparison to placebo group where it 
was reduced from 14.9 to 14 (Devinsky et al., 2017). Additionally, two double-blind, 
placebo-controlled clinical trials on 171 (Thiele et al., 2018) and 225 (Devinsky et al., 2018a) 
drug resistant Lennox-Gastaut syndrome patients documented a significant reduction in 
frequency of monthly drop seizures (atonic, tonic or tonic-clonic seizures that could have led 
to a fall) in the CBD treated groups than the placebo controlled groups. Considering the 
tolerability of CBD with promising seizure reduction potential in patients with Dravet 
syndrome and Lenox-Gastaut syndrome, the US-FDA approved CBD (Epidiolex; GW 
Pharmaceuticals) for the treatment of these two diseases (FDA, 2018). 
1.3.3.3.2 Anxiety, depression and psychosis 
The anxiolytic and antidepressant potential of CBD has been extensively studied and 
widely reported the literature. CBD treatment produces anxiolytic effects in rats exhibited by 
increased open arm visits in elevated plus maze (EPM) test (Campos and Guimaraes, 2008; 
Guimaraes et al., 1990; Campos and Guimaraes, 2009), increased number of punished licks 
in the Vogel conflict test (Moreira et al., 2006; Campos and Guimaraes, 2008) and reduced 
freezing behaviours in the contextual fear conditioning test (Bitencourt et al., 2008).  CBD 
also attenuates anxiety-induced rapid eye movement (REM) sleep disruption in rats caused 
due to repeated combination tests involving open field and elevated plus maze tests (Hsiao et 
al., 2012). Further, CBD treatment decreases panic responses in a number of animal models 
of panic disorders such as the elevated T-maze (Soares Vde et al., 2010), electrical 
   
  Chapter 1 
39 
 
stimulation of the dorsal portions of the periaqueductal grey matter (Campos et al., 2013) and 
prey vs predator paradigm (Uribe-Marino et al., 2012). CBD has been shown to have 
antidepressant like activity in healthy rodents in forced swim test (Reus et al., 2011; El-Alfy 
et al., 2010; Zanelati et al., 2010; Sales et al., 2018). Additionally, the antidepressant activity 
of CBD has been demonstrated in genetic (Shoval et al., 2016; Shbiro et al., 2018), olfactory 
bulbectomy (Linge et al., 2016), chronic unpredictable stress (Campos et al., 2013) models of 
depression. The anxiolytic properties of CBD is not limited to preclinical studies, it has been 
demonstrated in both healthy human volunteers (Crippa et al., 2004; Fusar-Poli et al., 2009) 
and social phobia patients (Crippa et al., 2011; Bergamaschi et al., 2011). CBD treatment 
also produces significant improvement of psychosis observed in schizophrenia (Leweke et 
al., 2012; McGuire et al., 2018; Leweke et al., 2018) and Parkinson’s disease (Zuardi et al., 
2009) patients. The molecular mechanisms through which CBD exert its anxiolytic and 
antidepressant effects are still not fully understood. One of the possible mechanism is by 
facilitating the 5-HT1A signalling, as several studies has shown that 5-HT1A receptor 
antagonist WAY-100635 diminishes its anxiolytic and antidepressant activities (Campos and 
Guimaraes, 2008; Soares Vde et al., 2010). The anxiolytic and antipsychotic effect of CBD 
might also be attributed to the enhancement of the endocannabinoid signalling by inhibiting 
the metabolism and uptake of anandamide (Fogaca et al., 2018) or by the activation of the 
TRPV1 receptor to facilitate presynaptic release of glutamate (Campos and Guimaraes, 
2009). In addition to enhanced endocannabinoids signalling, CBD may produce its 
antipsychotic action by acting as a partial agonist on dopamine D2 receptors similar to 
antipsychotic drug aripiprazole (Seeman, 2016). 
1.3.3.3.3 Alzheimer’s disease 
CBD has also shown to have protective role against Alzheimer’s disease in several 
animal models. For instance, CBD reduces amyloid β-induced expression of inducible nitric 
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oxide synthase (iNOS), interleukin-1β (IL-1β), glial fibrillary acidic protein (GFAP) and 
S100 calcium binding protein B in rodent astrocytes, thus attenuates reactive gliosis and 
inflammation associated with Alzheimer’s disease (Esposito et al., 2007; Esposito et al., 
2011). It has been suggested that CBD induced anti-inflammatory and neuroprotective 
properties are mediated through activation of PPARγ (Esposito et al., 2011). CBD treatment 
also prevents amyloid β-induced microglial activation in mice and reverses spatial memory 
deficit in Morris water maze test (Martin-Moreno et al., 2011). Chronic CBD treatment also 
attenuates object recognition memory and social recognition memory deficits in genetically 
modified mouse model (AβPP/PS1 mice) of Alzheimer’s disease (Cheng et al., 2014a; Cheng 
et al., 2014b). Studies have shown the efficacy of CBD and Δ9-THC combinations in 
reversing dementia in mouse models of complex frontotemporal dementia (PK-/-/TauVLW 
mice, taupathy) (Casarejos et al., 2013) and Alzheimer’s disease (AβPP/PS1 mice) (Aso et 
al., 2015; Aso et al., 2016).  
1.3.3.3.4 Parkinson’s disease 
Parkinson's disease is a slow neurodegenerative disease associated with progressive 
death of nigrostriatal dopaminergic neurons that results into several motor abnormalities such 
as bradykinesia, rigidity and tremor (Sethi, 2002). CBD exerts neuroprotective effect in 6-
hydroxydopamine-induced animal model of Parkinson’s disease and reduces progressive 
degeneration of nigrostriatal dopaminergic neurons (Lastres-Becker et al., 2005; Garcia-
Arencibia et al., 2007). Although no large scale studies have been conducted on human 
Parkinson’s patients, few reports suggested an improvement of psychotic symptoms and 
REM sleep disorder in Parkinson’s disease patients (Chagas et al., 2014a; Zuardi et al., 
2009). 
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1.3.3.3.5 Other diseases 
In addition to the above, CBD has also demonstrated its efficacy in pain (King et al., 
2017; Ward et al., 2011; Turri et al., 2018; Gamble et al., 2018), cancer (Shrivastava et al., 
2011; Elbaz et al., 2015; Ramer et al., 2012; Massi et al., 2004), diabetes (Weiss et al., 2006; 
Weiss et al., 2008) and cardiovascular diseases (Durst et al., 2007; Walsh et al., 2010; Rajesh 
et al., 2010). 
 Objectives 
As mentioned previously, epilepsy is a progressive chronic neurological disease 
characterised by seizures and associated comorbidities and almost one third of patients with 
epilepsy are refractory to one or more currently available AEDs. Not only that, the drug 
induced adverse effects are also alarming. Thus, an AED which can take control of both 
seizures and associated comorbidities is the need of the hour. As mentioned before, CBD has 
a multimodal action and it has shown its efficacy against a range of diseases and conditions. 
Further, several studies have demonstrated the beneficial effects of CBD against acute 
seizures, however the effect of chronic CBD administration on seizures and comorbidities 
associated with chronic epilepsy has never been studied. Moreover, the effect of chronic CBD 
treatment on survivability and comorbidities associated with any genetic form of epilepsy 
syndrome has never been evaluated. Therefore, this project was designed to investigate the 
effect of CBD on survivability, seizures and associated comorbidities using animal models of 
TLE and Dravet syndrome to cover both the acquired and genetic form of epilepsies, 
respectively. To fulfil the overall aim of this project, I conducted the following three studies.  
1. First, I evaluated the effect of chronic CBD treatment in a RISE-SRS model of TLE to 
assess its role on seizures and associated comorbidities such as motor control, gait and 
cognition (Chapter 2). 
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2. Secondly, I assessed the effect of long-term CBD treatment in a Scn1a-/- mouse model 
of Dravet syndrome to investigate its role on survivability and welfare of Scn1a-/- 
mice. The welfare parameters assessed were weight change, and total neonatal 
welfare, natural activity, reflex/response to touch, orbital tightening and body 
condition scores (Chapter 3).  
3. Finally, I investigated the effect of chronic CBD treatment in a Scn1a+/- mouse model 
of Dravet syndrome to assess its effect on survivability and comorbidities associated 
with Dravet syndrome such as motor dysfunction, gait abnormalities, social deficit, 
anxiety, depression and cognitive impairment (Chapter-4). 
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 Introduction 
Seizures, whilst the primary symptom, are not the only aspect of temporal lobe epilepsy 
(TLE) that affect a patient’s quality of life. A number of comorbidities (e.g. depression, 
anxiety, motor disorder, cognitive deficits, social dysfunction, etc.) also contribute to a 
reduced quality of life, in addition to the poor prognosis associated with TLE (England et al., 
2012). Furthermore, commonly used antiepileptic drugs (AEDs) such as valproate, phenytoin, 
and lacosamide are also known to produce a variety of cognitive, psychiatric, and motor 
adverse effects (George et al., 2015; Zaccara et al., 2004); thus therapies that do not carry the 
potential for adverse effects liability are in significant clinical demand. In this chapter, I 
investigated the effect of cannabidiol (CBD) in modifying seizures, motor function and 
cognition in a rat model of TLE. 
CBD has been shown to have antiseizure activity in several animal models (Do Val-da 
Silva et al., 2017; Jones et al., 2012; Rosenberg et al., 2017b; Klein et al., 2017). Given its 
anticonvulsant efficacy in Phase 3 clinical trials, in 2018 the U.S. Food and Drug 
Administration (US-FDA) approved CBD (Epidiolex, GW Pharmaceuticals) as a drug for the 
treatment of Dravet Syndrome and Lennox Gastaut Syndrome in patients older than 2 years 
old (Devinsky et al., 2017; FDA, 2018; Thiele et al., 2018). 
Despite the evidence in support of an antiepileptic action of CBD, few studies have 
investigated the potential for CBD to modify epilepsy-related behavioural comorbidities (Do 
Val-da Silva et al., 2017; Jones et al., 2012; Devinsky et al., 2017; Thiele et al., 2018). 
Further, no preclinical study has yet shown that sustained exposure to CBD not only reduces 
seizure burden in a TLE model but can also attenuate the severity of the associated 
behavioural comorbidities. Therefore, I assessed the effects of chronic oral administration of 
CBD on spontaneous seizures and associated behavioural comorbidities in the reduced 
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intensity status epilepticus induced spontaneous recurrent seizures (RISE-SRS) model 
(Modebadze et al., 2016). The RISE-SRS model shares several common features with human 
TLE including the post-insult epileptogenesis process without causing an overall damage of 
the brain, a similar electrophysiological profile (as observed during in vitro recording from 
human brain tissues) and spontaneous recurrent seizures (Modebadze et al., 2016). This 
model is, therefore, ideal for long-duration disease modification studies with candidate 
investigational therapies. Of note, the present study utilised a clinically-relevant treatment 
design, as animals were only enrolled to receive CBD well-after the onset of SRS. The results 
of the present study provide the first demonstration in a preclinical model of TLE to suggest 
that CBD may exert potential disease-modifying effects on SRS and attendant behavioural 
comorbidities. The work in this chapter has contributed towards a peer-reviewed publication 
(Patra et al., 2018). 
 Methods 
2.2.1 Animals and test substances 
All experiments mentioned in this chapter were conducted at the University of 
Reading under license (70/7672) UK Home Office regulations (Animals Scientific 
Procedures Act, 1986) and approved by the Animal Welfare and Ethical review board at the 
University of Reading. The animals were maintained in room with a 12h:12h dark:light cycle 
at 21°C and humidity of 50 ± 10 %, with ad libitum access to food and water throughout the 
study period. Male Wistar rats (>70 g; 3-4 weeks old; Harlan Envigo, UK) were used for the 
induction of reduced intensity status epilepticus (RISE). For this study, CBD (Batch No. 
6046727R) was supplied by GW Pharmaceuticals Ltd (Cambridge, UK). All other drugs and 
chemicals were purchased from Sigma-Aldrich (Poole, UK) unless stated otherwise. 
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2.2.2 Induction of reduced intensity status epilepticus (RISE) 
RISE-SRS was induced as per the method described by Modebadze et al. (Modebadze et 
al., 2016) followed by an initial recovery and epileptogenesis period. In brief, the animals 
were initially injected with a subcutaneous injection of lithium chloride (127 mg/kg; s.c.) and 
returned to their home cage for 24 hours. The following day (24 hours after lithium chloride 
injection), animals were injected with methyl scopolamine, a muscarinic cholinergic receptor 
antagonist (1 mg/kg; s.c.) to provide protection against the pilocarpine-induced peripheral 
side effects. After 30 minutes, the animals were injected subcutaneously with a low dose of 
pilocarpine (25 mg/kg; s.c.) and were observed for 30 minutes for the symptoms of seizure 
activity and scored in Racine’s scale (Table 2.1) (Racine, 1972). If the animals did not reach 
the Racine stage 4 i.e. ‘bilateral forelimb clonus and rearing’ they were injected with further 
doses of pilocarpine (50 and 75 mg/kg each; s.c.) at 30 minutes intervals until they exhibited 
this behaviour. Animals that did not reach Racine stage 4 after 3 pilocarpine injections were 
euthanised by a Schedule 1 method (CO2 asphyxiation followed by cervical dislocation). 
Table 2.1. Racine’s seizure severity scale (Racine, 1972) 
Score Observation 
1 Mouth and facial movement 
2 Head nodding 
3 Unilateral forelimb clonus 
4 Bilateral forelimb clonus with rearing 
5 
Generalised motor convulsion with forelimb clonus, rearing, falling and loss of 
postural tone 
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Once the animal started exhibiting ‘bilateral forelimb clonus and rearing’, they were 
immediately injected with xylazine (2.5 mg/kg; i.m.), an α2 adrenoreceptor agonist that has 
sedative and muscle relaxant properties. The animals were kept in the xylazine-modified SE 
condition for a maximum of 1 hour to reduce seizure severity and prevent seizure-related 
mortality. During this period the animals were held by the experimenters, with cotton buds 
placed gently inside the mouth of the animals to avoid tongue biting. Hypromellose eye drops 
(Medicom Healthcare, UK) were applied periodically to the eyes to prevent dryness. One-
hour post xylazine injection the SE was terminated by a subcutaneous injection of 1 mL/kg of 
‘stop’ solution containing MK 801 (0.1 mg/kg; Tocris Bioscience, UK), diazepam (ethanolic 
solution; 2.5 mg/kg; Hameln Pharmaceuticals, UK) and MPEP (20 mg/kg; Axon Medchem, 
The Netherlands). The animals were held (in hands) for another 30 minutes until they stopped 
having symptoms of SE. If the SE continued beyond 30 minutes, a further injection of ‘stop’ 
solution was given and held for another 30 minutes.  
Once the behavioural manifestation of SE attenuated, the animals were kept on a heat pad 
to maintain body temperature and allowed to recover. The animals were closely monitored 
until they become active, at which point they were injected subcutaneously with 0.5 mL of 
5% sucrose on one side of the body and with 0.5 mL of 0.9% saline on the other side of the 
body for rehydration. The animals were then hand-fed with moist powdered food (standard 
lab chow) and returned to their home cage. Twice daily welfare checks were conducted for 
another 3 days and weight was monitored. Any weight loss of more than 10% across any 2 
consecutive measurements then animals were euthanised by the above-mentioned Schedule 1 
method.  
The steps of RISE induction have been depicted in Figure 2.1. 
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Figure 2.1. Graphical representation of the induction process of reduced intensity status 
epilepticus (RISE) in rats. 1. The rats were first injected with lithium chloride (127 mg/kg; 
s.c.). 2. After 24 hours, they were injected with methyl scopolamine (1 mg/kg; s.c.). 3. 30 
minutes later, they were injected with increasing doses of pilocarpine (≥25 mg/kg; s.c. 
maximum 3 doses) at 30 minutes interval until the severity of seizure reaches Racine scale 
stage 4. 4. Xylazine was injected (2.5 mg/kg; i.m.) to reduce the seizure severity and the 
animals were physically restrained for 60 minutes. 5. A ‘stop solution’ consist of diazepam 
(2.5. mg/kg), MK801 (0.1 mg/kg) and MPEP (20 mg/kg) was injected subcutaneously for the 
termination of status epilepticus (SE). 6. After 2 weeks of post-induction, the post seizure 
behavioural battery tests (PSBB) were conducted twice weekly for the confirmation of 
spontaneous recurrent seizures (SRS)/epilepsy. 
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2.2.3 Confirmation of epilepsy 
The animals were confirmed as epileptic by either visual observation of bilateral seizure 
(Racine scale ≥3) or a total score ≥10 (using touch X pick up scores) from four consecutive 
post-seizure behavioural battery (PSBB) tests, as previously described (Modebadze et al., 
2016). The PSBB tests were conducted twice a week (Tuesday and Friday). The tests 
consisted of two tasks e.g. touch task and pick up task; with the scores obtained from these 
two tasks multiplied together to obtain a total PSBB score. In the touch task, the animals were 
gently poked on the rump with a blunt object (back side of a marker pen used consistently 
throughout the study) and the responses were scored by a previously trained researcher (Table 
2.2). During the pickup task, the rats were picked up by grasping around the body and the 
responses were scored by trained researcher (Table 2.3). However, only animals that were 
classified as epileptic within 4-8 weeks from the day of SE induction were used for the 
analysis of seizures and comorbidities in the RISE-SRS model to minimize any age-related 
variability (Figure 2.2). 
Table 2.2. Touch task in post seizure behavioural battery (PSBB) tests (Modebadze et 
al., 2016). 
Score Observation 
1 No reaction 
2 Rat turns toward instrument 
3 Rat moves away from instrument 
4 Rat freezes 
5 Rat turns toward the touch 
6 Rat turns away from the touch 
7 Rat jumps (with or without vocalisation) 
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Table 2.3. Pick-up task in post seizure behavioural battery (PSBB) tests (Modebadze et 
al., 2016). 
Score Observation 
1 Very easy pickup 
2 Easy pickup with vocalisation 
3 Some difficulty in pickup (rat rears and faces the hand) 
4 Rat freezes 
5 Difficult pickup (rat moves away) 
6 Very difficult pickup (rat behaves defensively or attacks the hand) 
 
2.2.4 Experimental design 
To study the effect of CBD on seizures and associated comorbidities, 20 epileptic rats 
were randomly allocated into two groups with 10 animals daily orally treated with 200 mg/kg 
CBD (Batch No. 6046727R) and 10 animals daily orally treated with vehicle (3.5% 
Kolliphor® HS, Sigma-Aldrich, Poole, UK). 10 age-matched, vehicle-treated non-epileptic 
control rats were also studied. The CBD-treated group was initially treated for 1 week with 
vehicle followed by 1 week with a titrating dose of CBD (starting at 50 mg/kg and increasing 
by 50 mg/kg in every 2 days) to reach the final daily dose of 200 mg/kg. Thereafter 200 
mg/kg dose was continued for 8 weeks until the end of all experiments (Figure 2.2). In line 
with the CBD-treated group both the vehicle-treated groups (non-epileptic/epileptic) were 
treated for 10 weeks with vehicle (Figure 2.2). 
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Figure 2.2. Study timeline. The study consisted of three groups: epileptic vehicle-treated, epileptic CBD-treated and non-epileptic vehicle-
treated (n=10/groups). Following the confirmation of spontaneous recurrent seizures (SRS) the epileptic animals were randomised to either 
vehicle or CBD treatments. The CBD-treated animals were initially treated orally with vehicle for a week followed by one week of oral tapering 
dose of CBD (50-150 mg/kg/day). CBD at 200 mg/kg/day was then administered orally for 8 weeks until the completion of the study. The other 
two groups (epileptic and non-epileptic) were treated with vehicle (3.5% Kolliphor®) for 10 weeks. Epileptic animals were video monitored for 
the assessment of seizure burden and seizure burden ratio. All the animals were assessed on their motor (rotarod and gait tests) and cognitive 
function (hole-board test) during the last two weeks. 
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2.2.5 Assessment of seizures 
All epileptic animals were video monitored 24 hours a day for 7 weeks (Figure 2A). 
Twenty CCTV cameras (TP-101BK, Topica, Taiwan) were established and connected to a 
PC, with video footage recorded using Zoneminder (v1.2.3; Triornis Ltd., Bristol, UK) 
software. Video footage obtained during the light phase (07:00 to 19:00) from initial 4 days 
(at the beginning of treatment; first bin) and final 4 days (before beginning of the behavioural 
experiments; final bin) were coded offline to analyse behaviour. The light phase was selected 
for coding as in this model ~65% spontaneous seizures take place during this phase 
(Farrimond et al., 2009). 
A blinded independent researcher was trained to identify and code severity of convulsive 
behaviour using a modified Racine scale (Table 2.4) as previously described (Sheffler et al., 
2009). Any score of ≥ 3 were recorded as these reflected clearly identifiable motor 
convulsions. Both the severity and frequency of seizures are equally important in estimating 
the seriousness of the disease, therefore seizure burden in each animal was calculated from i) 
first, multiplying each seizure severity with its frequency (number of occurrence) ii) then 
adding up all the scores obtained in step (i) (Barker-Haliski et al., 2015). The seizure burden 
ratio was calculated from the seizure burden by using the formula:  
Mean seizure burden ratio = 
mean seizure burden in final bin
mean seizure burden in first bin
 
A higher seizure burden ratio therefore indicates a worsening of the disease over time. 
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Table 2.4 Modified Racine scale used for coding seizure behaviour for TLE animal 
model; adapted from (Sheffler et al., 2009). 
Score Observation 
0 Normal behaviour 
1 Becoming motionless 
2 Forelimb and/or tail extension, rigid posture 
3 Myoclonic jerks or repetitive movements with head bobbing or “wet dog shakes” 
3.5 Unilateral or bilateral forelimb clonus 
4 Bilateral forelimb clonus and rearing 
5 Bilateral forelimb clonus, rearing and occasional falling 
5.5 Bilateral forelimb clonus, continuous rearing and falling 
6 Tonic-clonic seizure with loss of postural tone 
 
2.2.6 Assessment of motor coordination 
Motor coordination was assessed using an accelerating rotarod (Ugo Basile rotarod 
model 7750) where each animal was placed on a rotating rotarod apparatus that linearly 
accelerated from 5 to 33 rpm over 5 minutes. Latency to fall from the rod (in seconds) was 
recorded, with a maximum score of 300 seconds. Each animal performed 3 trials and average 
latency to fall from the rod was entered into the statistical analysis. The animals were 
returned to their home cage after each trial and an interval of 2 minutes was given between 
two consecutive trials. Animals were habituated to the stationary rotarod for 2 minutes/day 
for two consecutive days before the test day. 
2.2.7 Assessment of gait 
Effect of the disease/treatment on cerebellar function was assessed by monitoring of 
gait patterns. A non-toxic ink was used to mark the hind paws of the rats as they walked on 
white paper (100 cm × 10 cm) lining the floor of a transparent custom-made Plexiglas tunnel 
(100 ×10 ×10 cm) attached to a darkened box at its end. Animals were habituated to the 
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runway for two consecutive days before completing two trials on the 3rd day. Left and right 
stride length were measured by the distance between two successive ipsilateral foot prints, 
whereas the stride width was measured from the distance between one paw print with its 
contralateral stride length at right angle (Wecker et al., 2013). The first and last foot prints 
were not considered for evaluation (Wecker et al., 2013). The mean value of each parameter 
obtained from the two trials represents a biological replicate in statistical test. 
2.2.8 Assessment of cognitive function 
A hole-board apparatus made of Plexiglas (70×70×45 cm), mounted on a table of 72 
cm above the floor level was used to assess the cognitive function of the animals. The 
apparatus consisted of equally spaced 16 holes on its floor each of 2.5 cm in diameter. In this 
experiment, each rat was placed in the center of the hole-board and allowed to freely explore 
the apparatus for 10 min. Four accessible baits (Cheerios®, Nestle) were kept in four holes, 
randomly selected for each animal, but kept constant across all test days. Olfactory cues were 
eliminated by placing inaccessible Cheerios® in all other holes. Prior to onset of testing, 
animals were habituated to the hole-board for four days (two days without bait to let the 
animals acclimatise to the test arena followed by two days with accessible bait in all the 16 
holes to habituate the animals to the rules of the task). Animals were food deprived for 4-5 
hours before tests to enhance motivation to complete the task. Testing was conducted on three 
consecutive days with animals performing five trials each day. Head dips were recorded by a 
video camera (Sony DCR-SX21E) for later analysis. A head dip was scored when the head 
was introduced into the holes at least to eye level of the rodent. Errors consisted of head-
dipping a hole that was baited with an inaccessible Cheerios® (reference memory error; 
RME); or re-dipping a hole that had previously been baited (working memory error; WME). 
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2.2.9 Statistical analysis 
All statistical analyses of behavioural data from the RISE-SRS rats were performed using 
GraphPad Prism 6 software (GraphPad Software, Inc., USA). The normal distribution of the 
values was tested using the D'agostino-Pearson normality test. Seizure burden data obtained 
from epileptic animals (Section 2.2.5) were analysed by Wilcoxon matched pair test (non-
parametric), whereas seizure burden ratio was analysed by Mann-Whitney test (non-
parametric). Fisher’s exact test was further conducted to compare the number of animals from 
both the epileptic groups whose seizure was improved (seizure burden ratio <1). Data 
obtained from accelerating rotarod (Section 2.2.6), gait (Section 2.2.7) and hole-board 
(Section 2.2.8) tests were analysed by one-way ANOVA. If a significant main effect of group 
was found, then Holm-Sidak’s post hoc multiple comparison test was conducted to compare 
the non-epileptic vehicle-treated group with the epileptic vehicle-treated group (to observe 
the effect of disease), and the epileptic vehicle-treated with the epileptic CBD-treated group 
(to observe the disease modifying effect of CBD). Multiple comparisons were corrected in all 
cases. In the hole-board test, two animals from each of the epileptic vehicle-treated and 
epileptic-CBD treated groups did not respond (did not consume any Cheerios® during the 
habituation period), hence were excluded from this test. All data were presented as mean ± 
SEM. In all cases, p<0.05 was considered as the level of significance. 
 Results 
2.3.1 CBD reduced long-term seizure burden in epileptic rats  
To evaluate the effect of chronic CBD administration on disease progression, the 
effect of treatment upon seizure burden and seizure burden ratio was examined. Here, the 
epileptic vehicle-treated rats showed a robust increase in seizure burden from a median value 
of 25.75 (IQR=18.94-39.34) to 30.13 (IQR=21.00-49.91) over the course of the study 
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(Wilcoxon matched pair test, W=53, p<0.01; Figure 2.3A). On the other hand, CBD-treated 
epileptic rats did not demonstrate a time-dependent increase in seizure burden (Wilcoxon 
matched pair test, W=-31, p=0.13; Figure 2.3B) observed by a change of median value from 
28.50 (IQR=26.81-39.75) to 24.75 (IQR=19.69-35.94) in the same time period. 
 
Figure 2.3. Effect of chronic administration of vehicle/CBD on seizure burden in 
epileptic rats. A. Seizure burden before and after vehicle treatment. Median seizure burden 
was increased significantly in this group at the end of the observation period. B. Seizure 
burden before and after CBD treatment. CBD-treated rats showed no change in median 
seizure burden. Data were analysed by Wilcoxon matched pairs signed rank test; n=10/group; 
**p<0.01. 
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Interestingly, the seizure burden ratio was significantly greater in vehicle-treated 
epileptic animals compared to CBD-treated epileptic animals (n=10/group; Mann Whitney 
test, U=22, p<0.05; Figure 2.4A). Moreover, a significantly greater number of CBD-treated 
rats (7 of 10) showed an improvement in disease severity (seizure burden ratio below 1) 
compared to vehicle-treated rats (1 of 10) (Fisher’s exact test, p<0.05, Figure 2.4B).  
 
Figure 2.4. Dot plot and bar diagram showing effect of vehicle/CBD treatment on 
seizure burden ratio in epileptic rats. A. Median seizure burden ratio of epileptic vehicle-
treated and epileptic CBD-treated animals recorded during a 7-week continuous video 
monitoring period. CBD significantly reduced the seizure burden ratio compared to the 
vehicle-treated counterpart (n=10/group; data were analysed by Mann Whitney test; 
*p<0.05). Data are expressed as median, min to max, and interquartile range (IQR). B. 
Number of epileptic vehicle-treated and epileptic CBD-treated animals with seizure burden 
ratio below or above 1 (Data were analysed by Fisher’s exact test; *p<0.05). 
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2.3.2 CBD attenuated motor incoordination associated with epilepsy 
Motor coordination of the animals was tested using the accelerating rotarod. A 
significant difference in time spent on the rotarod was observed among the groups (One-way 
ANOVA; F(2,27)=5.996; p<0.01). Holm Sidak’s post hoc test revealed that both the non-
epileptic vehicle-treated (130.40 ± 3.99 seconds; p<0.05) and epileptic CBD-treated (149.00 
± 13.10 seconds; p<0.01) animals spent significantly more time on the rod, compared to the 
epileptic vehicle-treated group (97.87 ± 12.13 seconds). This indicates that chronic oral CBD 
administration attenuated the TLE-induced motor dysfunction seen in vehicle-treated animals 
(Figure 2.5). 
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Figure 2.5. Dot plot showing effect of chronic vehicle/CBD administration on motor 
coordination of rats in accelerating rotarod test. Mean time spent by non-epileptic vehicle-
treated, epileptic vehicle-treated and epileptic CBD-treated animals on accelerating rotarod 
(n=10/group). Non-epileptic vehicle-treated and epileptic CBD-treated group spent 
significantly more time on the accelerating rotarod compared to the epileptic vehicle-treated 
group. Data are expressed as mean ± SEM; data were analysed by one-way ANOVA with 
Holm-Sidak’s post hoc test; *p<0.05, **p<0.01. 
 
2.3.3 CBD did not exert any adverse effect on gait in epileptic rats 
The gait test was performed to assess left stride length (LSL), right stride length 
(RSL) and stride width (SW) of the animals. The mean values of LSL (Figure 2.6A) of non-
epileptic vehicle-treated, epileptic vehicle-treated and epileptic CBD-treated animals were 
respectively 144.10 ± 5.33, 143.80 ± 5.38 and 145.20 ± 5.85 millimetres, whereas the mean 
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values of RSL (Figure 2.6B) in these groups were respectively 142.80 ± 4.64, 144.80 ± 4.97 
and 147.30 ± 5.64 millimetres (n=10/group). Further, SW (Figure 2.6C) in these groups were 
respectively 41.58 ± 1.27, 44.30 ± 1.19 and 43.34 ± 1.94 millimetres (n=10/group). No 
significant differences between the groups were observed for any of these parameters (One-
way ANOVA; for LSL F(2,27)=0.019, for RSL F(2,27)=0.198, for SW F(2,27)=0.842 ; p>0.05; 
Figure 2.6A-C). These data show that chronic CBD administration does not have any adverse 
effect on gait of the TLE animals. 
 
Figure 2.6. Dot plots showing effect of chronic vehicle/CBD administration on gait of 
rats. A. Left stride length (millimeters) of non-epileptic vehicle-treated, epileptic vehicle-
treated, and epileptic CBD-treated rats (n=10/group). No significant difference in mean left 
stride length was observed among the groups. B. Right stride length (millimeters). No 
significant difference in mean right stride length was observed among the groups. C. Stride 
width (millimeters). No significant difference in mean stride width was observed among the 
groups. Data are expressed as mean ± SEM; data were analysed by one-way ANOVA with 
Holm-Sidak’s post hoc test. 
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2.3.4 CBD attenuated working memory deficits associated with epilepsy  
To assess the effect of CBD on cognitive performance, animals were challenged on 
the hole-board test of reference and working memory.  
A significant difference in number of reference memory errors (RME) was observed 
between groups (One-way ANOVA; F(2,23)=8.83; p<0.01). The Holm-Sidak’s post hoc test 
revealed that epileptic vehicle-treated rats (2.72 ± 0.38; n=8) made significantly more RME 
compared to the non-epileptic vehicle-treated rats (1.11 ± 0.09; n=10; p<0.001; Figure 2.7A). 
However, no significant difference was observed in between epileptic CBD-treated (1.95 ± 
0.34; n=8) and epileptic vehicle-treated rats (Holm-Sidak’s post hoc test; p=0.07; Figure 
2.7A). Interestingly, no significant difference was observed in between epileptic CBD-treated 
and non-epileptic vehicle-treated animals (Holm-Sidak’s post hoc test; p>0.05).  
Similar to RME, a significant difference in working memory errors (WME) was found 
among the groups (One-way ANOVA; F(2,23)=11.28; p<0.001). The Holm-Sidak’s post hoc 
test showed that epileptic vehicle-treated rats (1.87 ± 0.33) made significantly more WME 
compared to both non-epileptic vehicle-treated (0.99 ± 0.09; p<0.01) and epileptic CBD-
treated (0.58 ± 0.05; p<0.001; Figure 2.7B) rats. The data obtained from hole-board test thus 
showed that chronic CBD-treatment attenuated the working memory deficit associated with 
epilepsy in RISE-SRS rats without producing any adverse effect on their reference memory. 
A further correlation analysis was carried out between seizure burden and 
RME/WME, however no correlation was found between seizure burden and RME/WME 
(Appendix-1). 
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Figure 2.7. Dot plots showing the effect of chronic administration of vehicle/CBD on 
spatial memory of rats in hole-board test. A. Reference memory errors (RME) in non-
epileptic vehicle-treated (n=10), epileptic vehicle-treated (n=8), and epileptic CBD-treated 
(n=8) groups. CBD did not significantly affect the reference memory compared to the non-
epileptic vehicle-treated group. B. Working memory errors (WME). CBD significantly 
improved WME in epileptic animals compared to the epileptic vehicle-treated animals. Data 
are expressed as mean ± SEM; data were analysed by one-way ANOVA with Holm-Sidak’s 
multiple comparison test; **p<0.05, ***p<0.001. 
 
 Discussion 
In this study, I demonstrated for the first time that chronic oral administration of CBD 
improves seizure burden ratio, motor comorbidities, and cognitive function in the RISE-SRS 
model of TLE in rats after the onset of symptomatic seizures. My study further supports a 
growing body of evidence to demonstrate that CBD is a well-tolerated and effective therapy 
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for chronic seizures (Devinsky et al., 2017), as well as demonstrating the potential that 
chronic oral administration of CBD may confer disease-modifying effects in a preclinical 
model of TLE. As mentioned in the introduction, this work has been published in the journal 
Epilepsia (Patra et al., 2018). 
TLE is one of the most common forms of acquired epilepsy in humans (Jefferys and 
Jiruska, 2009). A number of FDA-approved antiepileptic drugs, such as valproate, 
phenobarbital and eslicarbazepine, have demonstrated disease-modifying potential in 
preclinical models of chronic seizure (Potschka et al., 2014; Brandt et al., 2006; Brandt et al., 
2010). Further, CBD  has been demonstrated to reduce seizure frequency and mortality in 
PTZ, penicillin and pilocarpine induced acute rat models of seizures (Chiu et al., 1979; 
Consroe et al., 1982; Hill et al., 2013; Hansen et al., 2009; Jones et al., 2010; Jones et al., 
2012). Not only that, in two independent studies conducted by Klein et al., and our group 
have shown that CBD is anticonvulsive in MES, 6 Hz psychomotor seizure, and PTZ acute 
seizure tests and corneal kindling model of chronic seizures in mice (Klein et al., 2017; Patra 
et al., 2018). Moreover, we proved that intravenous CBD (10 mg/kg) administration is able to 
reduce maximum seizure severity in a rat model of pilocarpine-induced SE (Patra et al., 
2018). Nevertheless, this is the first study to demonstrate the effect of CBD in a preclinical 
TLE model. Here, I showed that the vehicle-treated epileptic rats exhibited a notable, time-
dependent increase in disease severity over the course of the study. CBD did not significantly 
reduce seizure burden after seven weeks of treatment; however, it did markedly modify the 
natural disease course following SE, as demonstrated by no overall increase in the seizure 
burden from the first to final seizure monitoring bin (Figure 2.4). Interestingly, seizure burden 
ratio was significantly lower in epileptic CBD-treated animals compared to their vehicle-
treated counterparts, which suggests that CBD is disease-modifying in this model. It is also 
observed that a significantly greater number of CBD-treated animals (70%) showed a 
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significant improvement in disease severity (seizure burden ratio below 1) compared to 
vehicle-treated animals (10%).  
A number of antiepileptic drugs (e.g. phenobarbital, valproic acid, phenytoin etc.) are 
reported to have adverse effect on motor function characterised by dyskinesia in people with 
epilepsy (Zaccara et al., 2004; Ristić et al., 2006; Zaccara et al., 2013; Bainbridge et al., 
2017). Moreover, patients on phenytoin and valproic acid treatment sometimes exhibit 
Parkinsonism (Zaccara et al., 2004). While prior reports suggested that CBD is well-tolerated 
in non-epileptic rats (Jones et al., 2012), no studies have yet been conducted to examine the 
long-term effects of chronic CBD administration on tolerability and motor function in 
epileptic animals. Furthermore, no study has yet administered CBD for disease modification 
purposes after the onset of SRS. In this regard, the present study employed a clinically-
realistic treatment scenario in a preclinical model of TLE to demonstrate that chronic oral 
administration of CBD is associated with notable anticonvulsant efficacy, minimal adverse 
effects liability, and disease-modifying potential well after the onset of symptomatic seizures.  
It is well-known that humans and animals with epilepsy are more sensitive to adverse 
effects of antiepileptic drugs (Klitgaard et al., 2002), thus the present findings that chronic 
oral administration of CBD in rats with epilepsy was not associated with any adverse effects 
further supports the potential of this agent for chronic clinical use in epilepsy patient 
populations. In addition to these drug-induced adverse effects on motor function, motor 
deficits are one of the most common comorbidities exhibited by patients with epilepsy 
(Boelen et al., 2005). Here, I used two well-validated models of motor function, the rotarod 
and gait tests, to assess fine motor control and the gait of animals, respectively (Wecker et al., 
2013; Krishnakumar et al., 2009). Epileptic vehicle-treated animals fell from the accelerating 
rotarod sooner than the non-epileptic vehicle-treated ones, indicating that SRS produced 
significant motor dysfunction related to balance. Similar findings have been previously 
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reported using the rotarod test where motor dysfunction was exhibited by pilocarpine induced 
epileptic rats (Krishnakumar et al., 2009). Importantly though, CBD-treated epileptic animals 
remained on the accelerating rotarod for a significantly longer time than the vehicle-treated 
epileptic animals. Thus, I showed for the first time that CBD is not only well-tolerated by 
epileptic animals after prolonged oral administration, but that CBD reduces the severity of 
motor deficits induced by epilepsy.  
Epileptic rats performed comparably to healthy animals in the gait test which is 
consistent with lack of reports citing gait disorders in adult epileptic patients with TLE. 
However, AEDs such as valproic acid and lacosamide have detrimental effect on gait in 
human patients (Ristić et al., 2006; Bainbridge et al., 2017). I therefore wanted to eliminate 
the possibility that CBD may cause gait deficits. Interestingly in this study, chronic oral 
administration of CBD did not produce any changes in stride length or width in the epileptic 
rats. This result thus demonstrates that the dose of CBD necessary to reduce seizure burden 
was not associated with gait impairing effects in rats with SRS. Clinical trials conducted on 
Dravet Syndrome and Lennox Gastaut Syndrome patients also did not report any gait 
disturbances following CBD administration (Devinsky et al., 2017; Thiele et al., 2018). 
Whether these potential side effects of CBD are also absent in the general TLE patient 
population remains to be defined.  
Cognitive deficits are one of the most common comorbidities associated with TLE 
(Rzezak et al., 2017; Realmuto et al., 2015). For example, patients with TLE often exhibit 
poor executive control and working memory deficits (Lima et al., 2017), whilst amnesia or 
accelerated long-term loss of memory is also frequently reported in patients with TLE (Miller 
et al., 2017). Cognitive function in animals is typically assessed using spatial memory tasks 
measuring reference memory and working memory errors (Douma et al., 1998; Vawter et al., 
1997). Reference memory can be defined as long-term storage of acquired information that 
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remains constant over successive training sessions, while working memory is a form of short-
term memory that refers to storage and manipulation of information acquired within a trial 
session (Olton, 1979). Several spatial memory tasks e.g. radial arm maze, Morris water maze 
and hole-board, have been used to evaluate these two types of memory in rodents (Decker, 
2006; van der Staay, 1999). Here, I employed the hole-board task where epileptic vehicle-
treated rats exhibited impairment of both the working and reference memory aspects of the 
hole-board test. These findings are comparable with previous studies of spatial or 
hippocampus-dependent memory in rats with TLE, e.g. a delayed nonmatching to position 
task (Schipper et al., 2016), eight arm radial maze (Wolf et al., 2016), and Morris water maze 
(Kalemenev et al., 2015). However, reference memory of CBD-treated epileptic animals was 
not significantly different compared to both non-epileptic and epileptic vehicle-treated 
animals, which suggests that although CBD could not improve the reference memory, it 
provided protection against the epilepsy-induced reference memory impairment in these 
animals. Remarkably, the present study showed that chronic oral administration of CBD 
improved working memory function in epileptic animals compared to their vehicle-treated 
counterparts. The beneficial effects of CBD on memory have also been reported which will 
be discussed in greater detail in chapter 5 (Osborne and Solowij, 2017; Martin-Moreno et al., 
2011; Cheng et al., 2014a; Hindocha et al., 2015). Here, I demonstrated that memory deficits 
were improved by CBD which is a novel finding for TLE in rats. Although SRS are the 
primary cause of cognitive decline in TLE (van Rijckevorsel, 2006); the improved cognitive 
function in the CBD-treated epileptic group might be due to a seizure-independent 
mechanism rather than solely by seizure reduction e.g. anti-inflammatory/neuroprotective 
action (Schiavon et al., 2014; Pazos et al., 2012; Cassol et al., 2010). A further detailed 
investigation is thus warranted to shed light on the mechanism by which CBD improved the 
presently tested behavioural comorbidities.  
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 Conclusion 
In this study, I established that oral administration of CBD attenuated seizures, reduced 
motor deficits and improved cognitive function without affecting gait in a RISE-SRS rat 
model of TLE. Moreover, this study demonstrated that CBD has disease modifying effect in 
TLE and highlighted that it is a potential candidate drug for the treatment of spontaneous 
symptomatic seizures of TLE. Notably, this work has recently been published in the peer 
reviewed journal Epilepsia. 
 
   
   
68 
 
  
 
 
 
 
 
 
 
 Effect of CBD in improving 
survivability and neonatal welfare in 
Scn1a-/- mouse model 
  
   
  Chapter 3 
69 
 
 Introduction 
In the previous chapter, I demonstrated the efficacy of cannabidiol (CBD) against 
seizures and associated comorbidities in rat model of temporal lobe epilepsy (TLE). In this 
chapter, I will report the role of CBD on survivability and neonatal welfare in Scn1a-/- mouse 
model of Dravet syndrome which reproduces ataxia, seizures and premature mortality as 
observed in human patients. 
As mentioned in Chapter 1, the SCN1A gene encodes the NaV1.1 subtype of voltage-
gated sodium channels which regulates the inhibitory network of the hippocampal 
GABAergic interneurons (Malo et al., 1991; Yu et al., 2006). Therefore, a loss of function of 
this gene due to mutation leads to abnormal interneuron firing and subsequent disinhibition to 
promote the severe myoclonic epilepsy observed in Dravet Syndrome (Cheah et al., 2012; Yu 
et al., 2006). The present study employed Scn1a-/- mice that exhibit seizures and associated 
behavioural symptoms due to lack of NaV1.1 channel expression at GABAergic inhibitory 
interneurons (Yu et al., 2006). The Scn1a-/- mice differ from human Dravet syndrome by their 
complete loss of expression of NaV1.1 channels, but they reproduce the ataxia, seizures and 
premature mortality commonly observed in Dravet syndrome patients (Yu et al., 2006; 
Kalume et al., 2007). These mice start exhibiting symptoms such as seizures, ataxia, poor 
righting reflex from postnatal day 9 (P9) onwards which become progressively worse over 
time, with animals dying before they reach the age of P16 (Yu et al., 2006; Miller et al., 
2014; Kalume et al., 2007). Due to extreme severity and early mortality, this model is not 
suitable for studying complex behavioural comorbidities but does allow rapid assessment of 
antiepileptic drug (AED) efficacy to justify a larger study (Chapter 4). 
In addition to fast AED screening, the Scn1a-/- mouse model is also useful for the 
evaluation of a number of well-established parameters such as natural activity, 
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reflex/response to touch, total neonatal welfare, orbital tightening and body condition that 
reflect the health and wellbeing of animals (Ullman-Culleré and Foltz, 1999; Wolfensohn and 
Lloyd, 2007; Langford et al., 2010). For instance, the natural activity and reflex/response to 
touch (righting reflex) provide important information on the neonatal motor function 
(Wolfensohn and Lloyd, 2007), while orbital tightening is a potential indicator of pain in 
animals (Langford et al., 2010). Overall health of the animals can be assessed by neonatal 
welfare and body condition scores (Wolfensohn and Lloyd, 2007; Ullman-Culleré and Foltz, 
1999). In the present study, these welfare parameters were therefore used to assess the 
neonatal comorbidities associated with Scn1a-/- mouse model. 
The efficacy of CBD has been demonstrated in several animal models of seizures and 
epilepsy (Do Val-da Silva et al., 2017; Jones et al., 2012; Kaplan et al., 2017) including the 
rat model of TLE (Chapter 2). However, a disease modifying effect of CBD has never been 
assessed in Scn1a-/- mice. Furthermore, as stated earlier, the Scn1a-/- mice present with a 
severe epilepsy phenotype that results in premature death with no currently available 
antiepileptic drugs reported to be efficacious in extending their survival. Conventional 
antiepileptic drug diazepam improved the seizures in these mice but failed to extend their 
survival (Yu et al., 2006). This study was therefore designed to investigate the effect of CBD 
in Scn1a-/- mouse model to evaluate its potential to extend the survivability and modify 
disease associated comorbidities in the Scn1a-/- mice. 
 Methods 
3.2.1 Animals and test substances 
The present experiment was performed following UK Home Office regulations 
(Animals (Scientific Procedures) Act, 1986) under licence 70/8397 “Mouse Model of Dravet 
Syndrome” and was approved by the Animal Welfare and Ethics Review Board at the 
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University of Reading. All mice were maintained in 12h:12h light:dark cycle (experiments 
were conducted during light cycle 8:00-20:00 h), a room temperature of 21°C and humidity 
of 50 ± 10 %, with ad libitum access to food and water. 129S-Scn1atm1Kea/Mmjax heterozygote 
mice (Jackson Laboratory, USA) were maintained in the BioResource Unit at the University 
of Reading (UK) and bred together to obtain Scn1a-/- and wild type (WT) animals (Figure 
3.1). Scn1a-/- and wild type (WT) animals were maintained in the Unit as described earlier 
before entering the study and commencing drug treatment as outlined below. The maternal 
behaviour of the dams was also assessed simultaneously to ensure that any of the parameters 
observed in the study animals (Scn1a-/-/WT mice) were not affected by the dam’s behaviour 
(See 3.2.4.2). At the end of the study, animals were humanely killed by a Schedule 1 method 
(cervical dislocation). CBD (batch no. 6046727R) was supplied by GW Pharmaceuticals 
(Cambridge, UK). All other chemicals were purchased from Sigma-Aldrich (Poole, UK) 
unless otherwise stated. 
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Figure 3.1. Schematic diagram showing breeding and experimental design for this 
experiment. Male and female 129S-Scn1atm1Kea/Mmjax heterozygote (Scn1a+/-) mice were 
crossed to obtain Scn1a+/+ (WT) and Scn1a-/- mice used in the study. Tissue collection (tail 
clippings) and genotyping was conducted in between postnatal day 2 (P2) and P4. On P5 
these animals were randomised into four groups i.e. WT vehicle-treated, WT CBD-treated, 
Scn1a-/- vehicle-treated and Scn1a-/- CBD-treated (n=10/group). The animals were treated 
twice daily subcutaneously with either vehicle (ethanol: Kolliphor®: 0.9% saline=2:1:17) or 
CBD (100 mg/kg) from postnatal day 8 (P8) onwards until P25/death (whichever was earlier). 
Twice daily welfare was conducted to assess body weight, total neonatal welfare, natural 
activity, reflex/response to touch, orbital tightening and body condition scores. Survivability 
was also assessed.  
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3.2.2 Genotyping of animals 
Approximately 1-2 mm of tail tip was clipped from each animal at P2-4. DNA was 
extracted by incubating each sample at 75°C for 5 minutes followed by 95°C for 10 minutes 
(deactivation step) with 20 μL 5X PCRBIO Rapid Extract Buffer A (1u/μL), 10 μL 10X 
PCRBIO Rapid Extract Buffer B (PCR Biosystems, USA) and 70 µL PCR grade water. The 
volume was then adjusted by adding 900 μL PCR grade water followed by centrifugation at 
16000g for 1 minute. The supernatant containing mouse DNA was collected and kept at -
20°C until use. 
1 μL DNA sample solution was amplified in 20 µL PCR reaction mixture containing 
0.4 µL each of: 25 µM forward primer (AGT CTG TAC CAG GCA GAA CTT G) and 
reverse primers (Rwt: CCC TGA GAT GTG GGT GAA TAG; Rmut: AGA CTG CCT TGG 
GAA AAG CG), 10 µL taq mix red (PCR Biosystems, USA) and 7.8 µL Rnase-free PCR 
grade water. The reaction condition included an activation step at 94°C for 2 minutes 
followed by 15 cycles of denaturation (94°C for 2 seconds), annealing (65°C for 15 seconds) 
and extension (68°C for 21 seconds); and another 15 cycles of denaturation (94°C for 15 
seconds), annealing (60°C for 15 seconds) and extension (72°C for 21 seconds) which was 
followed by a final extension at 72°C for 2 minutes. 
After the reaction was complete, samples (10 µL) were loaded in 2% agarose gel 
(stained with 2 μL Syber Safe DNA gel stain, Invitrogen, USA) in 1X TAE (Promega, USA) 
buffer and run for 2 minutes at 70V in a gel electrophoresis apparatus (BIORAD, USA). The 
gel was then observed under a UV transilluminator (Syngene, UK; Figure 3.2).  
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Figure 3.2. Example result from PCR used for genotyping animals produced via 
breeding of the 129S-Scn1atm1Kea/Mmjax transgenic mouse line. Mouse tail DNA was 
amplified with primers for the wild type (WT) and mutated (Scn1a-/-) Scn1a alleles. The 
presence of a 357bp band indicates the WT allele, and a 200bp band indicates the Scn1a-/- 
allele. -ve: negative control; +ve: positive control. 
 
3.2.3 Experimental design 
Following genotyping, animals were randomly divided into four groups WT vehicle-
treated, WT CBD-treated, Scn1a-/- vehicle-treated and Scn1a-/- CBD-treated (n=10/group). 
They were injected subcutaneously twice daily with either CBD (100 mg/kg) or its vehicle 
(ethanol: Kolliphor®: 0.9% saline=2:1:17) from P8 until P25 or death (whichever was earlier). 
A twice daily welfare check was conducted throughout the entire duration of the study. Drug 
administration was conducted at 0800 h and followed by welfare checks. Conversely, 
afternoon welfare checks were conducted from 1600 h and followed by drug administration 
in order to provide the maximum possible time between doses. The experimental timeline is 
depicted in Figure 3.1.  
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3.2.4 Assessment of welfare scores 
3.2.4.1 Neonatal welfare 
Welfare scoring of neonates was conducted twice daily using a blinded spreadsheet 
that lacks the information on the genotype of the animals and the treatment (CBD/vehicle) 
given to them, to ensure the experimenter remained blind to both treatment and genotype. 
Neonatal welfare scoring (Table 3.1) was based upon a previously validated standardised 
approach used widely in murine models (Wolfensohn and Lloyd, 2007; Langford et al., 2010; 
Ullman-Culleré and Foltz, 1999). Here, the parameters used for the welfare assessment were: 
weight, natural activity (NA; 0-3), reflex/response to touch (RT; 0-3), orbital tightening (OT; 
0-2; Figure 3.3), body condition score (BC; 1-3) and surface temperature (ST; 0-2; data not 
shown). Finally, a total neonatal welfare score (TNW; range 0-8) was calculated by adding 
together scores from NA, RT, and ST.  
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Table 3.1. Welfare assessment sheet for neonatal mice; adapted from (Wolfensohn and 
Lloyd, 2007; Ullman-Culleré and Foltz, 1999; Langford et al., 2010) 
Parameters Observations Scores 
i) Natural activity (NA) 
Wriggling ++ (highly active) 0 
Wriggling + (active) 1 
Not active but can move 2 
Still 3 
ii) Reflexes/respond to 
touch (RT) 
Righting reflex +++ (time taken to return back on 
its feet: <1 second) 
0 
Righting reflex ++ (time taken to return back on 
its feet: 1-3 seconds) 
1 
Righting reflex + (time taken to return back on its 
feet: 4-10 seconds) 
2 
No righting reflex - (unable to return back on its 
feet within 10 seconds) 
3 
iii) Surface temperature 
(ST) 
Warm (~35°C) 0 
Partial cold (dorsal/ventral part of the body) 1 
Cold  2 
iv) Total neonatal welfare score (TNW; Sum of scores i to iii) 0-8 
v) Body condition (BC) 
Mouse is emaciated, skeleton is extremely 
prominent, vertebrae distinctly segmented 
1 
Mouse is underconditioned, segmented vertebral 
column evident, dorsal pelvic bones are palpable 
2 
Mouse is well-conditioned, vertebrae and dorsal 
pelvis not prominent, palpable with slight 
pressure 
3 
vi) Orbital tightening (OT)  
(closing of the eyelid or 
narrowing of orbital area- 
see exemplar Figure 3.3) 
Not present 0 
Moderately present 1 
Obviously present 2 
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Figure 3.3. Scoring of orbital tightening in mice to assess pain. Orbital tightening is the 
closing of the eyelid or narrowing of orbital area, a wrinkle might also be visible around the 
eye. Adapted from National Centre for the Replacement Refinement and Reduction in 
Animals in Research (NC3R) and Langford et al (Langford et al., 2010). 
 
3.2.4.2 Dam welfare 
A dam welfare score (range: 0-6; Table 3.2) was also measured to assess maternal 
behaviour where parameters e.g. milk in neonate’s stomach (0-2), nest building (0-2) and 
retrieval of young (0-2) were checked. These parameters were scored in comparison to the 
other WT C57BL/6 mice (not included in the study) maintained in the animal house. A high 
dam welfare score (5-6), indicative of a dam exhibiting weak maternal behaviours or 
impaired recovery from gestation and birth, was undesirable and increased the likelihood of 
rejection of neonates and so presented a confounding factor for a given litter in a study. In the 
present study, dam scores remained 0 throughout the study and so the responses of the pups 
were not considered to have been affected by variations in maternal behaviours.  
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Table 3.2. Welfare assessment sheet for dam; adapted from (Wolfensohn and Lloyd, 
2007). 
Parameters Observations Scores 
Milk in stomach (only applicable 
when the body colour is pink) 
Milk is visible 0 
Milk is slightly visible 1 
No visible milk in stomach 2 
Nest building  
Good nest making 0 
Some nest making 1 
No nest 2 
Retrieval of young 
Always 0 
Sometimes 1 
Never 2 
Total Score 0-6 
 
3.2.5 Assessment of survivability 
Due to UK Home Office limitations imposed upon the use of this model of epilepsy 
due to its severity, animal suffering was minimised by employing a validated, welfare scoring 
system (mentioned in section 3.2.4.1) alongside a mathematical model to predict death 
(Appendix I; developed by M. Bazelot, GW Pharmaceuticals, UK). In this way, any animal 
for which the model predicted death could be sacrificed 0.5 day before enduring the maximal 
severity of the disease. The model used an algorithm to predict death based on prior data 
obtained from untreated Scn1a-/- mice (n=19) that exhibited the maximum severity of the 
disease and died a natural death (data not shown). In this algorithm, the thresholds for each 
parameter (TNW, NA, RT, OT, BC scores) to predict death were obtained using the 
following procedure: (i) each parameter, measured every half day from birth for each animal, 
is averaged with a moving mean with a 1.5 day window; (ii) the least severe score for each 
parameter observed across the 19 animals over 0.5 day before their death was found; (iii) 
each of the 5 parameters exhibited by the animals in the study were compared to scores 
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obtained in (ii) twice a day; (iv) if each of the 5 parameters reached their respective threshold 
defined in (ii) at least once since P8, the animal would undergo a Schedule 1 procedure 
(cervical dislocation) within 0.5 day. Additionally, surface temperature (ST) threshold was 
employed such that if the sum of the ST scores over the last 1.5 days, was equal to or greater 
than 3, the animal would be killed by Schedule 1 procedure (cervical dislocation) within 0.5 
day.  
3.2.6 Statistical analysis 
Welfare parameters were analysed using SPSS 24 (IBM SPSS Statistics®, UK), whilst 
survivability data were analysed using GraphPad Prism 6 software (GraphPad Software, Inc., 
USA). Data obtained from welfare parameters were compared using a three-way ANOVA to 
observe the main effects of treatment, genotype and time, and their two-way and three-way 
interactions. If significant two-way interactions were found the Bonferroni’s post hoc test was 
conducted on any treatment×genotype interactions to assess the effect of CBD treatment on 
different genotypes (WT/Scn1a-/-). The Bonferroni’s post hoc test was also conducted for a 
significant three-way treatment×genotype×time interaction to compare the effect of CBD 
treatment with vehicle treatment at every time point of welfare assessment in both the WT and 
Scn1a-/- groups. In all cases, the post hoc test was corrected for multiple comparisons. Data 
from 2.2% welfare scores were outliers and were excluded from further analysis (±2.5*SD) 
(Miller, 1991). For the survivability data, survival curves from Scn1a-/- vehicle-treated and 
CBD-treated groups were compared using a Mantel-Cox test. No WT animals died during the 
study, so survivability curves were not compared. All the data are expressed as mean ± SEM. 
In all cases, p<0.05 is considered as the level of significance. 
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 Results 
3.3.1 CBD administration improved neonatal welfare 
3.3.1.1 Weight 
The mean weights of WT vehicle-treated, WT CBD-treated, Scn1a-/- vehicle-treated 
and Scn1a-/- CBD-treated group were respectively 7.41 ± 0.09, 7.34 ± 0.09, 4.85 ± 0.09 and 
5.43 ± 0.09 g. A three-way ANOVA showed main effects of treatment (F(1,612)=9.06; p<0.01), 
genotype (F(1,612)=683.41; p<0.001) and time (F(16,612)=13.01; p<0.001) on weight. Overall, 
the weight was higher in CBD-treated animals (6.39 ± 0.06 g) compared to the vehicle-treated 
animals (6.13 ± 0.06 g) and in WT animals (7.38 ± 0.06 g) compared to the Scn1a-/- animals 
(5.14 ± 0.06 g). Here, no three-way interaction among treatment×genotype×time was 
observed (F(16,612)=0.02; p>0.05; Figure 3.4A). Among the two-way interactions, the 
genotype×time (F(16,612)=18.36; p<0.001) and treatment×genotype (F(1,612)=13.96; p<0.001) 
interactions were found to be significant, whilst the treatment×time interaction was not 
significant (F(16,612)=18.36; p>0.05). The Bonferroni’s post hoc analysis was conducted for 
treatment×genotype which showed that CBD treatment increased weight only in Scn1a-/- mice 
(p<0.001) but it did not produce any effect in WT mice (p>0.05).  
3.3.1.2 Total neonatal welfare (TNW) 
The mean TNW scores in WT vehicle-treated, WT CBD-treated, Scn1a-/- vehicle-
treated and Scn1a-/- CBD-treated group were respectively 0.39 ± 0.04, 0.24 ± 0.04, 3.66 ± 
0.04 and 2.85 ± 0.04. Main effects of treatment (F(1,612)=128.78; p<0.001), genotype 
(F(1,612)=4850.12; p<0.001) and time (F(16,612)=57.89; p<0.001) on TNW scores was found. 
Overall, scores were better in CBD treated animals (1.55 ± 0.03) compared to vehicle treated 
animals (2.03 ± 0.03) and in WT animals (0.32 ± 0.03) compared to the Scn1a-/- animals (3.26 
± 0.03). A significant three-way interaction among treatment×genotype×time was observed 
   
  Chapter 3 
81 
 
(F(16,612)=5.46, p<0.001). Two-way interactions were observed for treatment×genotype 
(F(1,612)=62.74; p<0.001), treatment×time (F(16,612)=2.19; p<0.01) and genotype×time 
(F(16,612)=112.22; p<0.001). Bonferroni’s post hoc test was conducted for treatment×genotype 
and treatment×genotype×time interactions. The post hoc analysis for treatment×genotype 
revealed that CBD treatment significantly improved the TNW score both in WT (p<0.05) and 
Scn1a-/- mice (p<0.001). The post hoc comparison for treatment×genotype×time interactions 
revealed that CBD delayed the worsening of welfare scores in Scn1a-/- mice from P12 to P16 
compared to the vehicle-treated Scn1a-/- mice on respective days (p<0.01; Figure 3.4B). This 
post hoc test further showed that CBD improved TNW score in WT animals from P8-P8.5 i.e. 
in first day of treatment compared to the WT vehicle-treated animals on respective occasions 
(p<0.05; Figure 3.4B). 
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Figure 3.4. Plots showing chronic administration of CBD to wild type (WT) and Scn1a-/- 
mice on weight and total neonatal welfare (TNW) scores. A. Weight of WT vehicle-
treated, WT CBD-treated, Scn1a-/- vehicle-treated and Scn1a-/- CBD-treated mice from 
postnatal day 8 (P8) onwards (n=10/group). CBD had no effect on weight in WT mice 
compared to the vehicle-treated WT mice. No three-way interaction of 
treatment×genotype×time was observed on weight. B. TNW scores. CBD significantly 
improved the TNW score in WT mice from P8 to P8.5 compared to the vehicle-treated WT 
mice. CBD significantly improved the TNW score in Scn1a-/- mice from P12 onwards 
compared to the vehicle-treated Scn1a-/- mice. Data are expressed as mean ± SEM; data were 
analysed by a three-way ANOVA with Bonferroni’s post hoc test; #p<0.05; **p<0.01; 
***p<0.001; # represents WT vehicle-treated vs WT CBD-treated; * represents Scn1a-/- 
vehicle-treated vs Scn1a-/- CBD-treated. 
 
3.3.1.3 Natural activity (NA) 
The mean NA score in WT vehicle-treated, WT CBD-treated, Scn1a-/- vehicle-treated 
and Scn1a-/- CBD-treated group were respectively 0.24 ± 0.02, 0.21 ± 0.02, 1.64 ± 0.02 and 
1.35 ± 0.02. A three-way ANOVA revealed the main effect of treatment (F(1,612)=47.24; 
p<0.001), genotype (F(1,612)=3090.07; p<0.001) and time (F(16,612)=28.82; p<0.001) on NA 
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scores. Taken together, the NA score was better in CBD-treated animals (0.78 ± 0.02) 
compared to the vehicle-treated animals (0.94 ± 0.02) and in WT animals (0.22 ± 0.02) 
compared to the Scn1a-/- animals (1.49 ± 0.02). Further, a significant three-way interaction of 
treatment×genotype×time was observed here (F(16,612)=3.12, p<0.05). Two-way interactions 
were observed for treatment×genotype (F(1,612)=34.12.13; p<0.001), treatment×time 
(F(16,612)=2.30; p<0.01) and genotype×time (F(16,612)=81.61; p<0.001). Bonferroni post hoc 
analysis was conducted for treatment×genotype and treatment×genotype×time interactions. 
The post hoc test for treatment×genotype revealed that CBD improved natural activity only in 
Scn1a-/- mice (p<0.001) but not in WT mice (p>0.05). The post hoc analysis for 
treatment×genotype×time revealed that CBD significantly (p<0.05) delayed the worsening of 
NA scores in Scn1a-/- mice from P12 to P16 compared to the vehicle-treated Scn1a-/- mice on 
respective days (Figure 3.5A). 
3.3.1.4 Reflex/response to touch (RT) 
The mean RT score in WT vehicle-treated, WT CBD-treated, Scn1a-/- vehicle-treated 
and Scn1a-/- CBD-treated group were respectively 0.15 ± 0.02, 0.04 ± 0.02, 1.83 ± 0.02 and 
1.42 ± 0.02. The main effect of treatment (F(1,612)=112.78; p<0.001), genotype 
(F(1,612)=3958.19; p<0.001) and time (F(16,612)=32.25; p<0.001) on RT scores was found in 
three-way ANOVA. Altogether the RT score was better in CBD-treated animals (0.73 ± 0.02) 
when compared to the vehicle-treated animals (1.00 ± 0.02) and in WT animals (0.10 ± 0.02) 
when compared to the Scn1a-/- animals (1.63 ± 0.02). The three-way interaction among 
treatment×genotype×time interaction was also noticed here (F(16,612)=5.19, p<0.001). The 
treatment×genotype (F(1,612)=38.05; p<0.001), treatment×time (F(16,612)=2.27; p<0.01) and 
genotype×time (F(16,612)=61.73; p<0.001) interactions were found to be significant. 
Bonferroni post hoc test was conducted for treatment×genotype and 
treatment×genotype×time interactions. The post hoc analysis for treatment×genotype 
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revealed that CBD significantly improved the RT score both in Scn1a-/- (p<0.001) and WT 
(p<0.01) mice. The post hoc analysis for treatment×genotype×time showed that CBD 
significantly improved (lower value) the RT score in Scn1a-/- group from P12 to P14.5 and on 
P16 compared to its vehicle-treated counterpart on respective days (p<0.01; Figure 3.5B). 
The Post hoc test for treatment×genotype×time further revealed that CBD significantly 
improved the RT score in WT animals from P8-P9.5 compared to the WT vehicle-treated mice 
on respective days (p<0.01; Figure 3.5B). 
  
   
  Chapter 3 
85 
 
 
Figure 3.5. Plots showing chronic administration of CBD to wild type (WT) and Scn1a-/- 
mice on natural activity (NA) and reflex/response to touch (RT) scores. A. NA scores of 
WT vehicle-treated, WT CBD-treated, Scn1a-/- vehicle-treated and Scn1a-/- CBD-treated mice 
from postnatal day 8 (P8) onwards (n=10/group). CBD had no effect on NA score of WT 
mice. CBD significantly improved the NA score in Scn1a-/- mice from P12 onwards compared 
to the vehicle-treated Scn1a-/- mice. B. RT scores. CBD significantly improved the RT score 
in WT mice from P8 to P9.5 compared to the vehicle-treated WT mice. CBD significantly 
improved the RT score in Scn1a-/- mice from P12 to P14.5 and on P16 compared to the 
vehicle-treated Scn1a-/- mice. Data are expressed as mean ± SEM; data were analysed by a 
three-way ANOVA with Bonferroni’s post hoc test; ##p<0.01; **p<0.01; ***p<0.001; # 
represents WT vehicle-treated vs WT CBD-treated; * represents Scn1a-/- vehicle-treated vs 
Scn1a-/- CBD-treated. 
 
3.3.1.5 Orbital tightening (OT) 
The mean OT score in WT vehicle-treated, WT CBD-treated, Scn1a-/- vehicle-treated 
and Scn1a-/- CBD-treated group were respectively 0.00 ± 0.00, 0.00 ± 0.00, 0.50 ± 0.02 and 
0.25 ± 0.02. A three-way ANOVA showed the main effect of treatment (F(1,612)=56.67; 
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p<0.001), genotype (F(1,612)=483.67; p<0.001) and time (F(16,612)=65.42; p<0.001) on OT 
score. Altogether, OT score was better in CBD-treated animals (0.12 ± 0.01) compared to 
vehicle-treated animals (0.25 ± 0.01) and in WT animals (0.00 ± 0.00) compared to Scn1a-/- 
animals (0.37 ± 0.01). A three-way treatment×genotype×time interaction was observed 
(F(16,612)=6.78; p<0.001). Further, significant two-way interactions for treatment×genotype 
(F(1,612)=56.66; p<0.001), treatment×time (F(16,612)=6.78; p<0.001) and genotype×time 
(F(16,612)=65.42; p<0.001) were observed. Bonferroni’s post hoc test was conducted for 
treatment×genotype and treatment×genotype×time interactions. The post hoc test for 
treatment×genotype revealed that CBD improved OT score in Scn1a-/- mice (p<0.001) no 
such change was observed in WT mice (p>0.05). The post hoc test for 
treatment×genotype×time revealed that the OT score was better (lower) in CBD-treated 
Scn1a-/- group from P13 until P16 compared to the vehicle-treated Scn1a-/- group on 
respective days (p<0.01; Figure 3.6A). 
3.3.1.6 Body condition (BC) 
The mean BC score in WT vehicle-treated, WT CBD-treated, Scn1a-/- vehicle-treated 
and Scn1a-/- CBD-treated group were respectively 3.00 ± 0.01, 3.00 ± 0.01, 2.71 ± 0.01 and 
2.82 ± 0.01. The main effect of treatment (F(1,612)=36.37; p<0.001), genotype (F(1,612)=623.81; 
p<0.001) and time (F(16,612)=84.18; p<0.001) on BC score was observed in three-way 
ANOVA. Overall, the BC score was better in CBD-treated animals (2.91 ± 0.01) compared to 
vehicle-treated animals (2.86 ± 0.01) and in WT animals (3.00 ± 0.01) compared to Scn1a-/- 
animals (2.77 ± 0.01). A significant treatment×genotype×time three-way interaction was 
observed here (F(16,612)=4.82; p<0.001). The two-way interactions were observed for 
treatment×genotype (F(1,612)=36.37; p<0.001), treatment×time (F(16,612)=4.82; p<0.001) and 
genotype×time (F(16,612)=84.18; p<0.001). Bonferroni’s post hoc analysis was done for 
treatment×genotype and treatment×genotype×time interactions. The post hoc analysis for 
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treatment×genotype revealed that CBD treatment improved this score only in Scn1a-/- mice 
(p<0.001), but it did not exert any effect on WT animals (p>0.05). The post hoc analysis for 
treatment×genotype×time revealed that BC scores were higher (better) in CBD-treated Scn1a-
/- mice from P13.5 until P15.5 compared to the vehicle treated Scn1a-/- mice on respective 
days (p<0.01; Figure 3.6B). 
CBD thus well-tolerated by the WT mice and it delayed the worsening of the welfare 
scores in Scn1a-/- mice compared to their vehicle-treated counterpart. 
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Figure 3.6. Plots showing chronic administration of CBD to wild type (WT) and Scn1a-/- 
mice on orbital tightening (OT) and body condition (BC) scores. A. OT of WT vehicle-
treated, WT CBD-treated, Scn1a-/- vehicle-treated and Scn1a-/- CBD-treated mice from 
postnatal day 8 (P8) onwards (n=10/group). CBD had no effect on OT score of WT mice. 
CBD significantly improved the OT score in Scn1a-/- mice from P13 onwards compared to 
the vehicle-treated Scn1a-/- mice. B. BC scores. CBD had no effect on BC score of WT mice. 
CBD significantly improved the BC score in Scn1a-/- mice from P13.5 to P15.15 compared to 
the vehicle-treated Scn1a-/- mice. Data are expressed as mean ± SEM; data were analysed by a 
three-way ANOVA with Bonferroni’s post hoc test; **p<0.01; ***p<0.001; * represents 
Scn1a-/- vehicle-treated vs Scn1a-/- CBD-treated. 
 
3.3.2 CBD administration increased survivability 
As expected, none of the WT animals died during the study. Survivability of the two 
Scn1a-/- groups were therefore analysed using the Mantel-Cox test. Here, the median 
survivability in the CBD-treated Scn1a-/- mice was significantly higher (16.25 days) compared 
to the vehicle-treated Scn1a-/- mice (15.5 days; X2=8.61; p<0.01; n=10/group; Figure 3.7).  
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Figure 3.7. Plot showing chronic administration of CBD on survival of Scn1a-/- mice. 
CBD treatment significantly (p<0.01) increased survival compared to the vehicle-treated 
Scn1a-/- group. Error bars are SEM; Data were analysed by Mantel-Cox test. 
 
 Discussion 
In the present study, the effect of CBD on standard welfare parameters; such as natural 
activity, reflex/response to touch, total neonatal welfare, orbital tightening and body condition 
scores; was evaluated in both WT and Scn1a-/- mice. I showed that CBD was well-tolerated by 
the neonatal WT mice and that CBD delayed the worsening of these scores in such a severe 
animal model of epilepsy. Remarkably, it is established here that CBD treatment extended the 
survivability of Scn1a-/- mice; to date, this is the only drug that has increased survivability in 
this model. 
In this study, WT vehicle-treated pups become fully active and responsive around P11-
P12 from which stage the natural activity and reflex/response to touch scores were found to 
be zero. Interestingly, the reflex/response to touch score was found to be zero in the CBD-
treated WT animals as early as P9 and was better (lower) from P8 to P9.5 compared to the 
vehicle-treated WT animals. Reflex is a good indicator of neurological development in mouse 
pups (Fox, 1965), however the effect observed in this study was so small that it was unlikely 
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that CBD expedited the developmental process in these mice. I further demonstrated that 
CBD was well-tolerated and had no adverse effects upon natural activity and reflex/response 
to touch and total neonatal welfare scores in neonatal WT mice throughout the observation 
period which establishes the fact that the beneficial effects of CBD in Scn1a-/- mice have not 
been influenced by any other confounding effects. The tolerability of CBD on motor function 
are well documented in adult rodent models of hepatic encephalopathy (Magen et al., 2010), 
multiple sclerosis (Mecha et al., 2013), schizophrenia (Peres et al., 2016), catalepsy (Sonego 
et al., 2016; Gomes et al., 2013), seizures (Jones et al., 2012; Klein et al., 2017), epilepsy 
(Chapter 2) and Dravet syndrome (Kaplan et al., 2017). However, the effect of CBD on 
motor function in neonates has not been previously demonstrated. The current findings thus 
extend our knowledge by highlighting that sustained exposure to CBD is safe and well-
tolerated in neonates at the doses employed.  
Although the neonates perceive pain and distress they are unable to behaviourally 
express them (Wolfensohn and Lloyd, 2007). It is therefore difficult to use conventional 
behavioural methodologies to assess the disease-related suffering in neonates. Here, I scored 
the natural activity and reflex/response to touch to determine the motor function and 
wellbeing of the pups as described previously in neonates (Wolfensohn and Lloyd, 2007). In 
the present study, both scores were significantly higher, indicating worsening symptomology, 
in the Scn1a-/- mice compared to the WT mice. Previously it has been reported that Scn1a-/- 
mice start exhibiting the symptoms of limb tremors from P9 which progressively deteriorated 
to loss of postural control nearer to death (Yu et al., 2006), thus my results are in agreement 
with this study. As previously mentioned the total neonatal welfare score obtained from a 
combined scores of natural activity, reflex/response to touch and surface temperature and 
provides an overview of general health and wellbeing of these animals (Wolfensohn and 
Lloyd, 2007). A significantly higher total neonatal welfare score in the Scn1a-/- mice 
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compared to the WT mice therefore advocates that lack of NaV1.1 expression had a significant 
impact on overall health and welfare in Scn1a-/- mice.  
The current study further established that CBD treatment significantly delayed the 
worsening of natural activity and reflex/response to touch scores in Scn1a-/- mice compared to 
their vehicle-treated counterparts. These findings thus illustrate that CBD has a protective 
effect against motor deficits induced by the Scn1a mutation. Notably, I already demonstrated 
in the previous chapter that CBD improves motor function in RISE-SRS rats, thus this is the 
second evidence of CBD’s beneficial role upon motor function in epilepsy. Children with 
Dravet syndrome often exhibit motor deficits (Aljaafari et al., 2017), therefore these results 
indicates that CBD may be beneficial to treat motor dysfunction in those children. However, 
more focussed behavioural assays using Scn1a+/- mice, which survive longer to be tested on 
more conventional motor function tests (e.g. rotarod, static beam tests etc), are required to 
validate this and are described in a less severe model of Dravet syndrome in the next chapter. 
In line with the changes in natural activity and reflex/response to touch score, similarly 
beneficial results were obtained for total neonatal welfare score i.e. CBD treatment 
significantly delayed the worsening of this score in Scn1a-/- animals compared to their 
vehicle-treated counterparts. This suggests an improvement in the overall health status of the 
mutant animals after CBD treatment.  
Children with Juvenile myoclonic epilepsy often experience headache as a 
comorbidity associated with seizures (Dedei Daryan and Guveli, 2018; Ertem et al., 2017; 
Rozen, 2011). Both human and animals exhibit orbital tightening (closing of the eyelid or 
narrowing of orbital area) as a pain related physiological sign (Prkachin, 1992; Langford et 
al., 2010). So, this serves as a valuable parameter for the assessment of pain. Hence, the 
orbital tightening was measured in this phenotype as an indicator of pain. The orbital 
tightening score was found to be significantly higher, indicating worst symptoms, in Scn1a-/- 
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animals compared to the WT animals. Prolonged CBD treatment showed no effect on the 
orbital tightening scores of WT animals. CBD treatment has been reported to produce 
analgesia in several rodent models such as nerve injury (De Gregorio et al., 2019), 
osteoarthritis (Philpott et al., 2017) and surgical incision (Genaro et al., 2017) in rats, and 
nerve injury (Casey et al., 2017), corneal injury (Thapa et al., 2018) and chemotherapy 
induced pain (King et al., 2017) in mice. However, the analgesic effect of CBD in epilepsy 
model has never been studied. Here, CBD significantly delayed the worsening of the orbital 
tightening score in Scn1a-/- animals compared to their vehicle-treated cohorts. This highlights 
that CBD may have analgesic properties in neonatal epilepsy. Of note, this is the first study 
that indicates a possible analgesic effect of CBD in any epilepsy model. 
Body condition score is considered as a sensitive and reliable parameter to assess the 
health status of animals. It is a widely used technique for routine health check-up of 
laboratory, farm and pet animals (Ullman-Culleré and Foltz, 1999; Roche et al., 2006; 
Sapowicz et al., 2016). This method was also used to assess the health in several animal 
disease condition such as polycystic kidney disease in rats (Hickman and Swan, 2010), cancer 
in dogs (Michel et al., 2004) and hyperthyroidism in cats (Peterson et al., 2016). In our 
laboratory, body condition scoring is used for monitoring the health of epileptic rats. The 
scoring is done by overserving and palpating the flesh covering the bony protuberances of 
hips and vertebral column (Ullman-Culleré and Foltz, 1999). The present study showed that 
the body condition score was significantly lower (worse) in Scn1a-/- mice compared to their 
WT counterparts. This corroborates a previous study which reported a lack of body fat in 
post-mortem examination of Scn1a-/- mice (Yu et al., 2006). In this study, treatment with 
CBD in WT animals did not produce any effect on the body condition score. Interestingly, 
here CBD significantly delayed the worsening of body condition score in Scn1a-/- mice 
compared to the vehicle-treated Scn1a-/- mice. Previous study on Scn1a-/- mice demonstrated 
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that hand feeding could improve the survivability in these mice upto 2.5 days (Yu et al., 
2006). Therefore, it might be argued that CBD increased the feed intake here which overall 
improved the body condition score in Scn1a-/- mice. However, this is highly unlikely as CBD 
did not produce any impact on weight over the course of the study in neither WT nor Scn1a-/- 
mice compared to their respective vehicle-treated cohorts. Further, several studies proved that 
CBD has no effect on food intake or weight in adult healthy mice (Wiley et al., 2005; Riedel 
et al., 2009). Therefore, this is justified to interpret that the delay in worsening of body 
condition score by CBD-treatment in Scn1a-/- mice did not rely on increased food intake but 
may reflect an overall disease modification property of CBD.  
The present study further demonstrated that the vehicle-treated Scn1a-/- mice died 
prematurely with an overall medial survivability of 15.5 days which was expected with this 
severe epilepsy phenotype (Yu et al., 2006; Kalume et al., 2007). Interestingly, here CBD 
treatment significantly extended the survivability of Scn1a-/- mice when compared to their 
vehicle-treated counterparts (median survivability 16.25 days vs 15.5 days). This result is 
highly promising as standard antiepileptic drugs, such as diazepam, fail to extend 
survivability (Yu et al., 2006). An extension of survivability in this model was only shown 
after hand feeding (Yu et al., 2006) but as discussed in the previous paragraph CBD induced 
extension of survivability was not due to increased feeding but possibly due to its 
anticonvulsant and disease modifying property. This hypothesis is supported by a previous 
study which established the anticonvulsant effect of CBD in a similar but less severe model 
with haploinsufficiency of NaV1.1 channels (Kaplan et al., 2017). Overall, this is the first 
study which demonstrates the beneficial effect of CBD upon the survival of Scn1a-/- mice. 
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 Conclusion 
In this study, I characterised the Scn1a-/- mouse model using well established neonatal 
welfare scores and assessed the effect of CBD on welfare and survivability of Scn1a-/- mice. 
The welfare parameters were found to be significantly worse in the Scn1a-/- mice compared to 
their WT counterparts. Notably, this is the first study to demonstrate that CBD-treatment 
improves the welfare parameters and extends the survivability of Scn1a-/- mice. CBD is also 
the first drug that exerted such positive effect in this model. The Scn1a-/- mice shares several 
common features with human Dravet syndrome patients, therefore CBD may be useful to 
prevent premature mortalities and neonatal comorbidities associated with Dravet syndrome.  
Despite reproducing several key features of human Dravet syndrome, the Scn1a-/- mice 
differ with the human patients genotypically by their complete loss of voltage-gated NaV1.1 
expression and phenotypically by the extreme disease severity. Further, due to early 
mortality, this model limits the use of standard behavioural tests to assess intricate 
comorbidities such as motor dysfunction, social deficit, anxiety, depression and cognitive 
impairment associated with Dravet syndrome. This thesis therefore extended in the next 
chapter to investigate the effect of CBD using the Scn1a+/- mouse model that phenotypically 
and genotypically resembles the human Dravet syndrome. 
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 Effect of CBD in reducing 
premature mortality and comorbidities 
in Scn1a+/- mouse model of Dravet 
syndrome 
   
  Chapter 4 
96 
 
 Introduction 
In the previous chapter, I showed that cannabidiol (CBD) improved the welfare 
parameters and extended the survivability of Scn1a-/- mice. However, due to early mortality 
and extreme severity of the model it was not possible to assess intricate behavioural 
comorbidities. In this chapter, I therefore evaluated the effect of chronic CBD treatment on 
survivability and comorbidities associated with Dravet syndrome using a less severe Scn1a+/- 
mouse model that phenotypically and genotypically resembles the human Dravet syndrome. 
As mentioned in Chapter 1, premature mortality is common in Dravet syndrome 
patients (Sakauchi et al., 2011; Cooper et al., 2016). In addition, they exhibit multiple 
comorbidities including psychomotor delay, gait abnormality, hyperactivity, attention 
deficits, autism, sleep disorders, anxiety, depression, language impairment and severe 
cognitive deficits that have profound adverse effects upon the quality of life (Black and 
Gaebler-Spira, 2016; Brunklaus et al., 2011; Genton et al., 2011; Li et al., 2011). The current 
‘gold’ standard treatment for Dravet syndrome includes the combination of two or more 
antiepileptic drugs in the therapeutic regimen, such as benzodiazepines, valproic acid, 
topiramate, levetiracetam and stiripentol (Morimoto et al., 2018; Devinsky et al., 2017). 
However, these drugs often fail to adequately control seizures and are also associated with 
severe drug-induced motor and psychiatric adverse effects including anxiety, depression and 
memory impairments (Ristić et al., 2006; Chen et al., 2017a). As mentioned in previous 
chapters, CBD has been approved by the United States Food and Drug Administration 
(USFDA) for the treatment of Dravet syndrome patients, however CBD’s effect on the 
premature mortality and behavioural comorbidities associated with Dravet syndrome is yet to 
be established (FDA, 2018). Of note, in the previous chapter, I demonstrated the preliminary 
evidence of CBD’s efficacy on a severe Scn1a-/- mouse model of Dravet syndrome.  
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The widely used preclinical model of Dravet syndrome involves Scn1a+/- mice which 
resembles the human disease form (Miller et al., 2014; Yu et al., 2006; Han et al., 2012; 
Hawkins et al., 2017). Interestingly, the phenotype of the Scn1a+/- mice largely depends on 
their background strain with Scn1a+/- mice on a 129S background strain failing to 
demonstrate seizures and premature mortality that can be observed on C57BL/6 background 
(Yu et al., 2006). However, the reproductive performance of the Scn1a+/- mice on C57BL/6 
background strain is very poor which limits their use in any preclinical studies (Yu et al., 
2006). Fortunately, hybrid Scn1a+/- offspring obtained from a cross of 129S×C57BL/6 strains 
recapitulate several features of Dravet syndrome including seizures, premature mortality and 
other comorbidities such as social deficit, anxiety and memory impairments (Han et al., 2012; 
Yu et al., 2006), thus they are considered as a standard model to study drug effect on Dravet 
syndrome (Kaplan et al., 2017; Anderson et al., 2017; Hawkins et al., 2017). 
Efficacy of several conventional AEDs have previously been tested in this model. For 
example, a single intraperitoneal dose of carbamazepine (20 mg/kg), levetiracetam (10 
mg/kg) or topiramate (40 mg/kg) was shown to prevent premature mortality (Hawkins et al., 
2017).  Further, clonazepam (0.0625 mg/kg) was reported to protect the social deficits and 
memory impairment in Scn1a+/- mice following single intraperitoneal dosing (Han et al., 
2012). Not only that, CBD has recently been shown to improve seizures (100 mg/kg twice 
daily for 8 days; i.p.) and social deficit (10 mg/kg single dose; i.p.) in these mice (Kaplan et 
al., 2017). However, none of these studies used chronic doses of AEDs to observe their effect 
on comorbidities which are ether induced, made worse or both by several AEDs as mentioned 
before. The present study was therefore designed to observe the effect of chronic CBD 
treatment on premature mortality and several comorbidities such as motor impairment, social 
deficit, anxiety, depression and cognitive dysfunction in Scn1a+/- mouse model of Dravet 
syndrome. 
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 Methods 
4.2.1 Animals and test substances 
These experiments were performed following UK Home Office regulations (Animals 
(Scientific Procedures) Act, 1986) and was approved by the Animal Welfare and Ethics 
Review Board at the University of Reading. All mice were maintained in 12h:12h dark:light 
cycle, a room temperature of 21°C and humidity of 50 ± 10 %, with ad libitum access to food 
and water. The animals were group housed throughout the experiment except for 3 days 
during sucrose preference test when each animal was individually housed. This experiment 
was conducted in dark cycle (dim red light, 8:00-20:00 h). Male 129S-Scn1atm1Kea/Mmjax 
heterozygote mice (Jackson Laboratory, USA) maintained in the BioResource Unit, 
University of Reading (UK) were bred with female wild type C57BL/6 mice (Charles River, 
UK) to obtain Scn1a+/- and wild type (WT) littermate mice used in this experiment. At the end 
of the study, animals were humanely killed by a Schedule 1 method (cervical dislocation).  
CBD with batch no. 070214 was supplied by GW Pharmaceuticals (Cambridge, UK). 
All other chemicals were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated. 
4.2.2 Experimental design 
Here, Scn1a+/- were randomly divided into two groups and subcutaneously injected 
with either CBD (100 mg/kg twice daily; n=12) or its vehicle (ethanol: Kolliphor®: 0.9% 
saline=2:1:17; n=29) from P8 onwards until P52 or death (whichever was earlier). Similarly, 
wild type (WT) littermate mice (n=11) were injected with vehicle for the entire period of the 
study. Given that a significant number of deaths (~60%) were predicted to occur between 
P20-P27 in vehicle-treated Scn1a+/- a larger initial group size was utilised to obtain a 
minimum n=10 animals/group for behavioural assessment from P35 onwards. Of note, I 
accounted the possibility that CBD-treated animals might also die, therefore in the first run 
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equal group sizes were taken. However, the mortality was higher in the vehicle-treated 
Scn1a+/- group than the CBD-treated Scn1a+/- group, so in subsequent runs, a greater number 
of animals were included in the vehicle-treated Scn1a+/- group. 
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Figure 4.1. Schematic representation of breeding and experimental design for this 
experiment. Male 129S-Scn1atm1Kea/Mmjax heterozygote (Scn1a+/-) mice were crossed with 
female C57BL/6 WT (Scn1a+/+) mice to obtain Scn1a+/+ (WT) and Scn1a+/- mice used in the 
study. Tissue collection (tail clippings) and genotyping was conducted in between postnatal 
day 2 (P2) and P4. These animals were randomised into three groups i.e. WT vehicle-treated 
(n=11), Scn1a+/- vehicle-treated (n=29) and Scn1a+/- CBD-treated (n=12). The animals were 
treated twice daily subcutaneously with either vehicle (ethanol: Kolliphor®: 0.9% 
saline=2:1:17) or CBD (100 mg/kg) from postnatal day 8 (P8) onwards until P52/death 
(whichever was earlier). Since a higher number of deaths were predicted from P20-27, an 
initial larger group size was considered for vehicle-treated Scn1a+/- mice to obtain a minimum 
n=10 animals/group for behavioural assessments such as social interaction (P35-37), sucrose 
preference (P39-P41), elevated plus maze (P42) and motor function and radial arm maze 
(P45-P52) tests.   
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4.2.3 Assessment of survivability 
As seizure related deaths in this model were unpredictable, animals were video 
monitored continuously (24h×7days) throughout the study and any mortality observed was 
cross checked with the available video footage to confirm the reason of death. 
4.2.4 Assessment of motor function 
Fine motor control in animals were assessed by the accelerated rotarod and static 
beam tests. Animals were habituated to the stationary rotarod for 2 min a day for 2 days. In 
the accelerated rotarod test each mouse was placed individually on a linearly accelerating rod 
(4-40 rpm over 5 minutes; LE8500, Letica Scientific Instruments, UK) and average latency to 
fall from the rod (maximum 300 seconds) was calculated from 3 consecutive trials (2 min 
interval between trials).  
The static beam task was further employed to analyse balance and coordination (Sedy 
et al., 2008), where the animals were required to walk along a cylindrical elevated beam (100 
cm long, 0.9 cm diameter and 50 cm height from floor) and enter a dark enclosure at the 
beam end. The mice were habituated to the task for three consecutive days before the test day. 
Each day of the habituation period, the animals were placed 30, 60 and 100 cm away from the 
enclosure and allowed to traverse along the beam. On the test day, each mouse performed two 
consecutive trials (2 minutes interval between trials) with a maximum given time of 2 
minutes to complete the task (the nose entering the box was taken as task completion). The 
test was video monitored (Sony DCR-SX21E) and blinded offline analysis was conducted 
(Observer XT 12, Noldus, The Netherlands) to evaluate the average number of foot slips 
made from two consecutive trials. 
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4.2.5 Assessment of gait 
Gait test was conducted to assess the cerebellar function of the animals (Patel and 
Hillard, 2001). In this test, the hind paws of each mouse were marked with a non-toxic ink 
and the mouse was allowed to walk on a white paper (50×10 cm) placed on the floor of a 
custom-made plexiglass tunnel (50×10×10 cm). To obtain the left and right stride length, the 
distance between two ipsilateral paw prints was measured, whereas stride width was 
calculated from the distance between a foot print and its contralateral stride length at right 
angle (Wecker et al., 2013). The initial and last foot prints were not considered in 
measurements. All the animals were habituated to the test procedures and the apparatus for 2 
days prior to the test. On the day of test, two trials were conducted for each animal to obtain 
mean stride length (left or right) and width for that animal. 
4.2.6 Assessment of social interaction 
The social interaction test was conducted in the home cage of test mouse to assess the 
social behaviour of the animals (Sato et al., 2013). On test day, cage mate(s) were removed 
from the home cage of the test mouse and the mouse remained in isolation for 15 minutes. A 
novel wild type mouse of same strain, same sex and similar weight to the test mouse was then 
introduced to the home cage of the test mouse. Activity was video recorded (Sony DCR-
SX21E) for 10 minutes and the obtained video files were blinded at the end of all 
experiments. Time spent in active interactions (e.g. close following, sniffing, 
allogrooming/social grooming and mounting) and number of rearing (lifting the front paws on 
the air) occasions were coded offline using Observer XT 12 (Noldus, Netherlands). 
Aggressive behaviours were not considered as social interactions and were not coded. In this 
test, a reduced social interaction is considered as autistic like behaviour (Sato et al., 2013), 
while increased rearing occasions is sign of defensive escapes (Kaplan et al., 2017). 
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4.2.7 Assessment of anxiety-like behaviour 
The elevated plus maze (EPM) test was performed to assess the level of anxiety in 
animals (Chen et al., 2017c). The wooden test apparatus consists of two closed arms (50×10 
×40 cm) and two open arms (50×10 cm) connected via a central platform (10×10 cm) and 
raised at a height of 50 cm above the floor. Each animal was placed on the central platform 
facing towards an open arm. Activity was video recorded (Swann SRDVR-16440H, UK) for 
5 minutes. The video files were blinded and coded offline at the end of all experiments using 
Observer XT 12 (Noldus, Netherlands). Time spent on open arms was inversely related to the 
level of anxiety.  
4.2.8 Assessment of depression-like behaviour 
The sucrose preference test was carried out to assess the depression-like behaviour 
(Serova et al., 2017). The animals were separately housed during this test. Here, 24 hours 
before the test, animals were trained to drink from two bottles each containing 2% sucrose. 
On the first day of test, the animals were provided with a pre-weighed bottle of 2% sucrose 
and another containing a pre-weighed volume of tap water. The positions of the bottles were 
swapped after 24 hours to avoid any side preferences. After 48 hours, both bottles were 
weighed, and sucrose preference was calculated by using the following formula. 
Sucrose preference (%) = 
Sucrose consumption
Sucrose consumption + Water consumption
 × 100 
4.2.9 Assessment of cognition 
An 8-arm radial maze (each arm 60×10 cm; raised at 50 cm above the floor) was used 
to assess the reference memory (RM) and working memory (WM) of the animals. On four 
consecutive days, animals were given two 10-minute sessions of habituation to the test 
apparatus and rules of the test, separated by a 90 min interval. During the first two days of 
habituation, food rewards (1/4 Cheerios®, Nestle) were randomly scattered on the floor of the 
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apparatus covering all arms and food-troughs at the end of each arm. On the 3rd and 4th 
habituation day, food rewards were placed only in food troughs of four randomly selected 
arms (fixed for each animal during the habituation and test day). Food was withdrawn 4-6 
hours before the trial (both during habituation and test days) to motivate the animals to locate 
the rewards and thus perform the task. On the test day two trials of 10 min were conducted at 
90 min interval and the activity of the animals were video recorded for offline blinded coding 
after the end of experiment. Entry to a non-baited arm was considered as a reference memory 
error (RME), whereas re-entry to a previously baited arm from which the food was already 
taken is considered as a working memory error (WME). The mean WME or RME were 
calculated from the two test trials.  
4.2.10 Statistical analysis 
All data were analysed in GraphPad Prism 6 software. The percentage of animals from 
the Scn1a+/- vehicle-treated and Scn1a+/- CBD-treated groups that survived until the end of 
the study (P52) were compared by Fisher’s exact test. Survival curves of Scn1a+/- vehicle-
treated and Scn1a+/- CBD-treated group were compared using a Mantel-Cox test. Further, 
data obtained from the comorbidity assessment were checked for normality by D'Agostino & 
Pearson omnibus normality test. Data obtained from rotarod, gait, social interaction (active 
interaction), EPM, sucrose preference, RAM (RME) tests were normally distributed and the 
differences between the three groups were analysed by one-way ANOVA. If a significant 
difference was found then Holm-Sidak post hoc test was conducted between the WT vehicle-
treated and Scn1a+/- vehicle-treated groups (to assess any disease related deterioration), and 
between Scn1a+/- vehicle-treated and Scn1a+/- CBD-treated groups (to evaluate the effect of 
CBD in improvement/deterioration of the disease condition). On the other hand, data obtained 
from static beam, social interaction (rearing occasions), RAM (WME) were found to be non-
parametric, thus were analysed by Kruskal-Wallis test. Upon observing a significant 
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difference among the groups, the Dunn’s post hoc test was employed to assess the differences 
between WT vehicle-treated and Scn1a+/- vehicle-treated groups, and between Scn1a+/- 
vehicle-treated and Scn1a+/- CBD-treated groups. Multiple comparisons were corrected in all 
cases. Parametric data are presented in scattered dot plot in the figures and are expressed as 
mean ± SEM. Non-parametric data are presented in box plot in the figures and are expressed 
as median, min to max, and interquartile range (IQR). In all cases, p<0.05 is considered as the 
level of significance. 
 Results 
4.3.1 CBD increased survivability of Scn1a+/- mice 
The mortality rate was highest between P20-P27 in Scn1a+/- mice except for a single 
animal from the Scn1a+/- vehicle-treated group which died at P47. I reviewed the recorded 
video footages and confirmed that tonic-clonic seizures were the cause of death in all cases. 
Approximately 66% (19 of 29) Scn1a+/- vehicle-treated animals died before the completion of 
the study in contrast to only 17% (2 of 12) Scn1a+/- CBD-treated animals (Fisher’s exact test; 
p<0.0001) (Figure 4.2A). Further, survivability was significantly (Mantel-Cox test; X2=5.94; 
p<0.05; Figure 4.2B) less in Scn1a+/- vehicle-treated group (median survival 24 days) 
compared to the Scn1a+/- CBD-treated group (more than 50% animals survived until the end 
of the study so median survivability could not be assessed).  
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Figure 4.2. Plots showing chronic administration of CBD on survival of Scn1a+/- mice. A. 
Percentage of Scn1a+/- vehicle-treated and Scn1a+/- CBD-treated animals that survived until 
the completion of experiment (P52). A significantly higher number of CBD treated animals 
survived until the end of experiment compared to the Scn1a+/- vehicle-treated animals. Data 
were analysed by Fisher’s exact test; ****p<0.0001. B. Survival curve. CBD treatment 
significantly increased survival of Scn1a+/- mice compared to the vehicle-treated Scn1a+/- 
mice. Error bars are SEM; Data were analysed by Mantel-Cox test; p<0.05. 
 
4.3.2 CBD did not exert any adverse effect on motor function 
Motor function was assessed by both the accelerating rotarod and static beam test. In 
accelerating rotarod test, the mean total time spent on the moving rod by the WT vehicle-
treated (n=11), Scn1a+/- vehicle-treated (n=11) and Scn1a+/- CBD-treated (n=10) were 
respectively 90.33 ± 2.00, 97.76 ± 5.41 and 91.27 ± 5.14 seconds. No significant difference in 
time spent on rod was observed among the groups (One-way ANOVA; F(2,29)=0.86; p=0.44; 
Figure 4.3A).  
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On the other hand, in static beam test, the median number of foot slips made by the 
WT vehicle-treated (n=11), Scn1a+/- vehicle-treated (n=11) and Scn1a+/- CBD-treated (n=10) 
were respectively 0.00, 1.00 and 0.50. Here, a significant difference in number of foot slips 
was found (Kruskal-Wallis test, H(2)= 10.67; p<0.01). Dunn’s post hoc test revealed that 
Scn1a+/- vehicle-treated group made significantly (p<0.01) more foot slips compared to the 
WT vehicle-treated group, however no significant difference was observed in between 
Scn1a+/- vehicle-treated and Scn1a+/- CBD-treated groups (p>0.05; Figure 4.3B). A further 
comparison between the WT vehicle-treated and the Scn1a+/- CBD-treated groups revealed no 
significant difference in number of foot slips between these two groups (p>0.05). 
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Figure 4.3. Dot plot, and box and whisker plot showing chronic administration of CBD 
to Scn1a+/- mice on motor function. A. Mean time (seconds) spent on accelerated rotarod by 
the wild type (WT) vehicle-treated (n=11), Scn1a+/- vehicle-treated (n=11) and Scn1a+/- CBD-
treated (n=10) groups. No difference was observed among the groups. Data were analysed by 
one-way ANOVA and are expressed as mean ± SEM. B. Median number of foot slips made 
in static beam test. CBD treatment did not increase the number of foot slips by the Scn1a+/- 
mice compared to both the WT vehicle-treated and Scn1a+/- vehicle-treated mice. Data were 
analysed by Kruskal-Wallis test followed by Dunn’s post hoc test and are expressed as 
median, min to max, and interquartile range; **p<0.01. 
 
4.3.3  CBD did not produce any gait abnormalities 
The gait test was conducted to assess left stride length (LSL), right stride length 
(RSL) and stride width (SW) of the animals. The mean values of LSL (Figure 4.4A) of WT 
vehicle-treated (n=11), Scn1a+/- vehicle-treated (n=11) and Scn1a+/- CBD-treated (n=10) 
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animals were respectively 69.55 ± 1.39, 67.79 ± 1.33 and 70.51 ± 2.07 millimetres, whereas 
the mean values of RSL (Figure 4.4B) in these groups were respectively 70.42 ± 1.03, 67.58 
± 1.84 and 70.18 ± 2.16 millimetres. Further, SW (Figure 4.4C) in these groups were 
respectively 20.52 ± 0.55, 19.64 ± 0.62 and 21.29 ± 0.64 millimetres. In the gait test, no 
significant change was observed for left stride length (One-way ANOVA, F(2,29)=0.73; 
p=0.49), right stride length (One-way ANOVA, F(2,29)=0.86; p=0.44) and stride width (One-
way ANOVA, F(2,29)=1.87; p=0.17) among the WT vehicle-treated, Scn1a
+/- vehicle-treated 
and Scn1a+/- CBD-treated groups (Figure 4.4). 
 
Figure 4.4. Dot plots showing chronic administration of CBD to Scn1a+/- mice on gait. A. 
Left stride length (millimeters) B. Right stride length (millimeters) and C. Stride width of the 
wild type (WT) vehicle-treated (n=11), Scn1a+/- vehicle-treated (n=11) and Scn1a+/- CBD-
treated (n=10) groups. CBD did not produce any adverse effect on any of these parameters. 
All the data were analysed by one-way ANOVA and are expressed as mean ± SEM. 
 
4.3.4 CBD improved social behaviour of Scn1a+/- mice 
The social interaction test was conducted to assess the active social interaction and 
rearing behaviour exhibited in the home cage of the test animals.  
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The time spent on active interaction was significantly differed among the groups 
(One-way ANOVA; F(2,29)=13.58; p<0.0001). The Scn1a
+/- vehicle-treated animals (39.52 ± 
7.82 seconds; n=11) spent significantly less time in performing active interaction with the 
stranger mouse compared to both WT vehicle-treated (142.10 ± 20.39 seconds; n=11) and 
Scn1a+/- CBD-treated (138.00 ± 16.89 seconds; n=10) animals (Holm-Sidak’s post hoc test; 
p<0.001; Figure 4.5A).  
Further, a significant difference in number of rearing events was observed among the 
groups (Kruskal-Wallis test, H(2)= 16.18; p<0.001) with Dunn’s post hoc test revealing a 
significantly higher number of rearing occasions for Scn1a+/- vehicle-treated animals (median 
38.00; IQR=19.00-47.00) compared to both WT vehicle-treated (median 12.00; IQR=3.00-
21.00; p<0.05) or Scn1a+/- CBD-treated (median 3.50; IQR=2.00-6.75; p<0.001) animals 
(Figure 4.5B).  
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Figure 4.5. Dot plot, and box and whisker plot showing the effect of chronic 
administration of CBD to Scn1a+/- mice on active social interaction and rearing 
behaviour. A. Time (second) spent on active interaction in social interaction (SI) test by the 
wild type (WT) vehicle-treated (n=11), Scn1a+/- vehicle-treated (n=11) and Scn1a+/- CBD-
treated (n=10) groups. CBD significantly increased the active interaction time compared to 
the Scn1a+/- vehicle-treated group. The data were analysed by one-way ANOVA with Holm-
Sidak’s post hoc test and are expressed as mean ± SEM; ***p<0.001. B. Rearing events made 
in social interaction test. CBD treatment significantly reduced the number of rearing 
compared to the Scn1a+/- vehicle-treated group. The data were analysed by Kruskal-Wallis 
test followed by Dunn’s multiple comparison test and are expressed as median, min to max, 
and interquartile range (IQR). *p<0.05; ***p<0.001. 
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4.3.5 CBD reduced anxiety-like behaviour in Scn1a+/- mice  
The anxiety of the animals was assessed by the amount of the time spent on the open 
arms of an elevated plus maze (EPM). The time spent on the open arms differs significantly 
among the groups (One-way ANOVA, F(2,28)=5.11; p<0.05). The Scn1a
+/- vehicle-treated 
animals (11.17 ± 3.31 seconds; n=11) spent significantly less time on the open arms 
compared to both WT vehicle-treated (83.62 ± 22.69 seconds; n=11) and Scn1a+/- CBD-
treated (93.90 ± 28.09 seconds) animals (Holm-Sidak’s post hoc test; p<0.05; Figure 4.6A). 
4.3.6 CBD reduced depression-like behaviour in Scn1a+/- mice  
Depression-like behaviour is inversely correlated with sucrose preference (Murray et 
al., 2013). In the present study, sucrose preference differed significantly among the groups 
(One way ANOVA, F(2,29)=8.37; p<0.01). A Holm-Sidak’s post hoc test showed that the 
Scn1a+/- vehicle-treated animals (67.93 ± 4.42 %; n=11) had less preference to sucrose over 
water in comparison to both WT vehicle-treated (84.91 ± 2.02 %; n=11; p<0.01) or Scn1a+/- 
CBD-treated (80.82 ± 2.05 %; n=10; p<0.05) animals (Figure 4.6B).  
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Figure 4.6. Dot plots showing the effect of chronic administration of CBD to Scn1a+/- 
mice on anxiety-like and depression-like behaviours. A. Mean time (seconds) spent on 
open arms in Elevated Plus Maze (EPM) test by the wild type (WT) vehicle-treated (n=11), 
Scn1a+/- vehicle-treated (n=11) and Scn1a+/- CBD-treated (n=10) groups. CBD treatment 
significantly increased the time spent on the open arms of EPM compared to the Scn1a+/- 
vehicle-treated group. B. Mean sucrose preference (%) in sucrose preference (SP) test. CBD 
significantly increased the sucrose preference compared to the Scn1a+/- vehicle-treated group. 
The data were analysed by one-way ANOVA with Holm-Sidak’s post hoc test and are 
expressed as mean ± SEM. *p<0.05; **p<0.01. 
 
4.3.7 CBD improved cognition in Scn1a+/- mice  
The reference memory (RM) and working memory (WM) function in the animals 
were assessed using an eight-arm radial arm maze (RAM) test.  
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A significant difference (One-way ANOVA, F(2,28)=29.54; p<0.0001) in the number of 
reference memory errors (RME) was observed among the groups. The Scn1a+/- vehicle-
treated group (11.15 ± 1.17; n=10) made significantly more RME compared to both WT 
vehicle-treated (4.09 ± 0.53; n=11) and Scn1a+/- CBD-treated (3.6 ± 0.45; n=10) groups 
(Holm-Sidak’s post hoc test; p<0.0001; Figure 4.7A).  
Further, working memory errors (WME) were significantly different among the 
groups (Kruskal-Wallis test; H(2)=15.22; p<0.001). The Dunn’s post hoc analysis revealed 
that Scn1a+/- vehicle-treated group (median 2.5; IQR 1.50-14.00) made significantly more 
WME compared to both WT vehicle-treated (median 0.5; IQR 0.00-1.00; p<0.01) and 
Scn1a+/- CBD-treated (median 0.25; IQR 0.00-1.00; p<0.001) groups (Figure 4.7B). 
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Figure 4.7. Dot plot, and box and whisker plot showing chronic administration of CBD 
to Scn1a+/- mice on spatial memory in 8-arm radial arm maze test (RAM). A. Median 
reference memory errors (RME) by the wild type (WT) vehicle-treated (n=11), Scn1a+/- 
vehicle-treated (n=10) and Scn1a+/- CBD-treated (n=10) groups. CBD treatment significantly 
reduced RME of Scn1a+/- mice compared to the Scn1a+/- vehicle-treated mice. The data were 
analysed by one-way ANOVA with Holm-Sidak’s post hoc test and are expressed as mean ± 
SEM; ****p<0.0001. B. Median working memory errors (WME). CBD significantly reduced 
WME of Scn1a+/- mice compared to the Scn1a+/- vehicle-treated group. Data were analysed by 
Kruskal-Wallis test followed by Dunn’s multiple comparison test and are expressed as 
median, min to max, and interquartile range (IQR); **p<0.01, ***p<0.001. 
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 Discussion 
In this experiment, the effect of chronic CBD treatment upon premature mortality and 
comorbidities such as motor dysfunction, social deficit, anxiety, depression and memory 
impairment associated with Dravet syndrome using the Scn1a+/- mouse model was 
investigated. This mouse model appropriately represents the human Dravet syndrome both 
genetically by its haploinsufficiency of NaV1.1 channel, and phenotypically by exhibiting the 
characteristics such as seizures, premature mortality and behavioural comorbidities such as 
social deficit, anxiety and memory dysfunction. associated with the disease. Here, I 
demonstrated for the first time that CBD treatment has beneficial effect on survivability and 
disease associated comorbidities in this model.  
In the present study, chronic CBD treatment significantly increased the survivability 
of Scn1a+/- mice in comparison to their vehicle-treated counterparts: 66% of Scn1a+/- vehicle-
treated (19 of 29) animals died before the completion of the study compared to just 17% those 
treated with CBD (2 of 12). Not only that, the median survivability of Scn1a+/- vehicle-treated 
animals was only 24 days. Because of this higher mortality in vehicle-treated Scn1a+/- group a 
larger initial group size had to be employed to attain a minimum n=10 animals/group for 
behavioural experiments at the later part of the study. I further confirmed from the video 
recorded data that tonic-clonic seizure was the reason for death in Scn1a+/- mice, thus a 
significantly lower mortality in CBD-treated group suggests that CBD provided significant 
protection against seizure related premature mortality. Although exploring the mechanism of 
anticonvulsant action of CBD is beyond the scope of this study, it is worth highlighting that a 
previous study on Scn1a+/- mice suggested that CBD exerts its anticonvulsant action through 
GPR55 receptor antagonism (Kaplan et al., 2017).  
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As previously mentioned, seizures and premature mortality are not the only concern in 
Dravet syndrome. Comorbidities such as motor deficits including abnormal gait is frequently 
reported in patients with Dravet syndrome (Aljaafari et al., 2017; Fasano et al., 2014; 
Rilstone et al., 2012; Gitiaux et al., 2016). Not only that, several AEDs such as phenobarbital, 
valproic acid, phenytoin and lacosamide also shown to have motor adverse effects in epileptic 
patients (Zaccara et al., 2004; Ristić et al., 2006; Zaccara et al., 2013; Bainbridge et al., 
2017). In this study, vehicle-treated Scn1a+/- mice did not demonstrate any motor deficit on 
the accelerating rotarod. So, I assessed a different component of motor behaviour on static 
beam where the vehicle-treated Scn1a+/- mice exhibited motor deficits by making 
significantly more foot slips compared to their WT counterparts. Here, CBD treatment had no 
adverse effect on motor function in the Scn1a+/- mice. This result corroborates the previous 
finding that Scn1a+/- mice did not show any motor dysfunction in accelerated rotarod test 
following 3 days of CBD treatment (100 mg/kg; i.p.) (Kaplan et al., 2017). I further showed 
in the gait test that there was no difference in either stride length (left/right) or stride width 
among the groups. It is therefore clear that CBD was well-tolerated by Scn1a+/- mice, and no 
adverse effect was observed in gait or motor function. 
In addition to motor disorders, Dravet syndrome is linked to several neuropsychiatric 
comorbidities. For example, social deficit, a common feature of autism is often observed in 
Dravet syndrome patients (Berkvens et al., 2015; Wolff et al., 2006; Li et al., 2011). 
Although a case study involving only three children with Dravet syndrome reported an 
improvement in autistic behaviour following treatment with valproate, clobazam, 
levetiracetam and oxcarbazepine (Chepure et al., 2018), larger studies involving more 
patients are lacking in the literature. Conversely, several clinical studies have reported autistic 
traits in children prenatally exposed to valproic acid (Rasalam et al., 2005; Moore et al., 
2000). In this study, I investigated the effect of CBD on the social behaviour of the Scn1a+/- 
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mice. I observed that the vehicle-treated Scn1a+/- mice had significant social deficits 
compared to their WT counterparts which is in line with the previous studies conducted in this 
animal model (Kaplan et al., 2017; Han et al., 2012). These authors hypothesised that an 
impairment of GABAergic neurotransmission might be the underlying mechanism behind the 
social deficits in these mice. Han et al demonstrated that a single dose (0.0625 mg/kg; i.p.) of 
clonazepam, a positive allosteric modulator of the GABAA receptor could significantly rescue 
the impaired social behaviour of the Scn1a+/- mice when administered 30 minutes before the 
three-chamber social interaction test (Han et al., 2012). Further to this, Kaplan et al. showed 
that a single low dose of CBD (10-20 mg/kg, i.p.) also improved social behaviour of the 
Scn1a+/- mice in the same test and they anticipated the role of CBD in GABAergic 
neuromodulation (Kaplan et al., 2017). However, the dose and frequency of administration of 
CBD applied in the above mentioned study is impracticable in Dravet syndrome therapy in 
clinics where patients receive multiple doses of CBD (Devinsky et al., 2017; Devinsky et al., 
2018b). In the present study, the CBD-treated Scn1a+/- mice spent significantly more time in 
active social interaction compared to their vehicle-treated counterparts. I therefore 
demonstrated that CBD improved the social behaviour of Scn1a+/- mice after chronic 
administration using a dose (100 mg/kg, twice daily, s.c.) already shown to have an 
anticonvulsant effect in these mice (Kaplan et al., 2017). Apart from this model, the efficacy 
of CBD has also been demonstrated in attenuating Δ9-tetrahydrocannabinol (Malone et al., 
2009) and MK-801-induced (Gururajan et al., 2012) social deficits in rats. However, results 
obtained from behavioural assessment alone has its own limitation to explore the mechanism 
of action of CBD in the restoration of social deficits. A more detailed study using 
electrophysiological and molecular biological approach is therefore warranted to gain the 
molecular insight of CBD’s role in it. 
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In addition to impaired social behaviour, anxiety and depression are also major 
problems for patients with Dravet syndrome, severely impacting their quality of life (Wang et 
al., 2018; Jain et al., 2018; Chen et al., 2018). Although antiepileptic drugs such as valproate, 
lamotrigine, clobazam, gabapentin, oxcarbazepine etc have been reported to improve these 
behavioural comorbidities, several antiepileptic drugs like levetiracetam, topiramate, 
zonisamide etc progressively worsen these comorbidities (Chen et al., 2017a). The present 
study was therefore conducted to observe whether CBD has any effect on anxiety/depression 
associated with Dravet syndrome employing Scn1a+/- mouse model. The Scn1a+/- mice 
exhibits anxiety-like behaviour in elevated plus maze (EPM) and open field tests (Han et al., 
2012). Here, I observed a similar effect in EPM test where the vehicle-treated Scn1a+/- mice 
showed anxiety-like behaviour by spending significantly less time on the open arm compared 
to the WT animals. Further, a significantly higher number of rearing behaviours exhibited by 
the Scn1a+/- mice compared to the WT animals in the social interaction test could be due to 
their higher level of anxiety that compelled them to escape from the test situation (Mines et 
al., 2010). Interestingly, CBD-treated Scn1a+/- mice spent significantly more time on the open 
arm of EPM compared to the vehicle-treated Scn1a+/- mice. This illustrates that chronic CBD 
treatment has anxiolytic potential in this mouse model of Dravet syndrome. In addition, the 
reduced rearing numbers in the CBD-treated Scn1a+/- mice as opposed to the vehicle-treated 
Scn1a+/- mice in the social interaction test might be attributed to an anxiolytic effect of CBD. 
This is the first study to suggest an anxiolytic effect of CBD in an epilepsy model. However, 
anxiolytic effects of CBD have previously been reported in a chronic unpredicted stress 
model in mice using both EPM and novelty supressed feeding test (Fogaca et al., 2018; 
Campos et al., 2013).  
In the present study, the conventional sucrose preference test was employed to assess 
the depression-like behaviour in the Scn1a+/- mice (Serova et al., 2017). This test is based 
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upon the concept that depression-like behaviour in rodents is inversely correlated with their 
sucrose preference (Murray et al., 2013). Here, the vehicle-treated Scn1a+/- mice showed the 
typical depression-like behaviour i.e. a reduced preference to sucrose over water when 
compared to the WT mice. Remarkably, chronic CBD-treatment exerted antidepressant effect 
in the Scn1a+/- mice which exhibited an increased (normalised) sucrose preference in 
comparison with their vehicle-treated cohorts. The antidepressant action of CBD has 
previously been documented in genetic (Shoval et al., 2016), olfactory bulbectomy (Linge et 
al., 2016) and chronic unpredictable stress (Campos et al., 2013) models of depression. 
However, similar to the anxiolytic potential of CBD, its antidepressant effect has also never 
been studied in any epilepsy model, thus I am the first to demonstrate such effect of CBD in a 
mouse model of Dravet syndrome. Previous studies in naïve rodents have proposed that CBD 
exerts its antidepressant action via modulating the 5-HT neurotransmission or 
endocannabinoid signalling (Linge et al., 2016; Campos et al., 2013). Nevertheless, the 
underlying pathology of depression in epilepsy is complex and still unclear which 
necessitates a detailed mechanistic study to gain a better understanding on the antidepressant 
effect of CBD.  
Cognitive deficit is also a frequently reported comorbidity in Dravet syndrome patients 
which immensely depreciate their quality of life (Olivieri et al., 2016; Acha et al., 2015; 
Villeneuve et al., 2014). Several domains of cognitive functions including visual attention, 
executive functions, and verbal, visual and working memories have found to be impaired in 
these patients (Pascalicchio et al., 2007; Acha et al., 2015; Roebling et al., 2009). Dravet 
syndrome patients also have significant intellectual deficits including very low intelligence 
quotient (IQ) which adversely affect their social life (Akiyama et al., 2010; Villeneuve et al., 
2014). Furthermore, the existing antiepileptic drugs such as phenobarbital, phenytoin, 
topiramate etc. also possess negative impact on cognition in people with epilepsy (Chen et 
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al., 2001; Mei et al., 2006; Wandschneider et al., 2017). Previously it has been established 
that the Scn1a+/- mice exhibit spatial memory deficit in both context dependent fear 
conditioning test and Barnes circular maze test (Han et al., 2012). Here it was observed that 
the vehicle-treated Scn1a+/- mice made significantly more reference and working memory 
errors compared to the WT mice in the radial arm maze (RAM) test. Therefore, in agreement 
with the previous study by Han et al, I showed that Scn1a+/- mice have spatial memory 
deficits. Several hypotheses have been proposed to explain the underlying pathology of 
memory impairment in epilepsy. Seizure is a major contributory factor for cognitive decline 
during developmental process (Khan et al., 2010; Ben-Ari and Holmes, 2006) and this 
appears to be true in the Dravet syndrome animal model where animals exhibit seizures from 
an early age. Further, seizure related disruption of neural plasticity, an important factor for 
memory formation has also been demonstrated in other animal model of epilepsies (Zhou et 
al., 2011; Schubert et al., 2005; Lenck-Santini and Scott, 2015). In contrast, a previous study 
demonstrated that the memory deficits in Scn1a+/- mice might be due to the attenuation of 
GABAergic neurotransmission and this could be rescued by clonazepam, a selective GABAA 
modulator (Han et al., 2012). Similarly, another study established that a selective knock-
down of NaV1.1 channel at basal forebrain of rats resulted in memory deficits without 
manifestation of seizures, thus proving the concept that seizure is not the only contributory 
factor in memory loss exhibited by the Scn1a+/- mice (Bender et al., 2013). Moreover, 
removing cause of seizures does not always restore cognitive deficits in people with epilepsy 
(Helmstaedter et al., 2003). Interestingly in this study, CBD improved both the reference and 
working memory function of the Scn1a+/- mice compared to their vehicle-treated 
counterparts. A similar result was obtained in Chapter 2 where CBD improved working 
memory deficits in RISE-SRS rats. This is further consistent with previous reports of CBD 
restoring cognitive deficits associated with bile-duct ligation (Magen et al., 2010) and Δ9-
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tetrahydrocannabinol (THC) administration (Murphy et al., 2017) in mice, and iron 
overloading in rats (Fagherazzi et al., 2012), indicating this effect is consistent in different 
models of epilepsy and across species. Furthermore, a caregiver‐reported quality of life in 
childhood epilepsy (QOLCE) survey stated an improved memory function in the patients with 
refractory childhood epilepsy following CBD treatment (Rosenberg et al., 2017a). 
Nonetheless, the beneficial effect of CBD on memory function of Scn1a+/- mice was studied 
here for the first time. Although the present study illustrates the memory impairment 
associated with the disease and restoration of this deficit upon chronic CBD treatment, an 
additional, more comprehensive study is required to understand the molecular mechanisms 
behind CBD’s role in memory improvement in this model. 
 Conclusion 
This study is the first to demonstrate that chronic administration of CBD prevents 
premature mortality and improves behavioural comorbidities associated with Dravet 
syndrome in Scn1a+/- mice without the detrimental effect on motor function that is otherwise 
seen with current pharmacotherapy. In light with the recent FDA approval of CBD, such 
highly promising results obtained from the present study undoubtedly increases the chance of 
a wider acceptance of Epidiolex® (GW Pharmaceuticals, UK) among the patients with Dravet 
syndrome.
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 General Discussion 
In this chapter, I will summarise the overall key findings of this project and discuss 
their potential implications in a wider therapeutic context. I will also briefly outline the future 
scope of research in this area. 
The primary objective of this project was to investigate the effect of CBD treatment on 
seizures, premature mortality and comorbidities associated with epilepsy. This was achieved 
by evaluating CBD in three different models of epilepsy. The RISE-SRS rat model of TLE 
was employed to assess the effect of chronic CBD administration on seizures, motor function, 
gait and cognition (chapter 2). The Scn1a-/- mouse model which recapitulates several 
symptoms of Dravet syndrome was utilised to find out the effect of long-term CBD treatment 
on survivability and several welfare parameters such as natural activity, reflex/response to 
touch, total neonatal welfare, orbital tightening and body condition (chapter 3). Finally, the 
effects of chronic CBD administration on premature mortality and comorbidities such as 
motor dysfunction, social deficits, anxiety, depression and cognitive impairment were 
assessed in the Scn1a+/- mouse model of Dravet syndrome (chapter 4).  
In this project, chronic CBD treatment was found to reduce seizures in TLE animals 
and prevented premature mortality in the Scn1a+/- mice. A long-term CBD administration 
also increased survivability and improved the welfare parameters of the neonatal Scn1a-/- 
mice. Further, CBD was shown to improve social deficit and reduced the anxiety-like and 
depression-like behaviours in the Scn1a+/- mice. Most importantly, chronic CBD treatment 
improved the cognition and provided protection against the epilepsy induced motor deficit 
without producing any adverse effect on gait in both the preclinical models of TLE and 
Dravet syndrome. Overall, in this project, I have demonstrated the novel findings that CBD-
treatment can prevent premature mortality, reduce seizures and improve comorbidities 
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associated with epilepsy. In the coming sections, the beneficial effects of CBD in each of 
these domains and its wider implications will be discussed. 
Although the anticonvulsant property of CBD is well-known (Do Val-da Silva et al., 
2017; Jones et al., 2012; Klein et al., 2017), its effectiveness against spontaneous recurrent 
seizures (SRS), the primary feature of epilepsy has never been evaluated in any preclinical 
models of epilepsy. In this project, I demonstrated for the first time that CBD can reduce the 
SRS and has the disease modifying effect in epilepsy. Additionally, this result provides a 
strong basis for clinical trials of CBD on other epilepsies (especially TLE) beyond Dravet 
Syndrome and Lennox Gastaut Syndrome, for which CBD (Epidiolex®, GW 
Pharmaceuticals) has already gained the US-FDA approval (FDA, 2018).  
Another major concern in epilepsy is premature mortality (Dravet et al., 2005; Genton 
et al., 2011) and not a single study has assessed the effect of CBD in the prevention of 
premature mortality. Therefore, the present project is also first of its kind which demonstrates 
that CBD prevents premature mortality in epilepsy using the Scn1a+/- mouse model of Dravet 
syndrome. This effect of CBD could be attributed to its anticonvulsant action as all deaths 
were confirmed to be associated with seizures and the anticonvulsant action of CBD has 
already been established in the Scn1a+/- mice (Kaplan et al., 2017). Interestingly, previous 
studies have reported that the Scn1a+/- mice have decreased heart rate variability (HRV) 
(Kalume et al., 2013) and they may die due to a seizure-triggered ventricular fibrillation 
along with bradycardia at seizure offset (Auerbach et al., 2013; Kalume et al., 2013). 
Therefore, it is possible that CBD might have also played a cardioprotective role, in addition 
to its anticonvulsant property, to prevent the premature mortality in a severe form of epilepsy, 
such as Dravet syndrome. This hypothesis is supported by previous studies which 
demonstrated the cardioprotective effect of CBD against myocardial ischemic reperfusion 
injury in rats (Durst et al., 2007; Walsh et al., 2010) and type-I diabetic cardiomyopathy in 
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mice (Weiss et al., 2006; Rajesh et al., 2010).  However, this needs to be further investigated 
to understand the precise mechanism by which CBD prevents premature mortality in 
epilepsy.  
This project further established that CBD treatment improved the orbital tightening in 
the neonatal epileptic animals, which is a noteworthy finding as it suggests a possible 
analgesic property of CBD. The analgesic effect of CBD in various models of pain induced 
by nerve injury (De Gregorio et al., 2019), osteoarthritis (Philpott et al., 2017), surgical 
incision (Genaro et al., 2017), corneal injury (Thapa et al., 2018) and chemotherapy (King et 
al., 2017) have been demonstrated. Interestingly, I observed that CBD was well-tolerated in 
the healthy neonatal animals. Therefore, considering the safety profile of CBD and its 
potential analgesic effect in neonates, CBD could be a promising pain-killer for children. 
Nevertheless, in order to gain better understanding on CBD’s spectrum of analgesia in 
neonates, a well-designed study needs to be conducted on different validated pain models 
induced by repeated formalin injections, needle pricks or nerve injury (Bhutta et al., 2001; 
Anand et al., 1999; Gong et al., 2018). 
The protective role of CBD to attenuate motor deficits in adult epileptic animals was 
also established. Further, no adverse effect on gait of epileptic animals was observed 
following chronic CBD treatment in both the models studied in this thesis. The excellent 
motor-tolerability of CBD indeed proves its superiority over other AEDs such as 
phenobarbital, valproic acid, phenytoin and lacosamide which produce adverse effects on 
motor function and gait in the patients with epilepsy (Zaccara et al., 2004; Ristić et al., 2006; 
Zaccara et al., 2013; Bainbridge et al., 2017). Again, this result advocates the potential 
application of CBD as a combinational antiepileptic therapy with the above-mentioned AEDs 
as it would allow lowering the dose of the latter and this ultimately may minimise the chance 
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of drug induced comorbidities. Moreover, motor disorder including tremor, rigidity and 
bradykinesia are the common features of Parkinson’s disease (Sethi, 2002). Thus, CBD might 
have the potential to protect against motor symptoms associated with Parkinson’s disease and 
other disorders of motor function such as Huntington’s disease. As mentioned in chapter 1, 
some studies have already shown that CBD reduced progressive degeneration of nigrostriatal 
dopaminergic neurons in rat model of Parkinson’s disease (Lastres-Becker et al., 2005; 
Garcia-Arencibia et al., 2007). Further, a survey conducted on Parkinson’s disease patients in 
the Czech Republic reported 39 of 85 cannabis users had an improvement in motor symptoms 
associated with Parkinson’s disease  (Venderova et al., 2004). Additionally, a few small-scale 
clinical studies informed that CBD improved the psychotic symptoms and quality of life 
without causing any adverse effect on motor symptoms in Parkinson’s disease patients 
(Zuardi et al., 2009; Chagas et al., 2014a; Chagas et al., 2014b). However, a large-scale 
clinical trial is warranted to find out the effect of CBD on motor symptoms associated with 
Parkinson’s disease.  
Besides the protective role of CBD on motor deficits, its effectiveness in several 
neuropsychiatric comorbidities associated with epilepsy, including social deficits, has been 
illustrated in this project using the Scn1a+/- mice.  Although a previous study with a single 
low dose of CBD (20 mg/kg; i.p.) has been shown to restore the social impairment in these 
animals, it is therapeutically irrelevant in the context of epilepsy where patients receive 
multiple anticonvulsant doses of AED for a long time (Kaplan et al., 2017). In this project, 
for the first time chronic anticonvulsant doses of CBD have been demonstrated to improve 
social deficits associated with epilepsy. It is important to note that, in these experiments, 
CBD treatment was started at an early stage of the disease, which suggests that an early 
intervention could prevent the social impairment associated with epilepsy even with the 
higher anticonvulsant dose. Interestingly, social interaction deficit is a common trait in autism 
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(APA, 2013), therefore the results also cast a new light on the possible role of CBD in the 
treatment of autism. 
Anxiety and depression are the most commonly observed comorbidities across all 
forms of epilepsy (Wiglusz et al., 2012; Ottman et al., 2011; Tellez-Zenteno et al., 2007). 
However, the role of CBD on these two comorbidities has never been evaluated in any 
preclinical epilepsy models. This project is therefore also the first to demonstrate that CBD 
attenuates the anxiety-like and depression-like behaviours associated with epilepsy. Further, 
AED-induced depression and anxiety disorders are often seen in epilepsy patients (Jacoby et 
al., 2015; Gómez-Arias et al., 2012). Treatment with conventional AEDs such as 
levetiracetam, zonisamide and phenobarbital causes multiple psychiatric comorbidities 
including anxiety and depression in patients with epilepsy (White et al., 2010; Herranz et al., 
1988; Weintraub et al., 2007). Given CBD’s apparent anxiolytic/antidepressant effects it is 
tempting to speculate that CBD may be used as an alternative or in combination with these 
AEDs not only to help reducing seizures but also to prevent the drug induced comorbidities. 
The anxiolytic and antidepressant effect of CBD has previously been demonstrated in rodents 
using genetic (Shoval et al., 2016), olfactory bulbectomy (Linge et al., 2016), chronic 
unpredictable stress (Campos et al., 2013) models of depression and repeated combination 
tests model of anxiety (Hsiao et al., 2012). Anxiolytic effect of CBD has also been reported 
in social phobia patients (Crippa et al., 2011; Bergamaschi et al., 2011). In agreement with 
these studies my results suggest a possible application of CBD in the treatment of generalised 
anxiety and depression associated with other diseases.  
The present project further established cognitive deficits in two conventional preclinical 
models of epilepsy, which are in accordance with the reported cases of cognitive impairment 
in various types of epilepsy patients (Acha et al., 2015; Riikonen, 1996; Riccio and Vidrine, 
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2017; Liu et al., 2016; Verche et al., 2018). Most importantly, I established another novel 
finding that CBD restored the epilepsy induced reference and working memory deficits in 
both TLE and Dravet syndrome. Therefore, it seems reasonable to speculate that the role of 
CBD in improvement of cognition is not restricted to a specific type of epilepsy, but it has the 
potential to restore memory deficit associated with other types of epilepsies. Moreover, 
several AEDs such as phenobarbital, phenytoin and topiramate aggravate the adverse effect 
upon cognition (Chen et al., 2001; Mei et al., 2006; Wandschneider et al., 2017), thus CBD 
may essentially reduce their adverse effects if used in combination or perhaps replace these in 
certain circumstances.  
The beneficial effect of CBD on different types of memory have previously been 
described in several preclinical and clinical studies (Osborne and Solowij, 2017; Martin-
Moreno et al., 2011; Cheng et al., 2014a; Hindocha et al., 2015). For example, CBD has been 
demonstrated to attenuate working memory deficit in prenatal infection model in rats 
(Osborne and Solowij, 2017) and hepatic encephalopathy model in mice (Avraham et al., 
2011; Magen et al., 2010; Magen et al., 2009). Furthermore, CBD associated improvements 
in spatial memory were evidenced on Morris water maze test in Alzheimer’s disease (Martin-
Moreno et al., 2011), cerebral malaria (Campos et al., 2015) and hypoxic brain injury 
(Schiavon et al., 2014) models in mice. As well as spatial memory, CBD has been reported to 
improve social recognition memory in rodents both in transgenic (Cheng et al., 2014a; Cheng 
et al., 2014b) and iron overload induced Alzheimer’s disease model (Fagherazzi et al., 2012). 
Interestingly, CBD has been demonstrated to improve Δ9-THC induced deficits in verbal and 
recognition memory (Morgan et al., 2012; Morgan et al., 2010; Hindocha et al., 2015), and 
working memory (Englund et al., 2013) in human volunteers.  Therefore, in line with the 
previous studies my results suggest that CBD could be a potential candidate drug for the 
treatment of memory disorders.  
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 General Conclusion 
Overall, I demonstrated the novel findings that CBD improves seizures, survivability 
and comorbidities associated with validated animal models of adult and childhood epilepsies. 
This is also the first study to establish that CBD has disease modifying role in both preclinical 
models of TLE and Dravet syndrome. Notably, the results of this project (Figure 5.1) 
contributed significantly towards the US-FDA approval of Epidiolex® (GW Pharmaceuticals) 
in 2018 (FDA, 2018). This project also highlights the further potential for CBD to reduce 
comorbidities associated with epilepsy and its current treatment. Taken together this project 
enhance the existing knowledge on CBD and its role in epilepsy. 
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Figure 5.1. Pictorial illustration of the overall findings of this project. Effect of CBD-
treatment was investigated in RISE-SRS rat model of TLE, and Scn1a-/- and Scn1a+/- mouse 
models of Dravet syndrome. In RISE-SRS rat model of TLE, CBD reduced seizures, 
improved motor function and cognition without affecting the gait. Further, in Scn1a-/- mouse 
model, CBD extended survivability and improved several welfare parameters. Finally, in 
Scn1a+/- mouse model of Dravet syndrome, CBD reduced premature mortality, improved 
social behaviour and cognition, and reduced anxiety-like and depression-like behaviours 
without producing any motor adverse effects. These results formed a core part of the 
development and approval of Epidiolex® (GW Pharmaceuticals) in 2018. 
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 Future scope of research 
The primary objective of this PhD project was to evaluate the effect of CBD on 
seizures, premature mortality and comorbidities associated with epilepsy. I establish that 
CBD reduces premature mortality and improves seizures and associated comorbidities. 
Nonetheless, several questions remain unanswered which need to be investigated in future 
studies.  
It has been demonstrated that CBD improved spontaneous seizures, but it is still not 
clear how CBD exerted this role. Inclusion of in vivo electrophysiology techniques in future 
studies with similar experimental design may provide us with more information on CBD’s 
role in modifying brain network activities in the epileptic animals. For example, 
electrocorticography (ECoG) or EEG could be conducted in the Scn1a+/- mouse model of 
Dravet syndrome during P21-27 (peak mortality period) to demonstrate that CBD can reduce 
the epileptiform activity in Scn1a+/- mice. Of note, I have collected and preserved the brain 
tissues from each of my experiments for future use. In order to gain a better understanding of 
the molecular mechanism of actions of CBD, these tissues could be utilised for 
immunohistochemistry and Western blot analysis to map the distribution, expression and the 
intracellular signalling pathways of several important receptor proteins such as GPR55, 
PPARγ and adenosine A2A that have previously been reported to be involved in CBD’s 
antiepileptogenic and anticonvulsant action (O'Sullivan et al., 2009; Ryberg et al., 2007). It is 
to be mentioned that some of the blood and brain tissue samples derived from this project 
have been used to implicate the 1 carbon cycle in the mechanism of action of CBD and this 
work has currently been submitted to the journal PNAS (Perry et al., unpublished work). 
Here in this project, CBD prevented the premature mortality in epileptic animals 
possibly due to its well-known anticonvulsant effect. To further investigate, whether this 
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preventive effect of CBD could also be attributed to its cardioprotective action, 
electrocardiography (ECG) may be conducted in a simillar experimental set up alongside 
already proposed EEG. 
Although this project establish that CBD improves the comorbidities associated with 
epilepsy, it suffers from some limitations due to the lack of mechanistic insights which needs 
to be explored in future. Previous studies on healthy animals have shown that CBD exerts its 
anxiolytic and antidepressant effects by enhancing the 5-HT1A signalling (Campos and 
Guimaraes, 2008; Soares Vde et al., 2010), therefore in future studies (involving simillar 
protocol as used in my project) 5-HT1A receptor antagonist like WAY-100635 could be 
administered before the relevant behavioural tasks. An absence of beneficial effect on these 
parameters will indicate that CBD acts on 5-HT1A receptors to demonstrate its anxiolytic and 
antidepressant effects in epilepsy.  Further, it has been proposed that CBD’s anti-
inflammatory and neuroprotective action play important role in memory protection in 
Alzheimer’s disease (Esposito et al., 2007; Esposito et al., 2011). Therefore, the expression 
of inflammatory mediators such as iNOS, IL-1β, GFAP and PPARγ can be evaluated from 
the preserved brain tissues by both immunohistochemistry and Western blot analysis to shed 
light on CBD’s role in attenuating epilepsy-induced memory deficits. 
I demonstrated CBD’s beneficial role only in spatial memory, therefore future studies 
are recommended to explore whether CBD can also improve other types of memories such as 
fear and recognition memories. This could be studied by fear conditioning (Kemppainen et 
al., 2006) and novel object recognition tests (Pearson et al., 2014) using the same 
experimental paradigm used in the present project. Further, it might be interesting to see 
whether CBD acts on the acquisition and/or retrieval step of the memory process using 
specially designed memory tasks. 
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In this project, the animals were chronically treated with CBD until the end of 
experiment. This approach allowed us to explore the disease modifying effect of CBD, 
however inclusion of a washout period for CBD at the end of experiment (instead of 
sacrificing them) followed by repeating the behavioural tasks would allow us to gain insight 
into the possible curative role of CBD against the comorbidities and further demonstrate that 
if the effect is truly disease modifying or not.   
  Finally, having observed the positive effects of CBD on motor and psychiatric 
comorbidities, future studies to assess the role of CBD on several other neurological and 
psychiatric disorders such as Parkinson’s disease, Alzheimer’s disease, generalised anxiety 
disorders, depression and autism would also be interesting. 
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Figure I. Dot plot showing the correlation of seizure burden with memory function. No 
correlation was found between seizure burden and A. reference memory function in epileptic 
vehicle-treated animals. B. working memory function in epileptic vehicle-treated animals. C. 
reference memory function in epileptic CBD-treated animals. D. working memory function in 
epileptic CBD-treated animals. n=8/group; data were analysed by linear regression. 
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%% __________________________Loading GUI_________________________________ 
function varargout = EndpointGui2(varargin) 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', @EndpointGui2_OpeningFcn, ... 
                   'gui_OutputFcn',  @EndpointGui2_OutputFcn, ... 
                   'gui_LayoutFcn',  [] , ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 
    gui_State.gui_Callback = str2func(varargin{1}); 
end 
 
if nargout 
    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
    gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
  
% --- Executes just before EndpointGui2 is made visible. 
function EndpointGui2_OpeningFcn(hObject, eventdata, handles, varargin) 
handles.output = hObject; 
guidata(hObject, handles); 
 
function varargout = EndpointGui2_OutputFcn(hObject, eventdata, handles)  
varargout{1} = handles.output; 
  
%% __________________________Objects___________________________________ 
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function edit1_Callback(hObject, eventdata, handles) 
function edit1_CreateFcn(hObject, eventdata, handles) 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
set(hObject,'BackgroundColor','white'); 
end 
  
function edit2_Callback(hObject, eventdata, handles) 
function edit2_CreateFcn(hObject, eventdata, handles) 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
set(hObject,'BackgroundColor','white'); 
end 
  
function edit3_Callback(hObject, eventdata, handles) 
function edit3_CreateFcn(hObject, eventdata, handles) 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
set(hObject,'BackgroundColor','white'); 
end 
  
function NWSedit_Callback(hObject, eventdata, handles) 
function NWSedit_CreateFcn(hObject, eventdata, handles) 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
set(hObject,'BackgroundColor','white'); 
end 
  
function NAedit_Callback(hObject, eventdata, handles) 
function NAedit_CreateFcn(hObject, eventdata, handles) 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
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set(hObject,'BackgroundColor','white'); 
end 
function RTedit_Callback(hObject, eventdata, handles) 
function RTedit_CreateFcn(hObject, eventdata, handles) 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
set(hObject,'BackgroundColor','white'); 
end 
  
function OTedit_Callback(hObject, eventdata, handles) 
function OTedit_CreateFcn(hObject, eventdata, handles) 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
set(hObject,'BackgroundColor','white'); 
end 
  
function BCSedit_Callback(hObject, eventdata, handles) 
function BCSedit_CreateFcn(hObject, eventdata, handles) 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
set(hObject,'BackgroundColor','white'); 
end 
  
function Weightcrit_Callback(hObject, eventdata, handles) 
  
function Weightcrit_CreateFcn(hObject, eventdata, handles) 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
set(hObject,'BackgroundColor','white'); 
end 
  
function BCS_checkbox_Callback(hObject, eventdata, handles) 
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function OT_checkbox_Callback(hObject, eventdata, handles) 
function RT_checkbox_Callback(hObject, eventdata, handles) 
function NA_checkbox_Callback(hObject, eventdata, handles) 
function NWS_checkbox_Callback(hObject, eventdata, handles) 
function Weight_checkbox_Callback(hObject, eventdata, handles) 
function SurfTemp_checkbox_Callback(hObject, eventdata, handles) 
  
%% __________________________Loading parameters____________________ 
  
%% 1. Loading file 
 
function Load_File_Callback(hObject, eventdata, handles) 
function Load_xl_file_Callback(hObject, eventdata, handles) 
%uiopen 
[FileName,FilePath] = uigetfile('*.xls','File Selector'); 
global Param 
  
try 
    cd(FilePath) 
    Param = xlsread(FileName); 
catch 
    disp(strcat('you have to select a file or it does not work')) 
end 
  
%% _________________________Buiding model_________________________  
function Go1_Callback(hObject, eventdata, handles)  
  
%% 1.Averaging values 
 
global Param 
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global DeadAnimalNb 
global DeadAnimalind 
 
ind = find(Param(:,11) == 1); 
DeadAnimalind = []; 
for i = 1:length(ind) 
    DeadAnimalind = cat(1,DeadAnimalind,Param(ind(i),1)); 
end 
  
DeadAnimalNb = length(DeadAnimalind); 
  
AvParam = Param; 
  
for i = 1:max(Param(:,1))  
    ind = find(Param(:,1) == i); 
    for j = 3:8 
        for k = 3:length(ind)-1 
            AvParam(ind(k),j) = mean(Param(ind(k)-2:ind(k),j)); 
        end 
    end 
end 
  
%% 2.Death Day  
DeathDay = []; 
for i = 1:DeadAnimalNb 
    ind = find(Param(:,1) == DeadAnimalind(i)); 
    DeathDay = cat(2,DeathDay,max(Param(ind,2))); 
end 
  
%% 3.Death delay calculation 
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DayBefDeath = []; 
AnimalN = 0; 
for i = 1:max(Param(:,1)) 
   
    if isempty(find(DeadAnimalind(:) == i)) 
        ind = find(Param(:,1) == i); 
        for j = 1:length(ind) 
            DayBefDeath = cat(1,DayBefDeath,NaN); 
        end 
    else 
        AnimalN = AnimalN + 1; 
        ind = find(Param(:,1) == i); 
        for j = 1:length(ind) 
            DayBefDeath = cat(1,DayBefDeath,DeathDay(1,AnimalN)- Param(ind(j),2)); 
        end 
    end 
end 
  
global Param2 
Param2 = cat(2,Param(:,1),DayBefDeath,AvParam(:,4:8),Param(:,3),Param(:,9)); 
  
%% 3.Criterions calculation 
  
CritMatrix = []; 
  
global DelayParam 
DelayParam = str2double(get(handles.edit2,'string')); 
ind = find(Param2(:,2) == DelayParam); 
 
global NWScrit 
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NWScrit = min(Param2(ind,3)); 
%disp(strcat('NWS criterion >= ',num2str(NWScrit))) 
%set(handles.NWSedit,'string',num2str(NWScrit)) 
CritMatrix = cat(2,CritMatrix,Param2(ind,3)); 
 
global NAcrit 
NAcrit = min(Param2(ind,4)); 
%disp(strcat('NA criterion >= ',num2str(NAcrit))) 
%set(handles.NAedit,'string',num2str(NAcrit)) 
CritMatrix = cat(2,CritMatrix,Param2(ind,4)); 
 
global RTcrit 
RTcrit = min(Param2(ind,5)); 
%disp(strcat('RT criterion >= ',num2str(RTcrit))) 
%set(handles.RTedit,'string',num2str(RTcrit)) 
CritMatrix = cat(2,CritMatrix,Param2(ind,5)); 
 
global OTcrit 
OTcrit = min(Param2(ind,6)); 
%disp(strcat('OT criterion >= ',num2str(OTcrit))) 
%set(handles.OTedit,'string',num2str(OTcrit)) 
CritMatrix = cat(2,CritMatrix,Param2(ind,6)); 
 
global BCScrit 
BCScrit = max(Param2(ind,7)); 
%disp(strcat('BCS criterion <= ',num2str(BCScrit))) 
%set(handles.BCSedit,'string',num2str(BCScrit)) 
CritMatrix = cat(2,CritMatrix,Param2(ind,7)); 
 
global Weightcrit 
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Weightcrit = max(Param2(ind,8)); 
%disp(strcat('Weight criterion <= ',num2str(Weightcrit))) 
%set(handles.Weightcrit,'string',num2str(Weightcrit)) 
CritMatrix = cat(2,CritMatrix,Param2(ind,8)); 
 
global critVec 
critVec = cat(1,NWScrit,NAcrit,RTcrit,OTcrit,BCScrit,Weightcrit); 
 
CritDev = []; 
for i = 1:6 
    if i <= 4    
        CritDev = cat(2,CritDev,critVec(i)-nanstd(CritMatrix(:,i)));      
    else  
        CritDev = cat(2,CritDev,critVec(i)+nanstd(CritMatrix(:,i))); 
    end 
end 
NWScrit = CritDev(1); 
set(handles.NWSedit,'string',num2str(CritDev(1))) 
NAcrit = CritDev(2); 
set(handles.NAedit,'string',num2str(CritDev(2))) 
RTcrit = CritDev(3); 
set(handles.RTedit,'string',num2str(CritDev(3))) 
OTcrit = CritDev(4); 
set(handles.OTedit,'string',num2str(CritDev(4))) 
BCScrit = CritDev(5); 
set(handles.BCSedit,'string',num2str(CritDev(5))) 
Weightcrit = CritDev(6); 
set(handles.Weightcrit,'string',num2str(CritDev(6))) 
   
%% 4.Death delay calculation 
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NWSCheck = get(handles.NWS_checkbox,'value'); 
NACheck = get(handles.NA_checkbox,'value'); 
RTCheck = get(handles.RT_checkbox,'value'); 
OTCheck = get(handles.OT_checkbox,'value'); 
BCSCheck = get(handles.BCS_checkbox,'value'); 
WeightCheck = get(handles.Weight_checkbox,'value'); 
SurfCheck = get(handles.SurfTemp_checkbox,'value'); 
  
Vec = cat(1,NWSCheck,NACheck,RTCheck,OTCheck,BCSCheck,WeightCheck); 
CheckVec = []; 
for i = 1:length(Vec) 
    if Vec(i) == 1 
        CheckVec = cat(1,CheckVec,i); 
    end 
end 
  
Results = []; 
AnimalVec = []; 
for i = 1:DeadAnimalNb 
    AnimalVec = cat(1,AnimalVec,DeadAnimalind(i)); 
    ind = find(Param2(:,1) == DeadAnimalind(i) & Param2(:,2) <= 8); 
      
    SurfTempValue = 0; 
    for j = 1:length(ind) 
        TempValue = 0; 
          
        if SurfCheck == 1 
            SurfTempValue = SurfTempValue + Param2(ind(j),9); 
            if SurfTempValue >= 2 
                disp(strcat('Animal nb :',num2str(DeadAnimalind(i)),'--> death delay is 
:',num2str(Param2(ind(j),2)))) 
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                disp(strcat('Animal nb :',num2str(DeadAnimalind(i)),'--> body surface temp >= 2')) 
                Results = cat(1,Results,Param2(ind(j),2)); 
                break  
            end 
        end 
   
        if j < length(ind)            
              
            for k = 1:length(CheckVec) 
                if CheckVec(k) == 1 | CheckVec(k) == 2 | CheckVec(k) == 3 | CheckVec(k) == 4 
                    if max(Param2(ind(1):ind(j),CheckVec(k)+2)) >= critVec(CheckVec(k)) 
                        TempValue = TempValue + 1; 
                    end                 
                elseif  CheckVec(k) == 5 | CheckVec(k) == 6 
                    if min(Param2(ind(1):ind(j),CheckVec(k)+2)) <= critVec(CheckVec(k)) 
                        TempValue = TempValue + 1; 
                    end                
                end             
            end  
  
            if TempValue == length(CheckVec) 
                disp(strcat('Animal nb :',num2str(DeadAnimalind(i)),'--> death delay is 
:',num2str(Param2(ind(j),2)))) 
                Results = cat(1,Results,Param2(ind(j),2)); 
                break  
            end 
                         
        elseif j == length(ind) 
              
            for k = 1:length(CheckVec) 
                if CheckVec(k) == 1 | CheckVec(k) == 2 | CheckVec(k) == 3 | CheckVec(k) == 4 
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                    if max(Param2(ind(1):ind(j),CheckVec(k)+2)) >= critVec(CheckVec(k)) 
                        TempValue = TempValue + 1; 
                    end                 
                elseif  CheckVec(k) == 5 | CheckVec(k) == 6 
                    if min(Param2(ind(1):ind(j),CheckVec(k)+2)) <= critVec(CheckVec(k)) 
                        TempValue = TempValue + 1; 
                    end                
                end             
            end  
  
            if TempValue == length(CheckVec) 
                disp(strcat('Animal nb :',num2str(DeadAnimalind(i)),'--> death delay is 
:',num2str(Param2(ind(j),2)))) 
                Results = cat(1,Results,Param2(ind(j),2)); 
                break           
  
            else 
                disp(strcat('Animal nb :',num2str(DeadAnimalind(i)),'--> welfare scores are still 
satisfactory')) 
                Results = cat(1,Results,0); 
                break 
            end 
        end 
    end 
end 
  
set(handles.edit1,'string',num2str(cat(2,AnimalVec,Results))) 
  
%% _________________________Predicting death_______________________ 
  
function Go2_Callback(hObject, eventdata, handles)  
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global Param2 
global DeadAnimalind 
global critVec 
  
NWSCheck = get(handles.NWS_checkbox,'value'); 
NACheck = get(handles.NA_checkbox,'value'); 
RTCheck = get(handles.RT_checkbox,'value'); 
OTCheck = get(handles.OT_checkbox,'value'); 
BCSCheck = get(handles.BCS_checkbox,'value'); 
WeightCheck = get(handles.Weight_checkbox,'value'); 
SurfCheck = get(handles.SurfTemp_checkbox,'value'); 
  
Vec = cat(1,NWSCheck,NACheck,RTCheck,OTCheck,BCSCheck,WeightCheck); 
CheckVec = []; 
for i = 1:length(Vec) 
    if Vec(i) == 1 
        CheckVec = cat(1,CheckVec,i); 
    end 
end 
  
global NWScrit 
global NAcrit 
global RTcrit 
global OTcrit 
global BCScrit 
global Weightcrit 
critVec = cat(1,NWScrit,NAcrit,RTcrit,OTcrit,BCScrit,Weightcrit); 
  
  
   
  Survivability model script 
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AliveAnimalind = []; 
for i = 1:max(Param2(:,1)) 
    if isempty(find(DeadAnimalind(:) == i)) 
        AliveAnimalind = cat(1,AliveAnimalind,i); 
    end 
end 
   
Results = []; 
AnimalVec = []; 
for i = 1:length(AliveAnimalind) 
    AnimalVec = cat(1,AnimalVec,AliveAnimalind(i)); 
    ind = find(Param2(:,1) == AliveAnimalind(i)); 
      
    if length(ind) < 17 
        disp(strcat('Animal nb :',num2str(AliveAnimalind(i)),'--> welfare scores are still 
satisfactory')); 
        Results = cat(1,Results,0);         
    else 
          
        if SurfCheck == 1 
            SurfTempValue = sum(Param2(ind(16):ind(end),9) > 0); 
            if SurfTempValue >= 3 
                disp(strcat('Animal nb :',num2str(AliveAnimalind(i)),'--> body surface temp >= 3')) 
                disp(strcat('Animal nb :',num2str(AliveAnimalind(i)),'--> needs to be killed 
ASAP')) 
                Results = cat(1,Results,1); 
                 
            else 
                TempValue = 0; 
                for k = 1:length(CheckVec) 
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                    if CheckVec(k) == 1 | CheckVec(k) == 2 | CheckVec(k) == 3 | CheckVec(k) == 
4 
                        if max(Param2(ind(16):ind(end),CheckVec(k)+2)) >= critVec(CheckVec(k)) 
                            TempValue = TempValue + 1; 
                        end                 
                    elseif  CheckVec(k) == 5 | CheckVec(k) == 6 
                        if min(Param2(ind(16):ind(end),CheckVec(k)+2)) <= critVec(CheckVec(k)) 
                            TempValue = TempValue + 1; 
                        end                
                    end             
                end  
  
                if TempValue == length(CheckVec) 
                    disp(strcat('Animal nb :',num2str(AliveAnimalind(i)),'--> needs to be killed')) 
                    Results = cat(1,Results,1); 
                else 
                    disp(strcat('Animal nb :',num2str(AliveAnimalind(i)),'--> welfare scores are still 
satisfactory')) 
                    Results = cat(1,Results,0);            
                end                                                  
            end 
              
        else 
            TempValue = 0; 
            for k = 1:length(CheckVec) 
                if CheckVec(k) == 1 | CheckVec(k) == 2 | CheckVec(k) == 3 | CheckVec(k) == 4 
                    if max(Param2(ind(16):ind(end),CheckVec(k)+2)) >= critVec(CheckVec(k)) 
                        TempValue = TempValue + 1; 
                    end                 
                elseif  CheckVec(k) == 5 | CheckVec(k) == 6 
                    if min(Param2(ind(16):ind(end),CheckVec(k)+2)) <= critVec(CheckVec(k)) 
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                        TempValue = TempValue + 1; 
                    end                
                end             
            end  
  
            if TempValue == length(CheckVec) 
                disp(strcat('Animal nb :',num2str(AliveAnimalind(i)),'--> needs to be killed')) 
                Results = cat(1,Results,1); 
            else 
                disp(strcat('Animal nb :',num2str(AliveAnimalind(i)),'--> welfare scores are still 
satisfactory')) 
                Results = cat(1,Results,0);            
            end                  
        end        
   end 
end 
  
set(handles.edit3,'string',num2str(cat(2,AnimalVec,Results) 
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Summary
Objective: Epilepsy is a progressive neurological disease characterized by recur-
rent seizures and behavioral comorbidities. We investigated the antiseizure effect
of cannabidiol (CBD) in a battery of acute seizure models. Additionally, we
defined the disease‐modifying potential of chronic oral administration of CBD on
associated comorbidities in the reduced intensity status epilepticus–spontaneous
recurrent seizures (RISE‐SRS) model of temporal lobe epilepsy (TLE).
Methods: We evaluated the acute antiseizure effect of CBD in the maximal elec-
troshock seizure, 6‐Hz psychomotor seizure, and pentylenetetrazol acute seizure tests,
as well as the corneal kindling model of chronic seizures in mice following intraperi-
toneal administration. Median effective or behavioral toxic dose was determined in
both mice and rats. Next, we tested an intravenous preparation of CBD (10 mg/kg sin-
gle dose) in a rat model of pilocarpine‐induced status epilepticus. We defined the
effect of chronic CBD administration (200 mg/kg orally) on spontaneous seizures,
motor control, gait, and memory function in the rat RISE‐SRS model of TLE.
Results: CBD was effective in a battery of acute seizure models in both mice and
rats following intraperitoneal administration. In the pilocarpine‐induced status
epilepticus rat model, CBD attenuated maximum seizure severity following intra-
venous administration, further demonstrating CBD’s acute antiseizure efficacy in
this rat model. We established that oral CBD attenuated the time‐dependent
increase in seizure burden and improved TLE‐associated motor comorbidities of
epileptic rats in the RISE‐SRS model without affecting gait. Chronic administra-
tion of CBD after the onset of SRS ameliorated reference memory and working
memory errors of epileptic animals in a spatial learning and memory task.
Significance: The present study illustrates that CBD is a well‐tolerated and effec-
tive antiseizure agent and illustrates a potential disease‐modifying effect of CBD
on reducing both seizure burden and associated comorbidities well after the onset
of symptomatic seizures in a model of TLE.
Williams and McNeish contributed equally.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited and is not used for commercial purposes.
© 2018 The Authors Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy
Received: 15 October 2018 | Revised: 26 November 2018 | Accepted: 30 November 2018
DOI: 10.1111/epi.14629
Epilepsia. 2019;60:303–314. wileyonlinelibrary.com/journal/epi | 303
KEYWORD S
cannabinoids, gait, maximal electroshock, memory, motor function, pilocarpine
1 | INTRODUCTION
Epilepsy is a progressive, chronic neurological disorder char-
acterized by recurrent seizures.1 Approximately 65 million
people worldwide live with epilepsy, of whom ~30% are con-
sidered pharmacoresistant to the currently available anti-
seizure drugs (ASDs).2 Seizures, although the primary
symptom, are not the only aspect of epilepsy that affects a
patient’s quality of life. Several comorbidities (eg, depression,
anxiety, motor disorder, cognitive deficits, social dysfunction)
also contribute to a reduced quality of life in addition to the
poor prognosis associated with the disease.3 Furthermore, cur-
rently available ASDs are also known to produce a variety of
cognitive, psychiatric, and motor adverse effects4,5; thus, ther-
apies that do not carry the potential to increase the adverse
effects liability are in significant clinical demand.
Cannabis has been used since prehistoric times to treat
several diseases, including epilepsy.6 However, the thera-
peutic benefits of whole cannabis are overshadowed by its
psychoactive effects,7 which have limited its clinical use.
More than 100 phytocannabinoids have been isolated, of
which Δ9‐tetrahydrocannabinol, cannabidiol (CBD), and
cannabidivarin are considered most relevant in the treat-
ment of epilepsy; however, Δ9‐tetrahydrocannabinol has
poor clinical potential due to its psychoactive and potential
proconvulsive properties, which may limit chronic use.1,6
CBD has been shown to have antiseizure activity in several
animal models.6,8–10 Given its anticonvulsant efficacy in
phase 3 clinical trials, the US Food and Drug Administra-
tion (FDA) in 2018 approved CBD (Epidiolex; GW
Research) as a drug for the treatment of seizures associated
with Dravet syndrome or Lennox‐Gastaut syndrome in
patients 2 years of age and older.11–13
Here, we initially tested CBD in a battery of well‐estab-
lished preclinical seizure and epilepsy models following
intraperitoneal administration to define CBD’s pharmaco-
logical profile and differentiate it from other ASD standards
of care. Second, we investigated the efficacy of intravenous
(IV) pretreatment with CBD in the rat pilocarpine‐induced
status epilepticus (SE) model. SE is one of the most com-
mon medical emergencies in patients with epilepsy, and is
clinically defined as a seizure lasting >5 minutes or repeti-
tive seizures within this time frame without regaining con-
sciousness.14 The pilocarpine‐induced SE model is typically
sensitive to most ASDs when they are administered prior to
or commensurate with SE onset; nonetheless, this model is
useful to interrogate pharmacological efficacy in a severe
seizure model. Finally, there is little information on the
potential of CBD to modify epilepsy‐related behavioral
comorbidities despite its preclinical and clinical ability to
provide acute seizure control.6,8–11,13 Furthermore, no pre-
clinical study has yet shown that sustained exposure to
CBD not only reduces seizure burden in a temporal lobe
epilepsy (TLE) model but can also attenuate the severity of
the associated behavioral comorbidities. Therefore, as a
final step we assessed the effects of chronic oral administra-
tion of CBD on spontaneous seizures and associated behav-
ioral comorbidities in the newly developed reduced
intensity SE–induced spontaneous recurrent seizures (RISE‐
SRS) model.15 The RISE‐SRS model exhibits a similar dis-
ease progression and pathology as the traditional post‐SE
rat models, but with reduced mortality during the immediate
post‐SE period. This model provides a platform for the con-
duct of long‐duration disease modification studies with can-
didate investigational therapies. Of note, the present study
utilized a clinically relevant treatment design, as animals
were only enrolled to receive CBD well after the onset of
SRS. The results of the present study indicate that CBD
exerts acute antiseizure efficacy by multiple routes of
administration in several well‐validated preclinical seizure
and epilepsy models with a preclinical profile that is differ-
ent from other prototype ASDs.16,17 Moreover, this present
study provides the first demonstration in a preclinical model
of TLE to suggest that CBD may exert potential disease‐
modifying effects on SRS and attendant behavioral
comorbidities.
Key Points
• CBD is effective in a battery of acute seizure
models following intraperitoneal administration
• CBD is effective in attenuating maximum seizure
severity following intravenous administration in
rats
• Oral CBD can attenuate time-dependent increase
in seizure burden and motor comorbidities in a
rat model of TLE
• Oral CBD can reverse epilepsy-induced cognitive
deficits in a rat model of TLE
• This is the first study to demonstrate the disease-
modifying effect of CBD on spontaneous recur-
rent seizure and associated comorbidities
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2 | MATERIALS AND METHODS
All materials and methods are described in online
Appendix S1.
3 | RESULTS
3.1 | CBD demonstrates acute antiseizure
efficacy following intraperitoneal
administration in a battery of well‐established
acute rodent seizure models
CBD (intraperitoneal [IP]) was initially evaluated for acute
antiseizure efficacy in a battery of well‐defined rodent sei-
zure and epilepsy models (Table 1). These models have
formed the basis for ASD discovery for decades17,18 and
were thus employed to initially define the acute antiseizure
efficacy of CBD relative to standard ASDs.17 For the pur-
poses of the present study, we have also included the effi-
cacy data for the ASDs phenobarbital (PB), valproic acid
(VPA), and felbamate (FBM) as reported in the National
Institute of Neurological Disorders and Stroke public data-
base PANAChE (Table 1). The rotarod test was used to
determine the potential for CBD to induce minimal motor
impairment in mice and to calculate a median behaviorally
impairing dose (TD50). Male mice were found to be
impaired in their ability to perform on the rotorod test at a
TD50 of 272 mg/kg (95% confidence interval [CI] = 241‐
303) when it was administered IP 1 hour prior to testing.
In the antiseizure tests in mice, IP administration of CBD
prior to electrical stimulation was found to block tonic
extension seizures induced by maximal electroshock seizure
(MES) in male mice with a median effective dose (ED50)
of 80.0 mg/kg (95% CI = 65.5‐96.0), yielding a protective
index (PI; TD50/ED50) of 3.4. CBD was also effective in
male mice against clonic seizures induced by subcutaneous
administration of pentylenetetrazol when administered
1 hour prior to testing (ED50 = 120 mg/kg IP, PI = 2.3).
CBD was found to protect male mice against the 6‐Hz par-
tial psychomotor seizure at two different currents following
IP administration. With a 32‐mA stimulation delivered
1 hour after drug administration, CBD had an ED50 of
144 mg/kg, yielding a PI for this test of 1.9. Importantly,
CBD was also found to be effective and retained its
potency at the 44‐mA stimulation current in the 6‐Hz test
when administered 1 hour prior to electrical stimulation;
ED50 at this current and time point of 173 mg/kg (PI =
1.6). Additionally, in male corneal kindled mice, the ED50
of CBD was determined to be 144 mg/kg (PI = 1.9). Thus,
CBD demonstrates broad antiseizure efficacy in several
well‐validated mouse models of acute (MES, subcutaneous
pentylenetetrazol, 6 Hz) and chronic (corneal kindled) sei-
zures at doses well below the motor‐impairing dose.
In male rats, visual evaluation of minimal motor impair-
ment was scored by a trained investigator to determine the
adverse effects of CBD on behavioral performance. Naive
male rats were not found to be impaired on this test follow-
ing administration of CBD doses up to 500 mg/kg; thus, a
TD50 was determined to exceed 500 mg/kg (IP). In the
antiseizure tests in rats, IP administration of CBD 2 hours
prior to electrical stimulation was found to block tonic
extension seizures induced by MES with an ED50 of
53.2 mg/kg, yielding a PI of >9.4. Thus, as demonstrated
in male mice, CBD was effective in the rat MES test at a
dose well below the motor‐impairing dose. Based on this
demonstration of efficacy and tolerability in several well‐
established acute seizure models in rats and mice, CBD
was further evaluated in the pilocarpine‐SE model and an
etiologically relevant rat model of post‐SE TLE.
3.2 | IV administration of CBD reduces
severity of pilocarpine‐induced SE
The pilocarpine‐induced SE model is a well‐established
model of severe generalized seizures that is often used in the
pursuit of novel ASDs. Based on the acute efficacy of CBD
in the rat MES test following IP administration (Table 1),
CBD was administered by the IV route 1 hour prior to the
onset of SE to determine any potential for effect on maximal
SE severity. This dose of CBD was found to significantly
attenuate the maximum seizure severity (MSS; P < 0.05)
compared to the vehicle‐treated group (Figure 1A). To
demonstrate the validity of the protocol and tractability of
the model, we also evaluated the efficacy of a supratherapeu-
tic dose of PB (30 mg/kg IV). Administration of PB 30 min-
utes prior to SE onset significantly reduced the MSS
(P < 0.0001) relative to the vehicle‐treated group (Fig-
ure 1B). It should be emphasized that the doses of CBD ver-
sus PB tested in this model were not pharmacologically
equivalent (Table 1), as the IV dose of CBD was threefold
lower than the rat MES ED50 (IP), whereas the dose of PB
was 15‐fold higher than the rat MES ED50 (IP). Of note, no
mortality was observed in any of the experimental animals
during the behavioral seizure monitoring period. Thus, CBD
pretreatment was found to acutely attenuate MSS in this rat
model of SE to a degree consistent with PB.
3.3 | Chronic oral administration of CBD
attenuates seizure burden in the RISE‐SRS
model of TLE
3.3.1 | Chronic oral administration of CBD
reduces long‐term seizure burden
To evaluate the effect of chronic CBD administration on
disease progression, we examined the effect of treatment
PATRA ET AL. | 305
upon seizure burden and seizure burden ratio of rats dis-
playing chronic epilepsy. The seizure burden ratio was cal-
culated from the seizure burden in each recording session
by using the following formula: seizure burden ratio =
(mean seizure burden in final bin) / (mean seizure burden
in first bin). A higher seizure burden ratio therefore indi-
cates a worsening of the disease over time (Figure 2B and
2C), as is typical of post‐SE rat models of TLE.15,19 The
seizure burden ratio was significantly greater in vehicle‐
treated epileptic animals compared to CBD‐treated epileptic
animals (n = 10 per group; Mann‐Whitney test, U = 22,
P < 0.05; Figure 2B). Moreover, disease severity was
improved (seizure burden ratio < 1) significantly in 70% of
the CBD‐treated animals, in contrast to only 10% of vehi-
cle‐treated rats (Fisher’s exact test, P < 0.05; Figure 2C).
CBD‐treated epileptic rats did not demonstrate a time‐
dependent increase in seizure burden (Wilcoxon matched‐
pairs test, W = −31, P = 0.13; Figure 2E) observed by a
change of median value from 28.50 (interquartile range
[IQR] = 26.81‐39.75) to 24.75 (IQR = 19.69‐35.94),
whereas vehicle‐treated rats showed a robust increase
in seizure burden from a median value of 25.75
TABLE 1 Effect of CBD, PB, VPA, and FBM in acute mouse and rat seizure models
Antiseizure
Test
CBD ED50,
mg/kg
IP (95% CI) PI
CBD
TPE, h
PB ED50, mg/kg
IP (95% CI)a PI
PB
TPE,
h
VPA
ED50 mg/kg
IP (95% CI)a PI
VPA
TPE, h
FBM
ED50 mg/kg
IP (95% CI)a PI
FBM
TPE,
h
Maximal
electroshock,
mouse
80 (65.5‐96.0) 3.4 1 11.3 (9.39‐13.7) 4.0 2 213 (138‐274) 1.8 0.25 49.3 (39.8‐78.3) 9.1 1
Subcutaneous
pentylenetetrazol,
mouse
120 (98.5‐146) 2.3 1 13.9 (12.1‐16.0) 3.3 0.5 305 (212‐403) 1.3 0.25 219 (150‐331) 2.1 1
6 Hz, 32 mA,
mouse
144 (102‐194) 1.9 1 14.8 (8.92‐23.9) 3.1 0.5 139 (92.4‐197) 2.8 0.25 72.9 (55.3‐89.6) 6.2 1
6 Hz, 44 mA,
mouse
173 (136‐213) 1.6 1 No public data available 289 (242‐384) 1.3 0.25 97.5 (79.3‐122) 4.6 1
Corneal kindled
mouse
115 (77.5‐169) 2.4 1 9.42 (7.91‐17.0) 4.8 0.5 174 (135‐208) 2.2 0.25 No public data available
Minimal motor
impairment,
TD50,
mouse rotarod
272 (241‐303) 2 45.5 (41.8‐49.3) 0.25 390 (382‐396) 0.25 452 (363‐563) 1
Maximal
electroshock, rat
53.2 (39.1‐67.0) 9.4 2 2.61 (1.70‐4.04) 15.7 2 212 (167‐256) 2.2 0.25 35.0 (21.9‐52.3) 16.4 0.5
Minimal motor
impairment,
TD50,
rat open field
analysis
> 500 (ND) ND 41.2 (37.0‐46.6) 0.5 470 (431‐497) 0.5 573 (285‐886) 1
Maximal
electroshock,
formulation
vehicle, mice
0/4 protected 1 Methylcellulose; no public
data available
Methylcellulose; no public
data available
Methylcellulose; no public
data available
6 Hz, 32 mA,
formulation
vehicle, mice
0/4 protected 1 Methylcellulose; no public
data available
Methylcellulose; no public
data available
Methylcellulose; no public
data available
Maximal
electroshock,
formulation
vehicle, rats
0/4 protected 1 Methylcellulose; no public
data available
Methylcellulose; no public
data available
Methylcellulose; no public
data available
CBD, cannabidiol; CI, confidence interval; ED50, median effective dose; FBM, felbamate; IP, intraperitoneal; ND, not done; PB, phenobarbital; PI, protective index;
TD50, median behaviorally impairing dose; TPE, time to peak effect; VPA, valproic acid.
aData are from the National Institute of Neurological Disorders and Stroke PANAChE database (https://panache.ninds.nih.gov/ChemDetail.aspx?CHEM_ID=
2&TEST_NO=7B#seereport).
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(IQR = 18.94‐39.34) to 30.13 (IQR = 21.00‐49.91) in this
same time period (Wilcoxon matched‐pairs test, W = 53,
P < 0.01; Figure 2D).
3.3.2 | Chronic oral administration of CBD
to RISE‐SRS rats attenuates the severity of
behavioral comorbidities of TLE
Motor coordination
Motor coordination was tested with the accelerating rotarod
test. A significant difference in time spent on the accelerat-
ing rod was observed among the groups (one‐way analysis
of variance [ANOVA], F2, 27 = 5.996, P < 0.01). The
Holm‐Sidak post hoc test revealed that naive vehicle‐trea-
ted (P < 0.05) and epileptic CBD‐treated (P < 0.01) ani-
mals spent significantly more time on the rod, compared to
the epileptic vehicle‐treated group. This motor test indicates
that chronic oral CBD administration attenuated the TLE‐
induced motor dysfunction (Figure 3A).
Gait
The gait test was performed to assess left stride length,
right stride length, and stride width of the animals. No sig-
nificant differences among the groups were observed for
any of these parameters (one‐way ANOVA; for left stride
length, F2, 27 = 0.019; for right stride length, F2,
27 = 0.198; for stride width, F2, 27 = 0.842; Figure 3B‐D).
Furthermore, as animals were actively on CBD or vehicle
therapy during this motor performance test, this study
demonstrates that the dose of CBD necessary to reduce sei-
zure burden was not associated with motor‐impairing
effects in rats with SRS.
Cognitive function
To assess the effect of CBD on cognitive performance,
epileptic animals were challenged in the hole board test of
reference and working memory. In this study, an age‐
matched cohort of nonepileptic, naive rats was also included
to determine whether chronic CBD administration could
normalize behavioral performance. Chronic oral administra-
tion of CBD to epileptic rats was found to significantly
reduce the number of reference memory errors (RMEs) and
working memory errors (Figure 4). A significant difference
in RMEs was observed among the groups (one‐way
ANOVA, F2, 42 = 15.06, P < 0.0001). Here, the naive
vehicle‐treated (P < 0.0001) and epileptic CBD‐treated
(P < 0.05) rats made significantly fewer RMEs (Figure 4A)
compared to the epileptic vehicle‐treated rats (Holm‐Sidak
post hoc test). However, the CBD‐treated epileptic rats
made significantly more RMEs when compared to the naive
vehicle‐treated group (Holm‐Sidak post hoc test, P < 0.05).
Therefore, CBD failed to completely restore the reference
memory in epileptic animals to the extent of their naive,
nonepileptic controls. Working memory was similarly
affected (one‐way ANOVA, F2, 42 = 35.72, P < 0.0001;
Figure 4B), with the epileptic vehicle‐treated group
FIGURE 1 Acute administration of subtherapeutic doses of cannabidiol (CBD) attenuates maximum seizure severity to a similar degree as
supratherapeutic doses of the prototype antiseizure drug, phenobarbital (PB), in the pilocarpine‐induced status epilepticus rat model. A, Median
maximum seizure severity of vehicle (n = 15) and CBD (n = 12, 10 mg/kg intravenous [IV]). CBD or vehicle was administered to rats 1 hour
prior to systemic administration of the chemoconvulsant pilocarpine. CBD‐treated rats demonstrated significantly reduced maximum seizure
severity compared to vehicle‐treated rats. B, Median maximum seizure severity of PB (n = 13, 30 mg/kg IV) and its vehicle (n = 12). PB or
vehicle was administered to rats 1 hour prior to systemic administration of the chemoconvulsant pilocarpine. PB‐treated rats demonstrated
significantly reduced maximum seizure severity compared to vehicle‐treated rats (raw maximum seizure severity data), confirming the therapeutic
responsiveness of the model. Data are expressed as median, minimum to maximum, and interquartile range. Data were analyzed by Mann‐
Whitney test, *P < 0.05, ****P < 0.0001
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FIGURE 2 Chronic administration of cannabidiol (CBD) modifies the overall spontaneous seizure burden ratio and seizure burden in the
reduced intensity status epilepticus (SE)–induced spontaneous recurrent seizures (SRS) rat model of chronic temporal lobe epilepsy up to 7 weeks
postinsult. A, Study time line for the epileptic animals. PSBB, postseizure behavioral battery. B, Median seizure burden ratio of epileptic vehicle‐
treated and epileptic CBD‐treated animals recorded during a 7‐week continuous video monitoring period. CBD significantly reduced the seizure
burden ratio compared to the vehicle‐treated counterpart (n = 10/group; data were analyzed by Mann‐Whitney test, *P < 0.05). Data are
expressed as median, minimum to maximum, and interquartile range. C, Number of epileptic vehicle‐treated and epileptic CBD‐treated animals
with seizure burden ratio < or > 1 (data were analyzed by Fisher’s exact test, *P < 0.05). D, Median seizure burden before and after vehicle
treatment. Seizure burden was increased significantly in this group at the end of the observation period (n = 10; data were analyzed by Wilcoxon
matched‐pairs signed‐rank test, **P < 0.01). E, Median seizure burden before and after CBD treatment. CBD‐treated rats showed no change in
seizure burden (n = 10; data were analyzed by Wilcoxon matched‐pairs signed‐rank test)
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FIGURE 3 Chronic administration of cannabidiol (CBD) to spontaneously epileptic rats improves some indices of motor coordination 6
weeks after status epilepticus. A, Mean time (in seconds) spent on accelerated rotarod. The naive vehicle‐treated and epileptic CBD‐treated
groups spent significantly more time on the accelerating rotarod compared to the epileptic vehicle‐treated group (n = 10/group). B, There were
no significant differences in mean left stride length (in millimeters) of naive vehicle‐treated, epileptic vehicle‐treated, and epileptic CBD‐treated
rats (n = 10/group). C, There were no significant differences in mean right stride length (in millimeters) between naive vehicle‐treated, epileptic
vehicle‐treated, and epileptic CBD‐treated rats (n = 10/group). D, There were no significant differences in mean stride width (in millimeters) of
naive vehicle‐treated, epileptic vehicle‐treated, and epileptic CBD‐treated rats (n = 10/group). Data are expressed as mean ± SEM. Data were
analyzed by one‐way analysis of variance with Holm‐Sidak post hoc test, *P < 0.05, **P < 0.01
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demonstrating significantly more errors compared to the
naive vehicle‐treated group (Holm‐Sidak post hoc test,
P < 0.0001). Importantly, chronic CBD‐treated rats demon-
strated significantly fewer working memory errors com-
pared to epileptic vehicle‐treated animals (Holm‐Sidak post
hoc test, P < 0.0001). Interestingly, working memory per-
formance for CBD‐treated epileptic rats was superior to the
naive vehicle‐treated group (Holm‐Sidak post hoc test,
P < 0.05).
4 | DISCUSSION
In the present study, we have demonstrated the acute anti-
seizure efficacy of CBD in a battery of well‐defined and estab-
lished acute seizure tests in both mice and rats following IP
administration. Our findings are consistent with other reports
of the acute antiseizure efficacy of CBD in numerous preclini-
cal seizure models.10,20 We have also demonstrated that acute
IV administration of a subtherapeutic dose of CBD is able to
significantly attenuate the MSS in the rat pilocarpine‐induced
SE model to a similar degree as a supratherapeutic dose of the
prototype ASD, PB. Furthermore, we have demonstrated for
the first time that chronic oral administration of CBD
improves seizure burden ratio, motor comorbidities, and cog-
nitive function in the RISE‐SRS model of TLE in rats well
after the onset of symptomatic seizures. Altogether, the pre-
sent study further supports a growing body of evidence to
demonstrate that CBD is a well‐tolerated and effective therapy
for acute and chronic seizures,11 as well as now demonstrating
the potential that chronic oral administration of CBD may
confer disease‐modifying effects in an etiologically relevant
preclinical model of TLE.
All of the FDA‐approved ASDs exhibit acute anti-
seizure efficacy in one or more of the acute seizure and
epilepsy models presently used for the evaluation of
CBD.16,21 However, many of the FDA‐approved ASDs are
associated with significant motor adverse effects that may
limit clinical utility. In this regard, we presently provide
pharmacological data that suggest differentiation between
CBD and the FDA‐approved ASD, PB (Table 1). Of note,
the activity profile of CBD in these acute seizure models is
generally comparable to PB (Table 1). CBD is thus differ-
entiated from numerous ASDs with broad‐spectrum effi-
cacy, including another broad‐spectrum ASD, VPA
(Table 1), because of this wide margin separating anti-
seizure efficacy and minimal motor impairment in numer-
ous preclinical seizure models. The broad‐spectrum
efficacy and margin of safety of CBD are more directly
comparable to FBM (Table 1), which, like CBD, is also
approved for patients with Lennox‐Gastaut syndrome.22
CBD presently demonstrated efficacy in the acute mouse
MES, subcutaneous pentylenetetrazol, and 6‐Hz assays at
both 32‐ and 44‐mA stimulus intensities. CBD also demon-
strated a PI > 1.5 in the 6‐Hz model of pharmacoresistant
epilepsy at a 44‐mA stimulus intensity, which substantially
differentiates this compound from many other FDA‐
approved ASDs, including VPA.23,24 The activity of FBM
is also preserved in the 44‐mA version of the 6‐Hz assay
(Table 1); the PI of FBM is also much greater than CBD
FIGURE 4 Chronic administration of cannabidiol (CBD) to reduced intensity status epilepticus–induced spontaneous recurrent seizures rats
reduces onset of behavioral comorbidities of epilepsy in the hole‐board task of spatial memory. A, Mean reference memory errors in naive
vehicle‐treated, epileptic vehicle‐treated, and epileptic CBD‐treated groups (n = 15 mean trial/group). CBD significantly improved reference
memory error compared to the vehicle‐treated epileptic group. B, Mean working memory errors. CBD significantly improved working memory
error compared to the naive vehicle‐treated and epileptic vehicle‐treated groups. Data are expressed as mean ± SEM. Data were analyzed by one‐
way analysis of variance with Holm‐Sidak multiple comparison test, *P < 0.05, ****P < 0.0001
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in this assay (4.6 for FBM vs 1.6 for CBD; Table 1). As
the 6‐Hz stimulation intensity increases from 32 to 44 mA,
most ASDs lose efficacy or are only effective at motor‐
impairing doses16,17,23,25; thus, the finding that CBD
retained efficacy and potency at both stimulation intensities
in this assay at doses well below the mouse TD50
(272 mg/kg IP) suggests that CBD is highly differentiated
from other FDA‐approved ASDs (eg, PB and VPA;
Table 1) and suggests potential for efficacy in pharmacore-
sistant patient populations akin to FBM. Unlike FBM, there
have been no reports to date of hepatotoxicity or aplastic
anemia with CBD use,26,27 but whether other clinical
adverse events will emerge with greater clinical use of this
agent remains to be determined.
The presently reported ED50 values in these acute mouse
assays align with work reported by Klein and colleagues
using CBD provided by the US National Institute of Drug
Abuse10 and by an independent laboratory using the same
CF‐1 mouse strain.28 However, we presently report signifi-
cantly greater potency of CBD in the rat MES test than that
reported by Klein and colleagues (ED50 = 88.9 mg/kg [95%
CI = 69‐124] IP10), likely due to differences in compound
formulation, source, and purity. We also report that CBD
exerted dose‐dependent reductions in seizure score in the
corneal kindled mouse model of chronic focal seizures, fur-
ther suggesting that CBD is effective as an antiseizure agent
in an epileptic substrate (ie, kindled rodents). Altogether, the
presently reported pharmacological profile of CBD supports
further evaluation of its broad clinical utility for epilepsy.
IV administration of CBD also reduced MSS in the
pilocarpine‐induced SE in rats (Figure 1A), consistent with
earlier findings demonstrating efficacy of a preclinical
CBD formulation administered via the IP route.9 We
believe this is the first demonstration of the efficacy of IV
CBD against the onset of SE, with this route of administra-
tion most commonly employed in the treatment of clinical
SE.6,9 Although further studies are needed to define
whether IV CBD can effectively reduce MSS after the
onset of SE (eg, against benzodiazepine‐resistant SE), the
present results in the pilocarpine‐SE model further support
the acute antiseizure efficacy of CBD in diverse preclinical
models of seizure.
TLE is one of the most common forms of acquired epi-
lepsy in humans.29 Therefore, we investigated the effect of
a clinically relevant CBD administration protocol in the
RISE‐SRS model of TLE.15 We presently demonstrate that
CBD is disease‐modifying in this model, where all animals
exhibit SRS before being assigned to treatment groups.
Specifically, chronic oral administration of CBD signifi-
cantly decreased the seizure burden ratio of epileptic ani-
mals and improved reference memory function. Although
CBD did not significantly reduce seizure burden after
7 weeks of treatment, it did markedly modify the natural
disease course following SE, as demonstrated by no overall
increase in the seizure burden from the first to final seizure
monitoring bin (Figure 2). These findings are in stark con-
trast to the vehicle‐treated post‐SE rats, which demon-
strated a notable, time‐dependent increase in disease
severity (ie, seizure burden ratio increased). Disease sever-
ity, as characterized by a seizure burden ratio < 1, was
improved in 70% of the CBD‐treated animals, in contrast
to only 10% of vehicle‐treated rats attaining such a ratio
(Figure 2). Although several FDA‐approved ASDs have
demonstrated disease‐modifying potential in preclinical
models of chronic seizure,30,31 and CBD has been found to
be disease‐modifying in a mouse model of Dravet syn-
drome,32 to our knowledge, this is the first study to demon-
strate such an effect with CBD in any preclinical TLE
model. The third‐generation ASD topiramate has demon-
strated some potential for cognitive sparing and modifica-
tion of behavioral deficits when administered shortly after
SE onset,33,34 but no study has yet demonstrated such a
disease‐modifying effect when treatment is initiated well
after the SE insult (8 weeks in present study). Although
our study did not include a CBD washout arm, the present
results demonstrate that chronic oral administration of CBD
is associated with long‐term improvements in disease tra-
jectory in this rat model of epilepsy.
A number of ASDs (eg, PB, VPA, phenytoin) are
reported to have an adverse effect on motor function char-
acterized by dyskinesia in people with epilepsy.5,35–37
Moreover, patients on phenytoin and VPA treatment some-
times exhibit parkinsonism.5 Although we presently
demonstrate that acute administration of CBD is well toler-
ated at doses up to 500 mg/kg (IP) in naive rats (Table 1),
in line with prior reports,9 no studies have yet been con-
ducted to examine the long‐term effects of chronic CBD
administration on tolerability and motor function in epilep-
tic animals. Furthermore, no study has yet administered
CBD for disease modification purposes after the onset of
SRS. In this regard, the present study employed a clinically
realistic treatment scenario in a preclinical model of TLE
to demonstrate that chronic oral administration of CBD is
associated with notable antiseizure efficacy, minimal
adverse effects liability, and disease‐modifying potential
well after the onset of symptomatic seizures.
It is well known that humans and animals with epilepsy
are more sensitive to adverse effects of ASDs38; thus, our
present findings that chronic oral administration of CBD in
rats with epilepsy was not associated with any adverse
effects further supports the potential of this agent for chronic
clinical use in epilepsy patient populations. In addition to
these drug‐induced adverse effects on motor function, motor
deficits are one of the most common comorbidities exhibited
by patients with epilepsy.39 Here, we used two well‐vali-
dated models of motor function to assess the fine motor
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control, balance, and gait of animals. Epileptic vehicle‐trea-
ted animals fell from the accelerating rotarod sooner than the
naive vehicle‐treated ones, indicating that SRS produced sig-
nificant motor dysfunction related to balance. Similar find-
ings were reported previously in the rotarod40 test, where
motor dysfunction was exhibited by epileptic rats. In con-
trast, CBD‐treated animals remained on the accelerating
rotarod for a significantly longer time than the vehicle‐trea-
ted epileptic animals. Thus, we show for the first time that
CBD is not only well‐tolerated by epileptic animals after pro-
longed oral administration, but that CBD reduces the severity
of motor deficits induced by epilepsy.
Epileptic rats performed comparably to healthy animals
in the gait test, which is consistent with gait disorders being
rarely reported in adult epileptic patients with TLE. How-
ever, ASDs such as VPA and lacosamide have a detrimental
effect on gait in human patients.35,37 It should be emphasized
that animals were in the active CBD administration period
during this motor test, suggesting that CBD at the dose tested
did not confer any adverse effects on motor coordination.
Our results demonstrate that chronic oral administration of
CBD did not have any adverse effect on gait in rats with epi-
lepsy. Clinical trials conducted on Dravet syndrome and
Lennox‐Gastaut syndrome patients also did not report any
gait disturbances following CBD administration.11,13
Whether these side effects may also be absent in the general
TLE patient population remains to be further determined.
Cognitive decline is a common comorbidity associated
with TLE.41 For example, patients with TLE often exhibit
poor executive control and working memory deficits,42 and
amnesia or accelerated long‐term loss of memory is also fre-
quently reported in patients with TLE.43 Cognitive function
in animals is typically assessed using spatial memory tasks
measuring reference memory and working memory
errors.32,33 Reference memory can be defined as long‐term
storage of acquired information that remains constant over
successive training sessions, whereas working memory is a
form of short‐term memory that refers to storage and
manipulation of information acquired within a trial ses-
sion.44 Several spatial memory tasks (eg, radial arm maze,
Morris water maze, hole‐board task) have been used to
evaluate these two types of memory in rodents.45,46 Here,
we employed the hole‐board task, where epileptic vehicle‐
treated rats exhibited impairment of both the working and
reference memory aspects of the hole‐board test. These
findings are comparable with previous studies of spatial or
hippocampus‐dependent memory in rats with TLE, for
example, a delayed nonmatching to position task,47 eight
arm radial maze,48 and Morris water maze.49 In contrast,
CBD‐treated epileptic animals exhibited improved reference
memory function compared to epileptic vehicle‐treated ani-
mals; however, reference memory function was not restored
to levels seen in healthy animals. Interestingly, our study
shows that chronic oral administration of CBD improved
working memory function compared to both epileptic vehi-
cle‐treated and naive vehicle‐treated animals. However, as
we did not include a nonepileptic CBD treated group in our
design, we are unable to ascertain whether CBD has mem-
ory enhancement properties in healthy animals. A memory‐
enhancement effect would be unusual, as previous studies
using a radial arm maze have shown that CBD does not
improve working memory function in healthy mice.50,51
Given that the integrity of the blood‐brain barrier is com-
monly disrupted in epilepsy,52 a limitation of the present
study is that we did not determine whether higher CBD
concentrations were present in the brains of these epileptic
rats. Thus, the dose of CBD required to reach this concen-
tration might not be therapeutically significant in healthy
animals. Although SRS are the primary cause of cognitive
decline in TLE,53 the improved cognitive function in the
CBD‐treated epileptic group might be due to a seizure‐inde-
pendent mechanism rather than solely by seizure reduction,
for example, anti‐inflammatory/neuroprotective action.6
However, further detailed investigation is thus warranted to
shed light on the mechanism by which CBD improved the
presently tested behavioral comorbidities.
Epidiolex (CBD) was approved by the FDA in 2018 for
the treatment of seizures in the catastrophic pediatric ence-
phalopathies Dravet syndrome and Lennox‐Gastaut syn-
drome. The present study has demonstrated that CBD is
also a good potential candidate drug for the treatment of
spontaneous symptomatic seizures of TLE. Moreover,
chronic oral administration of CBD also reduced severity
of motor disorders and cognitive deficits typically associ-
ated with TLE, in line with prior demonstrations of dis-
ease‐modifying effects in a mouse model of Dravet
syndrome.32 Taken altogether, this study further illustrates
that CBD not only is a potent and broad‐spectrum ASD,
but may also find use to attenuate cognitive deficits associ-
ated with TLE well after the onset of SRS.41 More detailed
studies are thus required to investigate the potential mecha-
nism of action for CBD as a disease‐modifying agent for
the patient with epilepsy.
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